var title_f18_16_18688="Headache diary";
var content_f18_16_18688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 578px\">",
"   <div class=\"ttl\">",
"    Headache diary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 558px; height: 625px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bristol-Myers Squibb Company. Copyright 2001 Bristol-Myers Squibb Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18688=[""].join("\n");
var outline_f18_16_18688=null;
var title_f18_16_18689="Usual interstitial pneumonia CT";
var content_f18_16_18689=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Usual interstitial pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Exudative phase of UIP with ground glass and consolidative changes. No definite honeycombing is present. Subpleural curvilinear lines and mild traction bronchiectasis are visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18689=[""].join("\n");
var outline_f18_16_18689=null;
var title_f18_16_18690="Blebitis";
var content_f18_16_18690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Blebitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is a 32 year-old man with glaucoma who suffered minor trauma to the eye two days prior. He now complains of pain, redness and discharge from the eye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lawrence B Stack, MD. Copyright &copy; Lawrence B Stack, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18690=[""].join("\n");
var outline_f18_16_18690=null;
var title_f18_16_18691="Thyroid nodules";
var content_f18_16_18691=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Thyroid nodules (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/16/18691/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18691/contributors\" id=\"au5549\">",
"       Douglas S Ross, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/16/18691/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18691/contributors\" id=\"se4042\">",
"       David S Cooper, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/16/18691/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18691/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?18/16/18691?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The thyroid is a butterfly-shaped gland in the middle of the neck, located below the larynx (voice box) and above the clavicles (collarbones) (",
"     <a class=\"graphic graphic_figure graphicRef66834 \" href=\"UTD.htm?14/43/15024\">",
"      figure 1",
"     </a>",
"     ). Thyroid nodules are round or oval-shaped areas within the thyroid (",
"     <a class=\"graphic graphic_figure graphicRef76248 \" href=\"UTD.htm?5/29/5584\">",
"      figure 2",
"     </a>",
"     ) that can be caused by a number of conditions, most of which are not serious.",
"    </p>",
"    <p>",
"     This topic discusses the tests that may be performed on thyroid nodules, as well as the treatments that are available. Other thyroid conditions are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"      \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"      \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"      \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT DOES THE THYROID DO?",
"     </span>",
"    </p>",
"    <p>",
"     The thyroid produces two hormones, triiodothyronine (T3) and thyroxine (T4), which regulate how the body uses and stores energy. Thyroid function is controlled by a gland located just below the brain, known as the pituitary (",
"     <a class=\"graphic graphic_figure graphicRef63094 \" href=\"UTD.htm?18/19/18739\">",
"      figure 3",
"     </a>",
"     ). The pituitary produces thyroid stimulating hormone (TSH), which stimulates the thyroid to produce T3 and T4.",
"    </p>",
"    <p>",
"     Thyroid nodules are very common (",
"     <a class=\"graphic graphic_figure graphicRef76248 \" href=\"UTD.htm?5/29/5584\">",
"      figure 2",
"     </a>",
"     ); up to half of all people have at least one thyroid nodule, although most do not know about it. Thyroid nodules can be caused by many different conditions (",
"     <a class=\"graphic graphic_table graphicRef51803 \" href=\"UTD.htm?37/47/38651\">",
"      table 1",
"     </a>",
"     ). Reassuringly, about 95 percent of all thyroid nodules are caused by benign (non-cancerous) conditions.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      THYROID NODULE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Diagnostic tests can determine if a thyroid nodule is benign or malignant (cancerous); this information can help to guide treatment decisions. There are several diagnostic tests and each provides unique information about the thyroid nodule. However, not every person with a thyroid nodule needs all of these tests.",
"    </p>",
"    <p>",
"     Often, a test will provide a definitive answer about the type and cause of a nodule. In other cases, a test may be inconclusive and further testing will be required. Discuss which tests you will need and the results of these tests with your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Thyroid stimulating hormone",
"     </span>",
"     &nbsp;&mdash;&nbsp;Thyroid stimulating hormone (TSH) can be measured with a blood test.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If the TSH level is normal, the next step is to have a thyroid ultrasound and fine needle aspiration biopsy. (See",
"       <a class=\"local\" href=\"#H23393801\">",
"        'Thyroid ultrasound'",
"       </a>",
"       below and",
"       <a class=\"local\" href=\"#H5\">",
"        'Fine needle aspiration'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Low levels of thyroid TSH in the blood may indicate that a nodule is producing high levels of thyroid hormone. If the TSH level is lower than normal, the next step is to have a thyroid scan. (See",
"       <a class=\"local\" href=\"#H6\">",
"        'Thyroid scan'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       High levels of TSH may indicate autoimmune inflammation of the thyroid (called Hashimoto's thyroiditis). Another blood test, to measure levels of thyroid antibodies, is sometimes recommended in this case. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=see_link\">",
"        \"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23393801\">",
"     <span class=\"h2\">",
"      Thyroid ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;A thyroid ultrasound should be performed in all patients with a suspected thyroid nodule or nodular goiter on physical examination or with nodules incidentally noted on other imaging studies (carotid ultrasound, CT, MRI, or PET scan). Thyroid ultrasonography is used to answer questions about the size and anatomy of the thyroid gland and nearby structures in the neck. Thyroid ultrasound findings can be used to select nodules that require fine needle aspiration (FNA) biopsy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Fine needle aspiration",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most cases, the TSH level is normal, and the next step is the fine needle aspiration (FNA). FNA uses a thin needle to remove small tissue samples from the thyroid nodule. The tissue is examined with a microscope.",
"    </p>",
"    <p>",
"     Fine needle aspiration biopsy can be performed in the office with a local anesthetic (numbing medicine). It can be performed by palpation or using ultrasound guidance. You may feel mild discomfort as the anesthesia is injected, and you may feel some pressure during the biopsy, but the level of discomfort is similar to a visit with the dentist.",
"    </p>",
"    <p>",
"     This test is accurate in identifying cancer in a suspicious thyroid nodule. In some cases, the biopsy does not contain enough tissue to make a diagnosis, and a repeat biopsy is necessary. In other cases (10 percent), the result of the biopsy is indeterminate and surgery is necessary for a definite diagnosis.",
"    </p>",
"    <p>",
"     The results of the biopsy will be one of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Benign (noncancerous)",
"      </li>",
"      <li>",
"       Malignant (cancer)",
"      </li>",
"      <li>",
"       Suspicious for malignancy",
"      </li>",
"      <li>",
"       Follicular neoplasm (microfollicular nodules, including H&uuml;rthle cell lesions)",
"      </li>",
"      <li>",
"       Follicular lesion or atypia of undetermined significance (nodules with atypical cells)",
"      </li>",
"      <li>",
"       Nondiagnostic or insufficient",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Thyroid scan",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people do not have to have a thyroid scan &ndash; only those who have a low TSH level. In these cases, the thyroid scan is the first step after the blood test (instead of the fine needle aspiration).",
"    </p>",
"    <p>",
"     A thyroid scan can help to determine if a thyroid nodule is autonomous (\"hot\") or non-functional (\"cold\"). The scan is performed after taking a small dose of a radioactive iodine (a pill); technetium scans may also be used (an injection), but they are less reliable.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Thyroid nodules that absorb the radioiodine are usually",
"       <strong>",
"        not",
"       </strong>",
"       cancerous (called autonomous, hot, or toxic). (See",
"       <a class=\"local\" href=\"#H23394399\">",
"        'Autonomous (\"hot\") thyroid nodules'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Thyroid nodules that do not absorb the radioiodine are called cold, and have a 5 percent risk of being cancerous. Approximately 95 percent of thyroid nodules are cold.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The risk of exposure to radiation is small compared to the benefit of knowing the test results. Women who are pregnant or breastfeeding should not have a thyroid scan. Following a thyroid scan, patients should take care to flush the toilet and wash their hands after urinating because the radioactive substance is eliminated in the urine.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      THYROID NODULE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The appropriate thyroid nodule treatment depends upon the type of thyroid nodule that is found. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"      \"Diagnostic approach to and treatment of thyroid nodules\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Benign thyroid nodules",
"     </span>",
"     &nbsp;&mdash;&nbsp;Benign thyroid nodules usually develop as a result of overgrowth of normal thyroid tissue. Surgery is",
"     <strong>",
"      not",
"     </strong>",
"     usually recommended, and the thyroid nodule can be monitored over time. If the thyroid nodule grows, a repeat biopsy or surgery may be recommended. Some surgeons recommend excision of nodules over 4 cm.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Suppressive (thyroid hormone) treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a thyroid nodule is not cancerous, but the nodule is large, some clinicians will suggest a trial of thyroid hormone (T4) to shrink the nodule; this is called suppressive treatment. The American Thyroid Association guidelines do not recommend this treatment because only a small percentage of nodules shrink, and suppressive therapy may have side effects. Thyroid hormone levels should be monitored carefully during suppressive treatment. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=see_link\">",
"      \"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Malignant thyroid nodules (thyroid cancer)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Only about 5 percent of all thyroid nodules are malignant. Most patients with thyroid cancer have an excellent chance for cure or long-term survival. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21688?source=see_link\">",
"      \"Overview of follicular thyroid cancer\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8440?source=see_link\">",
"      \"Overview of papillary thyroid cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The treatment of thyroid cancer will depend on the type of cancer. Thyroid cancers require surgical removal of the thyroid gland and sometimes one or more treatments with radioiodine, followed by thyroid hormone (T4) suppressive therapy. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link\">",
"      \"Overview of the management of differentiated thyroid cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23394482\">",
"     <span class=\"h2\">",
"      Suspicious for malignancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nodules in this category have a 50 to 75 percent risk of malignancy. Patients with nodules that are suspicious for malignancy frequently have a total thyroidectomy because the chance that the nodule is a cancer is higher than the chance it is benign.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23394490\">",
"     <span class=\"h2\">",
"      Follicular neoplasm",
"     </span>",
"     &nbsp;&mdash;&nbsp;We frequently perform a thyroid scan in patients with biopsies that show follicular neoplasm. From 15 to 20 percent of follicular neoplasms prove to be cancer. Thus, if the scan shows a cold nodule, surgical removal (usually a hemithyroidectomy) is generally recommended. Thyroid nodules that absorb the radioiodine (autonomous or &ldquo;hot&rdquo; nodule) are usually",
"     <strong>",
"      not",
"     </strong>",
"     cancerous, and treatment depends upon thyroid function tests and other factors (see",
"     <a class=\"local\" href=\"#H23394399\">",
"      'Autonomous (\"hot\") thyroid nodules'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23394497\">",
"     <span class=\"h2\">",
"      Follicular lesion or atypia of undetermined significance",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most patients who have nodules with atypical cells require repeat FNA. The optimal treatment depends upon patient factors, such as risk for thyroid cancer, and the FNA and ultrasound features of the nodule.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23394353\">",
"     <span class=\"h2\">",
"      Nondiagnostic",
"     </span>",
"     &nbsp;&mdash;&nbsp;A nondiagnostic biopsy does not have enough cells for interpretation. It should not be considered a negative biopsy. For patients with nondiagnostic FNA biopsies, the FNA should be repeated using ultrasound guidance.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23394399\">",
"     <span class=\"h2\">",
"      Autonomous (\"hot\") thyroid nodules",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some thyroid nodules produce thyroid hormone, similar to the thyroid gland, but do not respond to the body's hormonal controls. These nodules are called autonomous thyroid nodules. They are almost always benign, but they can overproduce thyroid hormone, leading to hyperthyroidism. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"      \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If you have an autonomous nodule and high levels of thyroid hormone, you will usually be advised to undergo surgery to remove the thyroid nodule, or undergo radioactive iodine treatment to destroy the nodule. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"      \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If you have an autonomous nodule and normal thyroid function or minimal hyperthyroidism, the appropriate treatment will depend on your age and other health factors.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In young adults, autonomous nodules may be monitored over time.",
"      </li>",
"      <li>",
"       In older adults, radioactive iodine treatment or surgery may be recommended because high thyroid hormone levels pose a risk of an abnormal heart rhythm (atrial fibrillation) and bone loss (osteoporosis).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23394427\">",
"     <span class=\"h2\">",
"      Cystic thyroid nodules",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cystic thyroid nodules are usually benign nodules that have filled with fluid. These nodules may simply collapse when the fluid is removed. Cystic nodules are usually monitored for changes. If the cyst reforms or bleeds more than once, surgery can be performed to remove the thyroid nodule. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37111?source=see_link\">",
"      \"Cystic thyroid nodules\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The thyroid is a butterfly-shaped gland in the middle of the neck, located below the larynx (voice box) and above the clavicles (collarbones). Thyroid nodules feel round or oval-shaped, and differ from the surrounding normal thyroid tissue (",
"       <a class=\"graphic graphic_figure graphicRef66834 \" href=\"UTD.htm?14/43/15024\">",
"        figure 1",
"       </a>",
"       and",
"       <a class=\"graphic graphic_figure graphicRef76248 \" href=\"UTD.htm?5/29/5584\">",
"        figure 2",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Thyroid nodules are very common; up to half of all people have at least one thyroid nodule, although most do not know about it. Thyroid nodules can be caused by many different conditions (",
"       <a class=\"graphic graphic_table graphicRef51803 \" href=\"UTD.htm?37/47/38651\">",
"        table 1",
"       </a>",
"       ). Reassuringly, about 95 percent of all thyroid nodules are caused by benign (non-cancerous) conditions.",
"      </li>",
"      <li>",
"       Diagnostic tests can determine if a nodule is benign or malignant (cancerous) and can help to guide treatment decisions. Tests include blood tests, thyroid ultrasound, fine needle aspiration (removing a small piece of tissue with a needle), and thyroid scan.",
"      </li>",
"      <li>",
"       The appropriate treatment for a thyroid nodule will depend upon the type of nodule. Benign nodules can usually be monitored over time. If the nodule grows, a repeat biopsy or surgery is often recommended.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our Web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H151\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5395879\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23618?source=see_link\">",
"      Patient information: Thyroid nodules (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/12/30914?source=see_link\">",
"      Patient information: Multinodular goiter (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/10/36002?source=see_link\">",
"      Patient information: Thyroid cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5395905\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24452?source=see_link\">",
"      Atlas of thyroid cytopathology",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37111?source=see_link\">",
"      Cystic thyroid nodules",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8440?source=see_link\">",
"      Overview of papillary thyroid cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1990?source=see_link\">",
"      Overview of thyroid nodule formation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=see_link\">",
"      Thyroid hormone suppressive therapy for thyroid nodules and benign goiter",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=see_link\">",
"      Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"      Treatment of toxic adenoma and toxic multinodular goiter",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21688?source=see_link\">",
"      Overview of follicular thyroid cancer",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Thyroid Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.thyroid.org/\">",
"      www.thyroid.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Thyroid Foundation of Canada",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.thyroid.ca/\">",
"      www.thyroid.ca",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/thyroid.cfm\">",
"      www.hormone.org/public/thyroid.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Thyroid Conditions Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://thyroid.about.com/forum\">",
"      file://thyroid.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?18/16/18691/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?18/16/18691?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18691/abstract/1\">",
"      Heged&uuml;s L. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18691/abstract/2\">",
"      Ortiz R, Hupart KH, DeFesi CR, Surks MI. Effect of early referral to an endocrinologist on efficiency and cost of evaluation and development of treatment plan in patients with thyroid nodules. J Clin Endocrinol Metab 1998; 83:3803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18691/abstract/3\">",
"      Nam-Goong IS, Kim HY, Gong G, et al. Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 2004; 60:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18691/abstract/4\">",
"      Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 1993; 118:282.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f18_16_18691=[""].join("\n");
var outline_f18_16_18691=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT DOES THE THYROID DO?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           THYROID NODULE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           THYROID NODULE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\" title=\"figure 1\">",
"           Thyroid anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/29/5584\" title=\"figure 2\">",
"           Thyroid nodule PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/19/18739\" title=\"figure 3\">",
"           Brain pituitary anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?37/47/38651\" title=\"table 1\">",
"           Causes thyroid nodules PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f18_16_18692="Estazolam: Patient drug information";
var content_f18_16_18692=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Estazolam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/15/22774?source=see_link\">",
"     see \"Estazolam: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11263404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to estazolam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12432 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-EFB8DDA1F5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18692=[""].join("\n");
var outline_f18_16_18692=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263404\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013656\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013655\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013660\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013661\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013663\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013658\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013659\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013664\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013665\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/15/22774?source=related_link\">",
"      Estazolam: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_16_18693="AIDS-related Kaposis sarcoma - gingiva";
var content_f18_16_18693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AIDS-related Kaposi's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwBLCBvsqrHIEK44wK24omIB2gNjOe1ZVjJ5JUbUPQ8jqK2IZtx+bgY54AFeb1PegxjQGRHL5CkfKcA4NVxbDy/mG/1JA61oyPkBoSuPwH6U+PZIrD7mfmwvNVozeLM1IRG/7vduA/u4pWt2KEenXntWiYVc7wWC9uehpjbdu124GQcDk+/FLYvmRmGIJkj5kA6HvTCFLYwQpxn61cmdI0PlA/Ugc1TeYGTCx5455zWVx3IWwZfkCgge1RvJ8g+cPnuB0qvYJNHLcWTE+ZG++MuOWRuh/mKsSWEiNvllxHnlV6VVjPnRBckbwCYlZuOfX1JrMu76ezvbcRqSJcqHwMIcZFXZ7ld+2zSI5HJ2Fj/gK5rXr2a6+yQIpnully/JVcAH8jVqKMJzZX1a9+069G73u3yULMVcZQdzj3rndU1qDWDFawT/AGu7AdFcgooTux6Z49Kq6xdxLczwKq24uZVjdUjHKqMnJ781mzhZ0uLqFR5okKoYjjgdOOgFaxinqzjm29kQ3OlwRTE6jKpUjEKF8EgDk1W8P3LPqBtbZkRXzh5OSB1x/hT7qG7ll8q/hjiVULEgA5yOCCf6VRttkdvHFcShEBLIqcOx7ZI6Zre2hzt6nYRadpt1OLZvKaOBAAxXGTnLHP8AWsjUoorK7lv9NtsadOjROSMqH/2c0aXNJa6lJBq0HDxKFCHj1APrU8LPd2etXBlEWnwyNsgYcFtvTFSk+pcmnqjLNjbz2iXOTHGYQGwMZ96z2jGBJbIYQ8ewPIRiXt9Aa0bqIppKRRXO1gm6SEDO04yADnoazru5u4tOELoqRTuXVQOR06exq0mjGTi1exLpKvLCbO2t2kfdvuGVFZlUHqh68c1cWy06C1uJRdKvlzZglKknI527e/5d6zbYt5NxPAUt0RwV5+YEDoD15qC1mdLqO8EZMMcmWz8wyevWm1dmSdtzqbTUIFsmtVik84RnEZTaGB9CenPes60aYyWiXdqCtuxRWXDHLEn5gOvJ611f2hRJZiOGJnkUO0lx8saIe/HOeaY1tawz3Dx3CTQxyFyqnaM9sY7ZrJ6Kx0KzdznjbS6Zrqahexyy2ryHz/3YBBPYitvSbHUJdDiutLSFwBLcPBIobziW449hUOsi5tNLluNRUT2d2pdfLIVoXOcH1Yc45q34IS/W3gFhcrFEi/vvMA2E+ijv7t0ob0uFlzWH2VwNUtE1C2traW9jB3xg5eE98J3HpWrHf2syS3iiGG3i+RjMT5qe5jA459aw5zZ6P4qtzao0kiz5aSCTYu1uqE98E5xXXazpVnrgnW9jaBwu0TxHDjjv6j2NRJLr1NIc2q7GF4h060uLrTbOLCTyytIZwoJ2Y+Y8evvWfcWIguBp/h6W5S64LszZWJB/G3oPbvVnT5LoNst7Hz7i2Rpd0T8BMYXj+DOCdo9av+G9CmY3Et9e3MN9d/v3WLghegAODnFEU0tx253a25z8V9LYyeVeuJTDc+ZIioF8vqFZPVTnp2q1rGl3dvqtkpKLa30iTS7V3AFecbe+cCote0e1W8tYbK4lNyzmOeaQb/KUngsR/nFaMJntbdJZIJ54bOdASSGaIoDvT/dwcj600uqCSteLNzxHf2iaBPc3KTNLJgR8fu1PGPpziuZfVWhh1W+jZWu5pkigUHgkYAwPzNdHfSRyaJcSzxiN/s5byhltuRnn04rjvCs+ZtO1eaGIWelqBL5hJMjEkb/cjOaVubcblbYsa3Z/8IzrlrIU843MDm4i4JlJwWX29Qe1dH4et7pre6h0+6ZRFMWt7o/vFZCQcMO5GSD0pPG9mNa0CG905dzJcoUl55DdufwrU+DSz3Wn6hdygLbtKUjQHIBJyxGPcgfhVWvFMNPaW7mDJc6z4Z8QrZsLO6hKvNEEiaPeJWyV74ww6e9b6eJoEy9xavBFJkNJE6yKG7j1Bz6iun1OzguI/IuV+YvhQMAgg54PUdKw7iz0qITGfT4yrsWkWOIc+5x19aiU11LjSktnoczq1lZ3dxp1xZi2vpIsIyGXhoifuEE9RnI96fe6THHI32NrawhkUo6lWkBP+7nFTah4S8HTW63Al+xPuLvslIUr6EHp+FcxdX1jp1/HBoeoX93HjkMRIoPTAHBx071aUpfCzGUlH4xG0q4s4JTDaxaxDGCpnk8yOSJTxwM7cD3Fc7NNcWUwd49yMCkcqYI3+jY4JHTitjOq3WtxWev3E9nbTNt3HOxBjOSinn8fWuwt/C+kSabINO+2agTOrrFKPLDBTkley5wR3610wpO15vU5J1vetC9jhrf7VqYhthBHHNsCtLK5UPjp/wDqHWuv0T4b6hc2ztBp9xqFxj5WjtmKj/Zzjp9a9o0DxA2haLJaeH/Dmn2tqjbomuSZXZTzh8Y5GcdewqO/+IHiy6h2QSJCWOCLWAZA9i2a1jaK0WplJTm9WcD4e+FnifUYzNZaL9mjSTy5Yr1liYEdQvqOeD096mm+H5TSo9TOoaXYiC4EVwn+tmshnBkwOo7lfSjXb7xNcLLNqGp6gBgZDXJViOmdoIH6UuhaHfX0iSF/37qvmPKwAk45J+nqanncnYtUlHY4LVNEtLa8vp4dSivp7aQiS3hjco8LY/fxEjuecVpafZ6LJ9tgsprw2rSRXEJi4Me5fmwT6MDx+FejJ4HWxv7iUzK4VleCRSc5K4dT7D+tZ174RhsdXtpbC3fbdITJGOFAVskr6HnpSlBjWi1OSjtNJmTTfsy341KJ2Lo+1ACOHz7HIx9aseILHT11G2uraaVWhDpJvYMGLfwH2zzXXQeCki8QM4mT/SrcHJGDlD354yCOfasDWLSCO8WKxjkvYslTPGhK7h1Cnpx0LZwO2TVWbIVo7s8602SG5QWgMUXkJyQuA/JycnpjFQXF3Kl9nT2keyCnzGlOQSBhtvTI6fWuz1bwXpt1ZZAmN/KHuAkP3dn8QUt1IPr1zWC+iLJLFaPazFNodSgDeYqkn5ueOOwqm6kbK5l7j1sUbLXJI9NbTls2g06eQvOtrxvP/TTAyw/2Sce1VbuLRZZ4prdxJPuGUeNyNvQ7u2Pf6cVsaZpjtNLBHDJ5bT4iJJBz12njtnirNx4biME7zRo7xfIWQ4cN3XI4OPetI1Kken4L/Ihwh0f4s7nR9XtrjaIX+1AYBZWA5/GukjvlIEDIFcfeUkAivA7LxXci6VjC05ZgNmd5f0xz/Suts/E891OynTFt2BCf6WWQ569BXkyhZansxrnrAuLTKoGVJieQxq1bzxKuCYyccHrzXL6PfJJbYvITEcfM0akrn/ZOK6Oxmji2NBb74mUje4GV+opcp1061zU3q7MWnROASFUc/wCFRFIyu9ZCxPXB5JqBtWsyNjrGGHyHAyc9+lX7N0XPlsFx2bkY9qlxTN4z6mbJAiIBjO7kAjNBhZW4VdpHNSatqKWcaByZJJWxGijlm9P/AK9ZNzPqCgtPGCeixRPjB/2mqeRIuUynr8lxaRpfQPEk0OV2sDl07j61z9/4usI1KS3hniIy21cFj6Y7Cq/iHUboo8iSgMG2B06A56Ankn3rkIvDWonzLuPyEeZdzxFSRJ7exq1ZnFNzT0Nm41y31OGSSe/uLOwOUDxx5Cn8OtYup20q3KQ6TeSi3K7jdyr5bNx1xU0HhhtSsXzdSW80rAFHj2xoc9CvqPWmSXXlTyadrVoXuYWO2WJsxuOgOOuKq3u6Iyk0neTOb1bS0sY4Zlv0uLsyhQFO489TVTTpJYJ76Bx5gwXIBwQT149K68rAmmg6ra2kCOGQzBeQ2egFcpcW1vNMsOnytcXGPL81Qee+fy4rSMrqzM5JRacR0UgvkuC1wZLO2wwDH5n46AHtVOVobe2tpWto3kklEmCcEAdAD/dNaWl2aw3ttpf2pI/PwzsUBKSY6A+laPiCDTtPTTrCVxNdRuCzRAEEf41SlZ2RHLzRuyusTyQzXsd1DIrgjYY8bSOwPXNc/Kso0++826YSiYb4Tzuz/FXQSo91KFiWRbCEZO0Y+b/bPfirWl2KahouqqsPlxySDbIeGPI5pKQ5QurowfKjXToY4N009yoEpUcISR3+lS6luM9xbRQMRb2xU5bcVHFad1ZvYvZ6U4wYCzB8Els9wPWqeq3anWoQrE4VlkSI9cDv61Sd2Ry2Vmc7LZsZ1hgVjJKVCR9SQRU/mQx6M9vK7C4W53GHHBAGOtXtP0+WW4W5eXZIsiOoc4O3P+FU9UeKNHiTZLLNI0jsw5T5jgA+/ervd2MnFrU6zw7NbXN9e3F/bXFxGfLVI7OPzFUAdz3x6Vv6nLpFu0lrAxAt0VpB5eN2RkDPr7Uz4a6nbQeFRbRS7bjzGaQHtn0/AVxWualDcXuoJGmLVbhpAP4nbGBk/rUPV2NIR0TuQ63q80908Jw4UYC9eT9fQVc8Oai9lGLO3VTezDCXMh+WNccjJ7Dk8VR0bTNQnR5bMbFYFwWGcAdz/Kul07S7C2so726iZo7aESS7mzvc84A9OaiTilY0jGUncd/YNxqdoq211IsURMkTSgK0rd2C9lJ9eTWze6hstVtIyftU0O0Rq2WaVjtAyenc1GupvC1vaW5R9VvMMzHkpnnJ9Ao7Vn2UUM3iSK50u0mvL+GUx7XfGSBxI/oDkms1eT16GztHRdTttJsovD2lssmxppQFEcQy8xHb3+vajVri7fR4khg8vVMk28aHJDY6E+mOtXbe0Nv5l5fSLPelcNL0SNf7q+g/nWXaQ3Go+IFZ98cZh+T5iCEJ5b2J6Cs5S1OtQXLYj8LC0xpcLKuJIJZJovvM8hwGZ/xzXM+JZL6C/uo4rsQiV/KlQpn7o+RvqRgV2+hWlro2s6jCYlW33/unJ6ZAJUnvzzWVb6fHrt9rLxRo90WCCRjlIguCAD3ampWIlSulfcy9asb3TdGj0qCWKe+1BgCqxkysCMsSc8fyqxpnhT7JoEf9o7pSjtttiRsixnk4+83ueldjpOnW+m32o67cRnz1jEUbtkjP8RGfXoKs6fp91eWTi5URPIz5TuoPTJ9apvSxnGn712jiLm+T/hXVvbs0pundfliHKRKw3P7fL3967rwcltpcE+nWwFrBZyhIsHnD/MCT3JzjNN8K6Rp/2S83WiySSxIjbuQRsAIPtx0q7ZWWZH1K4TyriMtAYhyAF+6fy/nQm7WY4Q15h95axS3RgJDsUJBQYIPUH6iuO8T65Y6XYAXhCXHzDYp++R3Hsag8YeMhYF4rCMPfPIVRVO449fXmuasEf+0v7W1hEv8AUuDHE65jiOOMjuR+VdFHDcy5p7HJisYovlhqzJls5dWnXU/EMj6fYYzEijM0oPI2g9j6niuil13+0tMOh+FvD9nomjOR58rL51zclf8AnpKRnryAuMfpTItKuNXvDdajJLJuOcvwBznAHp7V1ljbWVnGzpFlycNg4ArsdSMFyxRwwozqPmmzI0Xw86ZDma4J6s4yfzPNdHZxXalRbILdUynmEYx9B3pg1iCwmcF4Y3UcKzc/Wom1NnYK8zIDn5mzhR61zSl1udcKcUdsl5DBbrAqjZtA3OAu89+azrzWlgGwxrKUOUUAHB7Vyk+qL9m2yvngcgZJNLayurpNcRtlW3Rqy459TTVV7ClBbGvLILt/mQqrH5k24J9c0ujTfZ7loEZ9iklSx5KnjFZ4u5ZZA0jDcd3AydpyasrCJWSVZsMpB45BB6ik7t6DSSOpudSd9iAj5OQAOlNk1RMfOssk7DaibT1xySew+tcxdhWv0xJIrFG2P0IwQce/WrVlqV0oPnRjKcM4OVYfzoux2vsa91pIvpIxcTuUJLSKrbRJkAbT/s+1acdssYijlSFYwPlEYAAUduKyIdQV0G87R/FikuZL2GMNptxDK+TmKcbSR7MO/wBRVRlYUoop+KNtzbeTDDKWSQAGMAFOONrHge+a5XWLbUb+4Et2lraMAN5ChpGx0xjAXHbGa6eTxNaC6az1SGWzu5FyqyL8knH8LDg1XvG+3wiG1EdxCwy25genOAexrWMk9TlrR6HIWdwlzBJJ5kcl4HaKYXQO3zEP3hgj2P0NdB4PnXWgUurZILlWZSyIQrYOCdufT1rIGmS6exMLLIjv5zi4/eMvA+6QASe3OelQfbJrU/ab24ktLOUbBknKns20cAHpW8Hd6nFNOKujzCW0eO3jnutMkHmgEOuIlTA7Acn17VsaTqECQjfqyyoxCmFoneT+dZ/n3V8kEWoO8NkzALE4cZIOMbumfc1q3Wn6LBYyyTWklqQQI5kYnHbJ5Oa82WujPWXkWU1jerHS7LUf3RK+Y140UeRzyPX2qfS/E/iCY73aeeEtj5Hcpj3bnNRaVHpVzJFsWwe2gO1Wl+RpMdWZFySe4zW7CftKG3sYIhbsxybWN4CT+OBUspHR2PjB1uVtmtrWSU4wouQDk+2BxW7FqmqvfN5VkkalchWKun03A5/SucktVnt7S3a3jgmj/dtdiAO/PfcOD6VA7WWixBDa3WrXssjQh4pdiMwPGQMDjvik431NY1GtDsb43V/EjyGCG4hcSI391h/SoJb2NS7S21xcyA7W6AZx6envXNWtxqltcNC9nbQsF3N5MTyhe/XIyar6h4xt7WNHjkiuNQfEccaxsg3Z9T1/OlyGzqj9YM1nbmSS0F3czjMVrChLRe4HoOOar6JIGt4ru61KWdnHzBSBHx1x6Y96ZpFxeWF9ez69cRW99IoljmZ+FjP8Kg+hrntW1W5nNx5Lxv5yFZWiQLGxz99Pf1FFkjHnejNLRmn1W5l1PzLjyXkZIQH2qEB44759ah1+aCQNKI44ri1lCRsTksOpyKxNNgtpMRQz3N7chcmOM+T5X/Aias6nK2kxwytcBpHYRmOZhJsz3Jxz9aOXXQXPpqWpr1LnT7j7IwkkmcTbHIOxsjOBVDX5FJiks/8AR70rlDbjblj61g2qO10ypG8lxvZHlRf3ZH1FaK2Tz30FqLrdKg3FY0+6Pr60W5WO6mjIGhajc2s13Kqq4+Zzn5s569eM1rz+HUjn0OeZ1QSsxmAY5GznHPf6etdDJp89nbXMpnLxzRbXMvLA56isjxN9nfUIZLSYz+XGGZCpG098evaq5mR7NJGpeop8J6hc28uWLfvSEz8ucbfTOKsaTexPG9xbyiGwiQbQQMsAOrE8D6Vm6nqAurGz8P6c8YggRZrt8f6zoSo9a2YITrc3mfY2h0mD/VRsuBK3qR6D0rN6G8NXZGPqz/2prNg8byxW80bL5pUAvk/w9wPesjxRbQ2RtbWKNIbpJSi46MjdDnqfeuw8QFS1mtzFtUvtEucCNv4W/Piuc1pBeeItKS7/AHc0TESMw4PTGPaqhLUVSOgs9hINWtbdXiuJDb4KOMKzdh+VcZp9ss+vACF/s8cu+RSM7EDc5ruZtQt21TUHuC8Uz26LaMFO9pFOCQo6ZrM0rS5o9Ra28qWORwN4d+WGNz5PvxVRlyrUynT59hkF1LFaarb2AhiS1aSdJtvzFGPQViaVpz6pJYwQwyCa6lIa5cZXjk49eOtdZrvh27k0WbUZ4Et1JWOKOHPzZOMH2r0zw/pMFnaadb/Z0aS3iAEjfwZ6/nS57K/cuNByly9jlrfw7FDBeWlpPLJeeVh5DkBMjjgcVQ1bTWh8M3FlYRtL5cYWWRsD5iRk+5Feiabp0ojuo41Mc880krs38Izhf0HSpLjQg1kbVVwrgrx29zXO20dyoq10eW6To99Lr09vpDoBawLFLcyDOXcAs31A7V2Oj6Amg6PaK0u/U1mMpKDLT5OPm9sVv+EdAksl1EXgC3Ut0QCvR1VQAfyro7WBYndtqs69CBnir5mTCgnq9zm7bTbuV5Hu1ZDMx2xsMqqDoMeprR0rT7e2uZZEhZp5Qocnnp0ro5Ft3kEazERuoYu4+62OlZ+TCryTsqjuegA/rUONtTojtZmRqmjabci9kumJhU+dtBxsYDr+lWvClikMQkkjiie5j3iPb0H/AOrFE00N667V2Wa/eJGPM+ntV6OVnAlY5ZOBt4wPT8qpCcUndDrhIrlzHJEJI4cMd/3VbqPqahuJEtEEoLOzMBgc5LHHAqXzTFFIpTMbEuQTncfc96xtU1AzNanZ8vnJ9zsAfagiS0uT3DLby+bG2Y2+eRVG0ZHYelef+M/FE9lNJp2mLJLdXJaeTniMHjJ9K0PEeqy2wEVnE0+oXb+TaQKer8ZJ9QMnmuJu0ayea1Nwlzc3B/0y5UZDMP4Bn+Ee3WurC4f2nvy2POx+JVJeyh8Q/wAOWSQXAvLkNc3Rzkjhcn09q6yyso5GSW4DIq/MFAAA9OvWsjSJVj2BAT+uKnn1B1ZYRyMnbg7iOe5/pXXUnd8qPOpwUfekbl1efaTJgqNw8tiO49eKa05RPK8oBFXGMbj+dZ9ozoC8g3SE44HH0HvTbuZlXaxVDjO0t1Nc7R2RloU9Quf3oP2aUDrmIDA9jmnW7NLulup/IUjIDnORSTSBid00e7HAXgUxYo9nMkTnr865qOVCc5dB0DRTXXmLMLmfPyKAcKT6npirdxGbVi+0zSyZUIj7gPXk/qaiikQgOZQOOgxgVLFM/mLhWyOdwq1FEXfUs2CGN/OunDTyZKxxghUHp/tH3Naq3KKQCQp25Ax+lY7XUyOQxJJOBuOeKRgk8m6Z2wOkZyB+OKTRalpY27e8jlcsuCVG3JAOM9qJYixLpOyjOBGqjAz71lQXqRMItm2PHAGBWjBeI8bMpIHXIHINPRlNpD5Ek8l2guAkq/daVdw/HB/lUsclylqDJKsk+0b417n2NUGvJUQvHFHOvRgrYOfbPFMQRXQEbNdW85G9WMZ/Eeh/OhLTQhu5uW1xLcgRqN0qrn/aUn2/wrA1Uz27ie2sLi5j5MjWbYlhYd9vBar1tPcQxfvdzleC0YOWHqR1zWm05ufmVWD7QwMgIOenXr7c5qoyaM5QUjio9WtpJrZ5tRu3twxDysgHltnhZBt3DjHPSq3irSRLdzX8c7ndGn7tWyjfMB0z7g8V1GsaRb6hGwvoYscMH6SA9gD/AIVyetaRf2MUTWV+uoRvKiiCfc209QSR8wHHXPatlJNHNKEo7HnMSS6ebZZ9JS4aUfIZ93zjP8Izj9KdeaXcG7MssFrZQs24oX+RB/d65P4VLqEk2qXzx28EM87/ADqbXe5gQc4HOPqahjNqbaT+01llu2ULbwmQgAH+I4/lXP5nStXY04NTkZRbxCSfyz8p04+WB9Rt3frVi3E88yeab+Z1z/rpyrJ9QBT7GC8sNGmkllaziCkbF+Q5PQnHNaNtELaFZLeRLTKDfPIxkkkJ6sEz396xcuxuo2JrXW202zE0Uk0dzgokbNIwfPHQjBwKv6NqMqzedfRrBExzAJVOFU/eI5wCa5TxBe3kcnmB3ktocQLLIgQlzySFHtS6dpsF5eR3erx3M0cgO1fLKRgDuTVWstRat+6b+s+P5E1SO20e6UhXy9yRhdvoM1zV5ri6lO0d/M00Nux+ypu43E8knjipPFN1bx6Qkdhp0cMXmbVudgRsjqB3PHerekXRhsYWWxMUUCbTJMh596WkVdDu5Ss3sVm1e6g1eC/a3EtvZrs8rzPMAyOeTz/hW1e37nQ2M0UduJWCQweXufB53bv6CueuJ7J9OvYzzNcSZDL17Yz6CtfTYHh06OR7eacwOCzPOO3dF/8Ar0c2moct3oR6yNPtrWCC2jUTyjYZ2BULgdz61h6/d3UunwW08jzwh1KTBCqn2JI5rp9RhfXrG+tZEmjvkYSW0Eq7Sy9sHofSue1K8u20GC2vLfbKrhY3I+9jIwfcUk9UJxepuaLFbRqkdi8luEUpcSA7st3Kjp+NXfD8F59kjmhhQw+Y2ZJH+duTzxSfDyzuGvDp1xYCGRR5hZn+/wDWu303w+dORrbCl1kdlUNkgHmpkzopU72Mq5SZISyJ5z9TGnB/DNZZni1CPZPZOywks/mLypH866yazuQJDuUI2NpI5WiGwFpCFYiRGOdwHI+tc9ztVM53QPD8sKS6knzPdA+ZC4A2oemD2OKv6fq1rDpiRyyjzYSYyijJJB4wBXRwafcESEOPJKY2sMmm2+jxWyt9mt41cc5C4zTb7hGjyrQ5nULJtQwEg83zoyihztArNtNAmg1a0j1J2luLY7kmZcIY8cfjmvQ7W0JffKmNrAAE4wfpVyW1jluoZbpd6FwBxx61UXcJ0jldO8PwPeC5S2QPFuJkK87j7+mKs6hpkk7xfZrdGkLbWlPVR3rrpJLYz+SHKu3VRx+NNkEaGMBsBQQOcZ96l6migkrMwfEGgSarpFppkErxRmQSSzDqu3kY/EVr+H7H7JZx/alBuXQbmb+LHerFvMIzgOpUdMmnzypK8ccUpBxtBxgfj70X6FqmuZsSWT9+Gwq7f4sVY3xyKBvUHGSSetZ5u8RgIm5196T7TG0581RvOOAMY9s0nuW4mpE8SKGxyejVUvS0rIIpAgVgzjHUelULy5TZmNtuD90frUKyqiKyDa/UlfmJ+vajmvoTZF67mmkMf2QZyN0jngKKidoi0X2kCQDlNx4FZ0dwzsYXbbkZAzRMSsbMnDjgdjTQrdzUmuII512qAcc5GQPoKja8JUgkA8gE8A/hVWRWQqSdrdTk4Iojg2GRjkJnAbOOcA896aT6CckOlmeSPCNj5dpX/D/69c9fXgCRxq4yhJYE8DHetLV7+CGBgoPmLwojHDnPWuD8SanJDb7HIVpssQQBtQHk/mQKuNNzaj3MKlZU4Ob6FTUtXW1vrnUVuFN15YSCUAjauOVHHXrzXIWt695fIASiE5IBzj3qvqFwL54olUIq5PLZyc1d0KzMRJIGf71etOShBRWyPnYQdSbm92dnFJDDZI3mHgEBB1HuaqxahHbv+6TB6b2GTVG5IQbUGXYevSnQW5SPzJNxmz0xx09K5HPsd0KDvqXLrUpCABLg4ycdc1Qa6Ytuk3bj69qlSOXcjCDzFDbivQY9CahuoIjIWkdY1Y5I3YA5zjk9Ki5t7KQqXO5MBgGI7mljvipO4hQThO5xVeS3siSRdoenyh+KjaO2WUMxic9T8/UelO6IdKRo212OW3k85AI6+1XYdQxuXecn9KwD5e3IcA9RjvSKd7kISM4yysDnNNS7GboSudM96paHbIGdX3YJ9jUn2hmRkLZY9xXOhJE4ikOM/j+NT2jTR8kc+uc09GZtSidBZoVcGYK+enNa1oSxMcUiGHJVh0KmuYjvW80Lnd8owxGAvtWtZSgA4IJJHI7nvVRjb4Sedt6m2I2UIYyFHQKP8abFDKJ1WZ9yk+uCD7Go7e5Cvv42gYJx0/CrsDmV9xZTFtPANJlxv0LluGU4V1IXuy8j6Vft7qdNzbd5/hYLuP0xWQAykm3Kshx97pSSXF1ZFWs1DjkvFuwSP9k+vtT0sM3J7i0ZZGkheEkcqB8hPqUPT8DWJLHZap+8s7lEkjJXzIhnBx0YdRV2y1WK7gaWFzKFYh1xhlI7EHvUE2n6Tfnz5bWHzuQZogUfPruXFUnYzcbs811fR7fw/oWuxwXLlYYo7dJFwu9m+Zhx16gGk8GaAI9DS5fTWF88gkS5uCEVR2Cg9R707xPp2tR6zY2lyI2xN9oe2HMIdjwSe/Hr6Vq67BrE9hcGxgkuVS4jhYx/MAdvIC+grl52rJdTq9im3dbHL+Ib21uLwQXCyrqLXO10zlVXAC47Yyc1fNxaaHcLFZ2Ul0SM+dMR5jt3Y5+6tWLnwfGNVsraWxultAhLsJMyeYeh9M98VLpfh921SZtXNxHaRxlDJINvnH3x0AHai6egOEos5TTJ5Z9TOo6sjOoucLCBkbyOPlrbsby6vLu03xyzzKzbLcfxOCRkjsOlb3iDTmjk0rXNNtpGjttpnjdcblXOHx64NVvDIkTxXeXFtIIzdwmS2DJwTkFufrRJ6hGMl7vc5TxRpl9J4jljv2AdYvtLxLkAewHc+9dbqUJfwgt1DFBELyIMhkuASQBnBX8DXWW+gvc6/calcKHneFIvwxzj8aii8FwrbahbBIXjZiiSSDL4PUD0xUueljVYdp6dTyvSoZbm9Ece1Y2jLvhMh2x0+ldtZ20QRhFaBZSqiQKuABj+ddbpmiQQ/Y7hIkhsoAYBgdun8xW9HokZuLidN43YxjocVEtTWnRsedQ25lZINQVg8R3QTdsehxU3/CGWOoXNtLao72Mu6Sdz1WQHA2+leg/Y44bd5NqSYBJB9O/Fa0cQgtwsAXa6ZAHQe9Sro3dBNnOf8I5akWs4Mi3UBGx14OMc/ga0fs7NJGQoV88t3I7irsIZItjPucphiOM1INrtgEqmMNzzS5jZU0jLurVJBsCADGOvftTba0WBGaRR1xk9hVpGT7YIYvnY5PTpimSMAZAjAo2T6nNLoaWshqurSKquu1fSoxg3KkBmDZOfQUkLobdtsaiXBy2e9QS3flrGyocAlc5wM1LHboacjwjPm4XaMnjJ5qCOQhSoOFHI3D+VUnumZflYKeuRyfxzVb7c7MHXerKOGbqMU7j5dCYSML13miG8kBWk4q5dFXkUSsCyn7q8jt0rn72d7iUS7mmkH3iec1oJJI0KGRwg2gkDrj60Dl3LBu9t191FG35c9SabLcxkdST05OBn29aoSRNJLE8CO5BwMjg1MSgYCNt7dCsfJB9zRZifcZPdeWyygYLcEYxU772BADbiOMHGaq3UHyfdUdMhjkgVcYqkMRWVAu1QCBhi30q1G4SdkmiAgmHe6qA38Tnp9KbbbpWkhO5lxkDoBUiwysSI4CQp3BmOMDqBj86kX7OJSJTmTy8Ix4HuDT5CLkJiaWZFgHn7GGQg6D0J61LMkihkQCMjIwnzEfU1Wm1KJBtj3b8Y2xnA7VSknnm/1kmxMdAearlXQlu5ekvoVQEIzTAAOuSSzd/oKrSXczx4kRUBdpARneQexPTHGapfaoLUHJUZJyc9a5TxH40jtonGmQ+dMOM9h7k9/pTjYiTsm2bmuahb6XB9ouZEQDOV9T/U15Fr+tS6tqUlzLwD8sanjYo6D/Gs/UtQvNUuTNeytK5PAzwPYCqrZDc5HHOa7aUVDV7ni4iu6ui2NG0ZWm5XluM9e1dJZz7AVX5lxnArH0nTJigeTMathlBHNbkGnBWPGSBzg9azrVkdWFws2k2rD0vrW3BZi87ccRjOD9TwKq3HiG6PFpFFAB/Fje35nirDWB25VcqOcYqMWI3coPxrkdXuepHC9jMd7y5y8s0zgnnJOKha0PJIr6D+Gfw+8J+IfAhm1HU0t9dumkiQvKALc7vl2xkjJwOp9a8y8TeFtQ0DV7jTtXg8mSEkq2MiVcna6kdjitJKUVc5oSpzk4dTh1g4+7+VJ5YUVuvp5DH5Se+fT6VGbQEk8Z9QKjnNPZdjG8tgRgn1xnipovOBwjMT14q+tqS5wQKnjg2kqQDgZ44qlIj2JXSa4VSXQOPUHBH1FWre4gcKFkIbP3T1qzbWu5RtUlif4u1WLjTYpAFaMk9Dng59a0UtDJ0Ex0N0q5Ei9uCCOauwXQfmLBAPHOBXOmCWynHlMJU9DyRU8EqTONjBHU52suOa2jO+zOKpR5d0dXFKwHPGRWlZyKyYxknjA6AVy8N0UKiQ4Hv1rbtnDxr5cgyePwqrXMEuXQ6OECCKNFcFuAoBPQdqiZg0r+Yjr6ntVW2lELgNx05IzWlJKrKWj+ZxjIHpQog3YoDyYr03SHEp4kkTjI7BueQP0q9bKsEjukgKFSTGTwT6is6ed9zFIy+OGUjqPalUCeGOS1fYY1JQEZHH8PtS06CTZ1SaKiC6ILTXxmWQPNHgDH3VHsB3rQttN+wWjQ2bRpNIxYmQ4ySeWrba5ilSBJ2Mk4GPkwPwPrVYadgm4lnzNuI2nogxwMf1rkafQ9z2dtTLOmhXZ7hkYghhhfmZh0qSSwN0h80IsLrhomQkkk859Kv3O3zFMmGkUZXyx0H9aWBZjsluQUWQ5AU/dB6A1BXs0c8llb3dlNbm2kNo+Y87s7gOOPQUr6FZ/Y4LOMGOWAjyp1GSuO2fTHFb88aWoggtg0OXw2eAFIyf1qeDYk0Q8sZHG9ehpNu9kP2cbFW1s0S3b7N80+0sgPAyO3NWIbRpVBmjIlbBxxnJ65qSVkhkYKwL9wDyuaf5yCFpZGeNgecHkY7UW6MEiKTT4JCqTx7kHIQdM57/AI1cntEWPEbqoBHyjkiozKI40lV9+/Oce1MMqbRvbbuO40k7oXK73RnzRiK6VQFMQzgdQc9sVBLcrAW2yY7bAP0qvqF+iXDKDkDqVPQ1k/2qBOc4V+obufxqG+h0xg2a9zcq4Z3YE8nI449KpwXscsJZHJKtjbnk+5rEa8R3d2Pzk/MQMVUlmKSl0ysUnUClctJWsdDf6hBFbs0TAyudpK/ex6VVt71fIA45HC4rDeF2IG/IxlSTV+2RBEVd2d0H3AMD9KFdit7pat7020xVwqK/OcUXzNPCzBW+U8E8YxVWXzHjDRw7FB5JGBVlMzjzbmZN33TsG4tVITX2iOOSMIHdwoYZO3kmoCXjnjlELtHIMbpeRn19KvJamJT5FqzNn5N3U9/5VHqFrdSxhbllTb/CGztGCeRT5OoluQXcT4YO27jdtjGf5VpWEbizjlSKOFQMFpD82PXFOsZIXtd+9GuD8mxc8YHX9Kis2l8kW6KFXld55bae2KtRE1dWHXEW1Y53eSQxyA4c4XB6ECp7ueBC6Rszy8riEbQB1H1qrKEjRXuJTcDgtGSRnB4H0wKqyX0UQYqAikkqCegNFktxcpYeF5IWYhY8g5C5JIx60huIYrKIfKZguCxABB9DWPcas8gKgk+uehrMklxlp33j0JwOfSlzpbA46e8bM2qtJKwj3SjoMcL7ZqtO7ylZLmXbjjapwPxrEvNaSE7YwP8AdFZN1qjzgF3ZmH/LNP6npSv8xLyOjuNVt7YYBBccYXtXOat4sPzxwDLc/KnJ+pPasa4juLlsDcqt2Hf6mpLPR2aSOPbtd2CIuQASfUnpT16i9Clc3t7qAAkcqh4KJ/nmpbaw2IA6Bj3HTH/1627bSnJ4TBU4wf1rTj0948AkqD6c1N7Fxp82phW+i7pRvi++eNgHJrVbQYYUUSQq4HzASHcQcfkDVp1e2KlkbaDkVoLqJaIHGGPAyMg/WhVH1Zq8HazSuipY6VPPDLePEZUU4ZxztNamneHoL24hWeZbG2clWu5xlVIGeQOcmpNNKRksylQ3JweK1jJEy7mbcp6AjIP1FXFp7mUqTUjIk020iVgrB1UlQ+0qGA6HB9fSqg02BnBWJfmPWumYeaD8obIxz3+lUWj/AHbiTICnG3Garli2RaSWm5z97o0MdzJFJGjMp+8ozyPQ9+fSneW1wih2lm2JsO9i2B2HJ4rsdLdLpGtJEglludsULStjyWLdRjp9K7K6+FlmLkWq65bDUWQOYXj2bgeOBnOMir9k3rFnPOvCLtU0Z40PD9y2nyX32aQWSMqGUqdm49ge9ZF7pwXLBSFA6AV9BeNrTX7fwJFa6hHp15YQSIDLaht8G35RkcDrxketeU3iwS6d5X2dkvllyZ9+VaPH3SvqPUU501FDw8pVfeXc88aB1Y8AHPNOCHhgvPT610F3pbxEvgMnXJqbQ9Ekv7iaNIJpm8osvlqTsPGCxHRa543k7HZVSj73Qx4A6DdjjuMVqeaHhUAMWAz0p19ZXViqR3VrJEzZxkcNjg1XeYIhBPzjHSqTktDGUFL3rFJ7cMgLKCfyqjLaJKF4IlXhWHFasrb2+XBBP5Vat7MHceM54yKlNp3RdSEHG00czHK0c4gvtyt0DYyDWvbyPaBTE37r2Oc1b1LS4rhPLuHwFHDY5U1z8E02mXDW14N0XbHp6iu6jVU9Op4mJwzo6rVHYW1yJ0AAwMcnvVxC6EFTlc5K/wCFYVs/lEOjfujyM/yNb1hKJU2hyWwSAf1rexyNmjCRPH8uA3JrKuoPsdy07b0gcHzNpG0n1bPStOzdCpyWUgcYXOT6H9aS4QTb0m+dGyCCOMYqJq60EtWds92jHy7ZgUwOTHtLe/596ri5lWNGjuBEA43jBJ/lzWU93JLMqvtRdvPLHr2xiob1ZtkaQQvOWbG1Y2Gcema893Z9QktjoLS8iimmZAWCvx5hwc9eBU51JDIzzuAzD14+uK50RyrEDHp7Kw43OGGPzPNV3iuRPHut1CsMYYgflSG4Rb3OgN1EYyI5nmmIy7Mv3/empq4a2EbsuD1A4OfQCsNUu+iNbxIckFnFRWsKCWRpLuPzd/3FGTjHUGizvcpQW1zXkvFiuZDHhi4DPuY9hgYp1xr0BEcLxPhlxIA2fyqhLHZkDzLjzJW4IJqkktoFk8u3eTGMZycH8OuaXK+4KKN9dZjlRY0DCPphjz9eKo6jqE7FvK3yHPO0HgVUivbiMs1tZnaBjaI/8aSWS8ZT5jRwBhuIJzn8qXIwVl0ILiR2DedkK3PJyfyFU55IRbNh2Mgxt7VehtLBUHnTO7kg7R8vH9BU0Xlq8kcFum3OAdvT86fsy+cybYNcrmC3y3AJbsfXNW54pWjdJ5E+XhdvPPrVzSrGU3M0RfyhnjJANWTbW1t5iTfvGYgoQC2W9PT/APVQoaEt2loZ1jDbyRZdndx14xzWhFbSWtykkapGkz7fnOSDVV0nhmJs4ncoc+xUc5q9cZvkjkklODzlB36/hVJJBrv0H3dpbxGYXVyQHQsP94fw4FVNJmS088eTuVsYG3Pze351fSOLy9zjeQCAZOfY5qvKY4wQvzIp2qVHaqsKKVrMmm1C7njSWPyw4O0xlT8oHHJ96qJbh2L3Uj73z04B4qtLeiEtkqqNx/hWTcayN58os7D0HAqedLcfIbb3P2K5WWAlRFwSFxu47+1VrrVUCN84XuFBrAmuppQ29toPYVUkmiiY72UkdyetRzyexMnFLU0ptTlkYmNTyTlmOP0qnJIA5NxICeuD/KsS912OOJtrAnoBjisW/vrtbma3uYpYJ42KPHKpQow6gg8gijl6sz9or2OkutVht8FDuxwR2rNFzf6ky+WrCN22qxHBb0B9az7CPDrLI25hyAwzg+n19627fyDuR2z3IycZPWnayE076IItHaO7eG43ebGdsuHVhkdQGBwfwzWkNIiRVEA3MxChDjlicDk++KUTQySmSRgXfGdgAHHsOBU0pEqeXuJBGDkdqlySGqcpdTU1nwxBpNxJpqObzVLdlF5IriOCGRsYiQHlyMjcx4GfrjFn0sx53oqvuKlN27kHB5HB5HbIrcn1u5u7JrfUhbXswCrDeSx/6TEox8vmD7wIGPnz9arJchFQMN2Bt5HAHtVTcZbFUYTivf3/ADKCQ3CnaqZJ+prQRCkKvLgKowfrWj/aGlppP72Cb+0WdgSZCIwh5VhjuOmPxpmj30NrHfXcISe9RUjtklAZYyxO6XaeCQAAM8ZOaUYpPc39pdaRK7JG0e6QYQ89azRbqjMY2BYHnI6VqNAsjPJPdxM7xLOpjAbljyjdNrdciqtxAsal4j8o5OGqZR6mlOfRMhV9iKJGxu54q/BNlQmN2Mc+lZYHnup2gHHytVu1QeYgXcxJ5x/jUrQ1dmrvc6PT1Cp95H3D5gTyPpVe9jVpWVkGQfvA9af9nfAaDnpkdwOxpzNHGrh/nPQqeCK6fI4mle5s+CbDT7S+k1jVJEW201ROIsfNLL0VR+NWfGepmfV9M12PUYLnUhtmiihClLVByEbuWyT1/KuQnOyMbnGxhtK561llvJkycjn0wTTdRRjaxKoc9R1G/wCv6+863XPFOrX0V0738ireAGWJVVUYAYAx/nNUYNEuYtOW/vHtUV9rJF5w8xge+0dqoJELxB5rmFFX5pCDtXjIHHc1rWetRRQxo9tGsceSwjQAsccZPXHStL3fMyXDlXLTRzuqQqY3Cse3ygZGO9bmiapJoEc0drfxR219btDcYjJIUqcEdwcnFc/dztLKrqnDcNjoKkWEDe0jcD14rBStK6Np0VKCjItadZW+o201wW+23FugRbCeYq0uRgOh7kf3a4oRkMC3zFc7lYc5/wAg1tRGW3vIbmDAaKQPGQcHIOaNZki1K/u7+FEtTPLvFuvOM8k5+uamU+aN+ppGjbS+/wCBjW7ECM53yE7jj0rcgbCDzDz2Fc9MDEWCjaMY4q3aTlmG88AYHNOLRx14OLNS8jErFiuE4xz3rG1CyW7jKN8rfwsexrUSZdm1jlc8gdqjePzJQWyMdvap1UuZBzKVPklsc3Y3MtjO1reBhEWw2RyvuPaunsi9u6ODuTPDdmHtWdrli17bGW3GJo+ckY3DqRTfDV4Z7ZreVWY/8siW5BJxtx7mvVozVSNz5/EUnSlZ7M6zILBlBIbnrU7Erbl9p4H41lwO0chinVkdBtZWXBFasbBl4PB9q0aOdPsaxhgUBxeXJyNx2W5JHHHU057cSRn/AEnUHCNkFoipx371sTaPEdqwa9FeRRBV3CNTk4yaiudLuYLQML2NoySijyRlc/jnFcLptdD6eEkysdPtni/4+rkIq8eYOv15qrPYaVuSOS4vXOdoAUDH6/rW/aadPJprTPqsDzGXy3hEa748dzUM+lyyAmW/j9OEAyPWpdN9i4yuzEfTtNZQY/O+UEjLD15zSRJpgLFIpN5XgknBHf8AnWhdWYEZYXwIHB2jH41WeKNkU/bGZx1PQD6etK1uhTl5iPPZpxFaD5eMkZBp0txLa2pCW8CbHyQTjPpx+NV7iO1jAEkjytIN+4jgDHTH171PeC0XTUKRlQzKzIckYxjqfxpXJKtxdeZ5jS3KgD5TsycnHFJD9laWGORZnI4wejDBwOPepxNbbd6QRRtkAgjIIx1/xpftaNDJgKq9scA0X7lLyG2/nBn8uxRY9pQFsdTz3/Sm/vjPsdkQAZOCSTSf2gGTJkG48HI4qs90mzDEEnjPtUtruXFdye8kSSdJt7GTH3z0Y+4/AUTyGT54hsK8heoNZ5mT5+Tz6Cq73YQ43ZB96jmRVjWmnDIu44duATziqv21oAFL5XOAAOKzJLkY6sQMdeMVTmvY4lJL4A4xmldtkuSW5sf2s6HoenSqd7qVzKCRIY1POK5u816GJxGsi7uwzkk+w61iX2tXTbkSIjnHzcY9vam0+pm6iv7qOnuLqLJMm6Ru/P61lXuvw22QSEP156Vxt7dXsysZJSvpt4//AF0up3VpdxxpaaXBZhFG+XzpJZZGA5LMxwM+igVUacTlq4iadkjZTXri/vRb2MQllILhWbaCFUk5JI4wCaz7LVY7q+jbVZLsWhz5htApkPHAXfx16k9q5qeKVpSVRmHbAq7DHmzZzIRNnHl7TnHOTn8uPetuRJHEq85SaZqPcafFqhuIbRrmwjcMbe/m+aVcchmj249sYxUUurPc3ks/mkCWRnKtI0hAPbcxLNgYGSc1ltpl+dIOrfZZxpbXH2U3O0+X5u3dsz67ecelVorZ2vDACpIYqWU5HHcGm6empjHFNSXKjo0vpnwqqXbNaFu8w2vKw/3QaqQ24ij8uIc46nrVy1SPYSzYOerDJFc8oI9qnUlu2W1uNw+bdvzj5Rimte3CKdpwM9+oNQS4M2Izn8KeIxkksCV5HvWfKjpUnYtw6tcqy+exlx/EvDAf1ratNUWVA4YEY/i/qK5cA+gDL3FSwOFk3JjJPI/vCptYu7aszp5LhbhNr/Jnpt6U6IiFw3zMo5IBxkd+axUJ4dGKk9BVmG6LKqyKDjgsOppX11NFDT3WdLe6ik7uIAqwgARo4G5VAAGSAATjv3qokwf5ipVQRxnOKxmlCkbTlR3qQXKZ+9jPanKVxRhy6I67TZ7CKyvobq2aR7iMLFKpGYmBz0PY8A47VXRTHOgDo0R6FMj9KxYb0LFtVwB7d6uwXwAC5HGME96bmmkuwcjV/M9Fs7+0aTfq8ZuIRC6IRjduI+Un6Y/CudldBHhiBj+IjJxVZZy0MUrvFsYnCLINwI9R261UuJy4fB3KegArbn00OaFN8xK80McpO8oUG+PCbizg8D2rRufEM+uavZ3Xi1muLaDETrAio5TqenesWSRZIoQEiD7QvyDB47/X3qVICzb5MBPT/GpUmnoaShHdr59Tf8TeLZdTsX0zTNPtdP0RJQ8cKR4c47sc9a51TyDkPu+Ug9B71oNCLZmW8glCRbTJEBtOw479s9jVyKGOSW4Fmv2XT3XzVinPmMzAdAcdTVNSk9WZQcaceWKKdvYMyCRopJADtLqh257YIqO3snvJAiJLNK5wscalifwFfRPhn7OvheA+HbRPLdPMUTHarMeoJ5OfwxTNV8QaLomnIb24g02SdSm2BN7RvjJ+6Ox7nrW6oJdTz5ZjPmcYx19T5zv7U2zyQSRNGy/eVxtYe2KwXUOvAK9ePWu/8c61Z+I7q3ntbJ4p1i2zTSvkykdGwP8APNcZfW5QFgnzEflXLWhZ3R6mGnLlXMrMwLhSRyOO1Z5dlbIzgcmt2eLzIQAhDdKyLqMrxznPp+lSkVO0m0WrCZnPb5iAeOla8W0ZOdzE1zMDPC7+WG+7kJnrWrb3W8t5nytjGPStFscE466GqsgjIwAQ2RXM6hF/ZeppcxjFtIcnH8LCtSG5JYKBu45qa8tBfWMsJX5iPkOehq6VXlkYYmh7SFups3sk+o2lnfGCQ3U7eUzAHEpx8uPVuxxVlhDDOYYPtAKIBIs67WV8fMMemeneoNEvLPWNH0SzbX7bTH0yBraezui6ASbifOjZeCxyM9+K1PEl3Dea2JoJmnWOCOF7l1wbhlXBcjtn3r0+bm1PBSadmc+k11CgVTIv+0pIzxWlY6jcrMsjzEYBXDN1B7f4VSS9CNtfaCuOCf61cSaMsA0gjbuTg/5FeZFp7M+snOcVZxLdk/2W6EqEYbgkNyPxrSluHkRg75JHasUxooOGjYdc9qRSFjLKV+marlfczVa/Q0JZHeML5jEZ+Yev/wBamGPCAE4XAOP8KpyXDDGBjI4zVGa4bgljjv7UmrblxXMbMp3JtMhKjhSOoqWK62LtfYQECDdztHt6VzxuAE68jp71X/tJN/LMcdhUuUTRQkdLvgUcykkdMVDLJEqbSNwBzwayrO5iuQzm5ht1U4JfczfgoGT+lGrXdmirHpk1zNKv+skniWNfoqhifzpO1rhGMuayRZ+0+WcKExjkE8VVnu1CjzJETB61kbZ5H/fTsFJPQYFNazjERZv3rE4yTk1F0a+zlsWbnWIF4Vy/YBTn+VZNxrMhYrFExz0wKcYgu0AbgPWmFQ752qAeMCovqaPDu17kv2q5uLRQjKhYfM7ckH0x0qKCYw2zRTQ2V0x58y4g3MPp82P0pxiKqqsxz2FMERc8kgevvTcmtmEMLTa95XLlrrGp2kfl2N59iU8kWcMcOfqVG4/nWY9skzF33u8hLMzMSSc8knuavrGhJ+6focU54cY2YYqec8baltvc0jRpxdlEx59LjYLvBAbkZFU5tGidC0HyOTn1Fb0yl9yvyfzqnHEY8hdwHUDrQpOOxnUw8Zbo5r7PLDcKkmFz3I61ZktkMTbhhjkD3rcnhjuQolG2ReQTVZofn2mM/KDjHb3rRVLnI8LyehzF7a3Ag8oSt9l3bwmTgNjGdvTOO+M1NotmkU28tuYKSFz+h9K3J7ZVDAfOuc+1Q2dskd2qqyBXXJJXp3wa1VRvRnC8JCE+ZItsqLGSFYKvJOe1MgRdu4klj2PNWGjzG4VQA2SuOx9KboqIzmOVcvn73cf/AFqbjfY6YvlspISCNkG5EAWh1bcAuRjJ4HWtC/MUc2IQf7pB+nUUlpp9y9q0sME7xg5Z44WdR7EgcVlyvob3SWpnsjKpeM8H5SCPWmiPeCy49SP8KtLGpLFcMO+DTtkZtwUZvP3EOjLhQvGMHPJPOeOOKlo0uwttxHJG44OB608k5XIxnpmolAVl5LZ9O3tViRNyjcTjHFZs2i7FZmw+4D8qsW7BZsyIrj/bHH6U1IsJn86l461BtGN1qXprUCBZkTaNxTaHB5AB6dQPmH+RVeTPClh+GaniT5NwaluYdsg2OrZ7rzn/AAquXqEW07NlAxsuWy2c/Spor2a3cFZGZRwRninygodpDAH17VDAyRXAZ41lVTko3Ab24pGu6Ney1GF2KzqAW5DdhXTWECyxbAwEgGF4+9xnGe3FefyoWbeFCqSeB0HtW7oGpGLbG7fLnAYnkVcJWepzVaV1odLfXMbokjztPIy4JaQ/KB0X3AqvBPuiO4sw68HAFRxR/PMSOecfSpYoos/e6jr2rTmbMFBLQ9D+GnjVtMuf7N1By2luS0chHMJP/stbnirxhpdpfGKys7S/gKiUsoBBk9z34ryVkwAV3ccECpGmXPQ7fQcVtGrJKxxSwsHU9okb/irUNP1GZZdN0+G0BUO6jg78cj0xXL3KKdjFcZ6A9qm88MXHJDdCfWlZfMG2QgP09qVubVlpKGiMK7RuVXC7eRnvWNdW+0/KxJbrmumuo1wc4Jx3rJuYsZckemfasbNGjlY519qOSPTHvQ8pJDfxYwT60t0FCsCMe/rVeJ8D5ufbFO5m4ly0Yqfp2rbtJMknPGenpWFbygMWxyOfqK6HQ7qO3u4p2t0uY4zzDMPkf2OKRMnZXOwnj1+30vRT4TvdIsbSSBmuIZZYUlabcSXJfk5GPpisnVZdQlvW/tmaG5vxEu6SCRHUjBx9zjNO1/XbJtLa5/4RTQp3g+bDxscDv3rlbbUo9Q1A3drZW2mwNHtNvagqgIH3uT1PevSoS5ongV6bhV16m2Yd3lnGPesvxChWyLABS8gGcc4/yK1fNCrzycdqq3wS9gaJwykYK5HcV5l0fXRu9TnreSWOGQrdeQI0LqHLHzCDjaowee/OBxSG/vB92Y4B9KddR+XIQQEwfmA9PpVby933fmAGeDjFRJ9mdVJL7SLA1e+xt83vnG0dahk1C8bIM7An0A4pCFPUqufQ5q/baDqc2mnUY7KcWe7i4cbYz2Jycbu3TNZLmexrL2UF71kYkwnuZAjTT5LBWwcgAnk47/StexsTCpiiyyBjgngt74q+LEW8aXGCzKoUEnke9S2UZwrFdxBJGeAK3inscicbuaEt7bYhZhtGOBjPOKsm1IG5cDdzuPb3pWDMVB/hOfpxVlgggRfX8K0UVYTk2yjKjYZF545FQxxIuV8zcR949hVssockMcdMdao7zLLjOFLZ5GM0nZFavQZdY2/IBjAVT7VWchG27Tgd8YzWmLfdGATgDoO9V3gy5B45wD6UnF3uONTSxQKNguCcn9KmtkJAJ5AGcetTwxjZKCTkH0rbis7PTba7sNf0u/t9YaWKSGUHbsiJG4FTx93JB5/CqjDmepnUqqGiMSODexBXAPI/OrF1AsZQFdzZ5IPet/xRDoVvqwh8NSXc1nGgVprhgTI/UleBx2/CspgrJhx7/Wq9mtUZxrSlaWxln92PunLdAPrVaaMDDZAYnpj9a0buIBQXwvHygVTEMjR78OVUgM23hSegJ6Vm49DWM1a5SdTJwcH0IpQu44fGegNaVzp9zZmD7ZbvA08Ymj3j78Z+6w9jiqk0ZR+ufSsnBpm0JKZc0HRLfVhevqOtafo9nZxb3lvGLM5P3VRBy3IGSOnvWJFBBHBPczXERkt5YNtsNw+0ozMH2v1XAA5x3q3Myny2dflBy2OCV74Pasq52qpEaSKNxO5iMEZ4465HetYy02PPr0mpO70f4HY2S6LcX8MN/YWulWtzZpLBcC5uJzGDuI3KvLsw45HVRzzWGbHy7zyCxFwhIKuux/qV6g+1RfbWuTZoq+XFFELeMA5faOeT3GSSPTOK9h1rUll+FWg2tvo6w3dz+8ur2aNC0ojOHkViS5ZmK/N6ZrpjJTvbocjvRcVa/Np6f0jyR7M+Ypm2+ld18ILKS98XRWFrrd7pizW8jP8AZJlQOygFUKtkMOWJGM4B6CuWujtkkU9c8E0yGWWHa8TyR4OQykrj3B7fhWUZqMrnbXw7rU3FOx3Xxol0S41nSP8AhH1TyIrJ438i38mLPmcFRgZOd+ccdK8xlTCltp5Pb0rpdR1Ka+SD7bcSTJGhUNK5YjPU5POTxWNcIoUnnZyfrU1Jczuh4Wj7KCpvoU0XCn5WPFaE8JjQAnPA4NPs45DFDCUCq7eYzdyMcVbkUMW55rPoOTtNIzHPykLn6UsETPhuffNTTRcjhWLdquWMDeUSUOTx9KhK7sdnNaJWACoeh/pS7jF/AGUjkY4q7Ii+UwVSc8VBJH5cYx8p6detXaxClfcrNMHjYRwRr8wyxyzd8Dk9KgAG8eYqgDnAHFaeh6XNrGsWmnWjIk11KIUeXhVJ7nv/AFq14s8NX3hfUmsNTMTTjlTESQ6dmBPrz15yDRyu3MCqQUvZ313MQpbyO4JeJcfIwGRntn/Gqy74m3DKt6ZqZ1AYbGJPvURDE/MO/OKg2UdDet78+RETk54J9KspcEA7ScnuKwtPk2Nz0yCR7V0tt9lMciqBkpgbjyPemk31Oeb5dLEcc07EnLfhSi6cZBOV9xzSwEglQTxSpBwzupKn36U7NEXRJFcLg5G3/a/pUyS7j1PHc1VV0yAF6GrJJEZC4HPfrVxl3M5xXYR4twJPpj8KyNRieMEgfL0roX5UOOncelZl+m6FiBz1xTkjG/c4y9AUZPQDtWapJIxmtm7j27lI4HNZzYBPv2pIb8iWBR8oBBH8VdBZ7RGMkD05rChGQcA4PStayU7l5JHvSMnqdDbWUl7ELaKCSXz8xoqoTuOOQPWuZMdlp9/Jp9tZaha39vhZxdSA5OOcLtBHPT2r1jR9UgXQIZLd7oXVrZtZrGkDGOFnf5pt445U/XNcH8Q7iGXxnHNAZHjW1jtzNKpV5GQEFiDyCffmuzDOzseTjE5JStsUVuGUbdpB65pGlkkQsc49R1rWuLMdWGAcD9KeLJfLB6c9DXnqnI+pdaCOc8hQu51LgjJBGc1ow6HaMgbzSokz8kTZKAdmz0JPP0p5tzJcfLkxrznNasBzH5McWB1ZqunHuRVqt/CzIg0m3tmjn/czEknyGQvtC4xuzwcntzxW66XWoXIuNQYzXBUAOeAqjoqgcKAOgGKeLcRxY2kkng561q26jyUTGcDk4/TNdEIqOiOOc+Z3lqc9rdmw0yU5G5SCuO/NZkIZIt2zjgMSOFOOB9etdje2YntZo8oMrlTnoetcepPzxFzgPl1zgZHQ4+maTVmbUneNh8eW+dflOcM305ouGICg/dIPB70zHlyKM7k2859e1STI5GWJIC5FG6ZtoikInLDkhW68VM1n5NvbTpcRS7nKtEud8fXGc+vqK7LXtC8L2Xh03Nj4ja91cyK0cCKAqKQNysvUY5O4n2xXM6lHZi++0abb/Z7WQAJC0m9lIADEn3OTTdPlWpnTxCq/Df7rECRMzAqOhJNVb9DG6gMT33DnrV4kAkoNgbjjtVC/3OxVMhVGcUp2SKitRbZwsW8Dkgg46064urm/vXur6eS4ncfNJI2W4GB+gAquoAA2jIHbNWI8OqBST0HIqLXsglFJtl22hy/BwcdagnKxHa3HHy5PJHsK04owByOW4UCvWbbX/B0PgX7NOlvNdWlgIf8ASYMs8hU5UNjJ554rrjTujzqteVNpqN7ng0zMp2H7mcjIp8WoXlpb3UNpdTQ210u2aJG+SQe4p1yVdAzAKV6gdz6fSoVcoAWUFsdPSuaTcXuehFJok1GW1luFlsbWe1tfKSJUlcv8yqN5DH1OTgdM1nySZ4Tjj07VPNdyyWwtd22BZDJjsGOMkfXFNiUCQsw42kA++Kxk7s6KUOVFGYF2jRCsYchQzkgKM9SewHrSXWiy2l7p0OqkLa3kK3Stb3EbFojn5lbO0H5TgNjPtmpL1MxIwxnJGD0Iq1o9xDHa/Y763e4slla4VYZBFIkpUDcH2nIwAMHjnPWqp2tqebjpy59NjLFpNZ3AiaSCZRtKSRMGUqyhh9DjqPXI7V1MNzeSWlvD57mKFCsaSNkRg8kL6DPNZswsI9PtRawS/bn3C+dpNyvzlSgwNrDrnJ6mtW3tpYQikpKrRh90TbhhunuD6g9KpLleg6dRTiuZaoqvbO7/ADAbm5GaS4ilgdBIoIxhgK0JCUOwncAMBjxio9rSo/mMhA6E9TScex1Rm+pSuZZLp5Z5GLyucsT1aqXku4VeT3wT0Fa7xCLdIjlQFxkVVkC+UR1Lcc9cVk7vcp1VFDrGPtGSVztG7gD1qwIWkJjXGeTnOK1vBWg3HiPU4bCzRld+XkIykS4PLcj06d67fWfDWj22j29pNbrZ3V1LJdSTyvykMasPKRmznJ2kDnIJGeAa6I0eaNzzZ4qMJ2erZymj+DJdS8F6xrsoMQtUEtoSR+/VCRL8voOMN6jFZ6xqtrwOMevWu28Q+NbPVtE8mDRYLfU3h+wPcy4d0tcZIU4GCT2+vXiqHh3RP7T8MeI7zyDLPaWo+xjdjdKMs5HIBwoGR6NWipxvaIU681Fzr6a7fccZeIsN1JHFKsyg/LIARuHrjrVW6QK2GYEnBCg9K0b1IVmL2byNbEAo0ygMcqM5A98/gBWJfyPNNnIAXuOxrGXunp0489rGz4X1NdC8T6ZfzYSK1k8yQCMOzgZyAP7xzgHt17VF4q1q88Uazc6rdALJMcBASVjQfdUZ/wAk5rHZ8n5+eOCD1pEm2KYyDjtio5rrlK9ilP2iXvWsVpQVkO48rS2wywSTheCc9cetTPEWzIVI5znNNgi3PJIoOI1DcfXAH61mkbuV0QpjBAJ5zgmtWFyyx5ypxjNZ6qFJ+nT3qVXZRGCScZ/nRYzkr7mqJSMHrgd61hCkyO9m7zRqNznyyCvHOQO2e9c+r4G5/XGavWd9PaPJ9nmdBKvluEbG9fQ1cGluc9SEt4l9Y4sDB3D1AqRo9xJHHoaXTYo7pw+5hEv3+nHoAKfE0RkMRJjdGx8w7e47VpymPtL6E9spZDxvReSh4zWddRlFIb5TjpWhNdJaOBAd+Tlj2omSO9CsrrkDkVpyqWiMJNp6nGasgVWPB71iMmcZGPeun1q3CPtVlCkcHNYiogG3OWHesbWdmVdcuhBArfwDnqMVq2T5IB4xUMMZVsdhVqBBuAAFSLmvuep6DKL/AMN/ZrPULaBBYNA9tLMIsTmQN5hz1yO/bGK434oSxXWrWU8UyXLQxpDNOo4lkC4LfTPfvXX2EU8eg6OdL0Kx1ENETNcG0EreZuPyN3GOOT1qH4j2NrL4c1KU2FpavZtbbHt0C4lbHmRHHDYBz7V0UviR5ta3LIwHZXmDOwChR/KnzhXcIABgfiKz4mAc7ucAAkepFWoQ2C4wQeDnv71EVdHpOVnqEUCsAIxgY5HvU5TyUCKAN2TnGSTUlop2uWHJ+9njvWhf2ZtrdJp0mEUkBljPlHk52ryTyuepHt61qo36C57OxQjUSBFAbaP1OK3IdNuINNtb2WJvs0zlEJ9R3wex7H2pmg6eiWNxql/GJbW3dYYoD0nmYZCt/sgfMR36V0GjWX9pO97qBa5mb5VB+VQMdeO3YKOBSbUdWYTqdVsv6sZsMETFCSQvIY46fhXFeINOe2YSQhWiwxI289fXvXsL2MSQlESPkDPyjcMe9c/qulLNC6Mo2kHIH8/rUc3MXRxPLLyPKY41mhdySXyMY6Yp4lJjK/eIG0Y7AGt+XRzbLLKiM8CHDsONmem76+tZd1Z+WwZAdpzz6VaVj0VNSM+ZAAS2MMcH1+tQrIUdCfmQ5/DtWmIRKh4JQDBI6ioZ4vLVcICp6MB2puL3Q79GQpJGmDg56nPaopA5yyjqBk1ZcRgdeT2piJgBVbJP3RWbuw0KUUB8xsghO2RwRVmNFjkC9CDjFThWhyCGHse9JaIbudyowIxnc3rTS95IznPS7NKEME81QDtHAPasvV2kEixFuSB0461syRlYCpycjOB6VmXMaSOXw4bHRuc1vV2sjKlYqpPMlh9kVtsLOHKkZywGMj8KgnBVWLEjHylQOtW4YnAy4+ZRkHsKZNETGVJzkZOOMn2rF7Gy3MlUwBkA5OATSleQOQm78602iXC7flwOD1AzTI4w0quCeBjnoK55I3U0ihcx+ZDGmO3HtT4rZgpAPB9c1rQWJkG7HTpkVbtbPdKFxgdAR60RvsefVnGUm2YiWm3jbkj2rVs7cIirgcDqPStNrHyceacJ69apf6ptiNk447fhWyjbcS12ElByqkAjHJFRbAQRhVUdwKe8gJ3YYnrkGnEZKr1zyadjVNlWWN2dSRuB67jioJoVXzFC7QVA4PvWkxCEDGWHGPWoSjSyNkDk5bjrntWTSQnd6MtaLc3Vi4eznmt3zkmNiO3f161fcSTorySys/ChWJYbPXJPGD296gt7eQZJjOepANXY3RlKqAD02k1cKiWhHKua6MyVBGv3RgDBA7V1HgnxjD4c0+9sb6wN1b3DFkKMFZCy7W5PqAKxJIMgggkZrPeNlLABSSeMjpWqbTujSVCFaPLMh1IwAoYZZ3jWNAPtGN2QMEcdgentWDLGZWcRjJJxweK07pTvw5y2OnbBqCS3DMPKQgd8HvWFT3jtpe4iovlpAIz/AKzocUreXHGFD/e5AxTprfyQGJDMQcmo44w+3AA5rJm2j1GSS/IRhgrfpTwfLsGQOMzOD8vYDnB/OppLQhh5gXBIxg9agu/KAZI85UgA9j600rEXTdkQEFSoGCAeauRR77fC4znOWFV7GNppPL6LjLH0FbEUTwQl/fCg0JXIqStoUGbHykcjr6ZqJc4DBunOateSTl8nrmmGAlcsOeuBRuCaHRXBQhskH1qzdXhmBlZ2aU/eJ65rMbg4IHPqKp3svkumGOBycd6tJ2sclaKT5ka8d6u8gsfwNS+ecko3B965VbvZIVydoPAq6l58gPPXpSS1JnNSRo3nz8hjkdAeazvKPmZjAzn9KnFyXY8ZqWJFkwcY4pmMdNCWON/k8wAFumDV20hBky5x/d4q5HbLNpiTEjKHZn1p9tCAoIwOO9NwsxJ3R3ugQWFjpiA211Nc3Gnveu8dy0aybWIMYC+gFc18RIYbWzl+xwtDZzQRzRRFiSNwBy2f4vWt7TmtdN07SXuLvVDMUa4iFsVEcJJIKjd345HvXMeP7yO+hupopLmQSbQWuCu/Pp8vGPTFbQfvI5JK6k/JlWCErMnAJYY4Per0UTRsjs2MH8ql0+3AQPLncfu4PWtJbaOUEjKegI6VCdjssiGBVDf8tFWb5WYjHBxnB9a63x/qsyzvokFylxZJGmJGQKwBIIRSvUYC8nrTNIgS+XT4ZYZ50t422wrGfKiIycsT13YyTnHasDW7aS3vlaVhcPJEHjkjbAXPzYKnkYBAxxW+0Dnjy1KqculzR0ISXUNnpkwU2kc7XTIPvSMQFC/0+ma76zsHjBhACCP5SB0Brl/B1t5481kQKh2KwHJPUkn27V3kKKq7V5X0rKWu5y15e9aJVks024OSTxxWXeWqxtuADAEcMMiuhlyASRzWbcIWByevTipM02jnPsW+/a4t1tobhh5bQlcpMD1ADcfh+XpXI6ravHNclLZo7eAjcOWMOTxlscjPHNd5c2ocsGG5GBznuayr7MnyyqxuApEc6qGYjGNrA/e9m6/WtFJNWkb0qrg7o4ALFdu8pkjLEZIwFJPpiqghAbaSGyMYzjHpV7VtNLsD0kQBVKn7voPoKp2sOZFhkL+cvoc7vr6U7tdD0vaq17jpNKdYmnEQkiThpF5CmqQgypYcHPHtXXaTocsspV7mO2jIwd4L7vbaBXQ3fhq0tlhmknN3M38TQhVA9lz/ADqZbXSMJYxXseYQaXe3hxErup6u3Cj8a2NO0NrKJmmw8eBu8k/Pz1wO+P0ruI7IbVBA24wPT8qGsEJJxg9Mis4qSfMZSxTehwwEU0IMKTJGw484Yf8AEdqwZbN45mWRixPQZ/KvSdTsFuJZLhkAldcb09cccVzd1Z/vDFcxss6cZPGPzrSUud2e5vQxCtYxvsgjh3EN0Gew/Os6eFiMRnBIwcjOPxroriJgnluWXjBHGM9qpxwogPmRjOfb+dE1fQ6oytqZUVvszkEKw6DtV7TNOkuDkLiIHmtDS9Ka7YPINqZ44611lpYJHGNq4UdB3rFU77nLXxNlZMpQ6Va2e0PHFdzAcpk+Uh9CRgufXBA+tQTacssy7I4oCSANmQoyepyTxXUWVhNfXSW9pHumYZxnAA9T7VX1SxksrqS1uF2ypjIHIwRnP61coO1zgVVX31Oc1a32xuskYWaMlHT0PqPr1rmb5DGDhR1Gflz0rqr8NHI8oG9eAc965rV3Lpujxz04pqalGx6NCelmZwOQhBG30HSpSzL2yxqrBnAVjgdP/r1t6Tp0l5OBk7U6uf5Cs3OyN5yUdWVrKynu5UjjXLk43dhntmui0/RBFgEEkckkfyrotN0+G3tMLGokBDCQkk49B2rQEOXJOCW5PGMms3GTOGeIbZzz2OzIRRhcgNjlh71mX1iQQ6KqkHqO9do0OFORx2rN1K3VlO0YU/dz0NYS0HCo2zjxMN2043Z788+lVr23MmCBhe+e9Qa7us7sOnQ84z+dNW78wccDqf8ACuylUU42Z2xk0kyCSPacuu4AYB9f/wBVVpHKD/R8Z755qxI6chiw9/aqNwrK25eQf7o6/wCFEjpjZkTuZptkwLBRgkcYqOERCQ75AiA5DEe/+FKd3OSFB447VTklzIc8gccDrWTNVroh11Lu+6544XH86pxq0zCOMAvnjB/nUq281wSyKSCcZxxW5p9mlopYEtJjJYikryYVJxpqy3JbCyW1t0QfO5OZG9T7e1KV3TFew4+g9asKxCeYc8DJFRQb9shwBuHLHuPatdkkcl27tkc0aJuVTkD9arbAmFUnHXP9KtkKGGePSom5ySPoKppMauU5YtyM3Tb04rnNelELK2eSM4rq2wY3GcZGK4bxnIIYxnpjHFOKOfETtFsx1vi05IJz9eK0ba8XgmQEHqK5C3uCX549K1IZiO/PoauULHn0a/OjsrGbf1OPxrYgIKLgH8q5GxmHTPvXTadISq5449ayex1I37PdsCkts647VrwRhwOn41nWCnyhmt7SjHbTrNPGk6J8xifO1uOnFOOxUnodVaS3cWi6dHpmqabZBIz5sMjoGL7j85yD1GPyrhfiHNcGRReXUF1O7IPMhIKkAZxwAM10D69Y5BPh/T8n/ak/xrkvGVzFeXlt5NrHaIwJ8qLJAwOvPetYK80cVVOFOTtb7jqLK2aS6aNdyrGcDPp0rfSzC/w/h0qPwla77USsCSSTkjrXQGMdOv1FYKF9TStWtKy6DNAuLyG3vIlha707aftFupUyICMb1B6gegrE1BLR7mxgsple3nkKTBB5T5kG0ZH8OAF6Egkdqu36yRfPbu0cyjarKxUjPvXJStJc6jbW84HzOseB0PIz/Om8SoWhIVOPM3O56R4VtpIdKtYpSFKoGkHT5z1rpYscBQQfeszT3+UBBhQMADsK006j9RWs1ZnBzX1YkmcAdR0PNQS42sp5OT+NSz9dw7c/SqztlRt6471IXM+9cchDz/erIvk3Dj61qTHLZA/E1RnALHkDjuOtW4jUjkdbiuJRvt1QzDg7FAL/AIdM+/eo/DE8JtGAWLzJD5kzD5nJ52oSegXGSB3OSa2r22ElrIm0g5xyPWsXQ7RYYt+0KXcNgVnByU0jecrwOntUwnToOoPWrUgJjALFiSOp5qK1KqmBzU7Daq567hyfrWlRWVzGLux4UAdOPrQYyPenR444pzdDmnHYXmULpBngYz27GqetQrNbIZpBIw5jkxzGOwJzll6jB6Vqyqe5J96zL2LCuCTx6VDTsaQlZnJyzAqQ4JXGAOhzUFsv2q5RUjJdm2qrdM/WpPFEJgjNwhyQMNgdc1Q8Iapaan4it7OJ1FxtZioOflA5J/OiFRSfK9ztdVqDkehWmlQwwRGFi20fOWwAzZ6qPT+fWpfJ2jkjAFa+wSRsVXGTn8Og/lSRQp5qmUExjqBxu9vauiULPQ8rnb1NHwvF/Zkct5cbUXy98pYcon8K/UnnHsPWuQ1e8l1C+nupAA8rZxjoMYA/KtTVL150W3D5iQ7jj/lo56sf6e1Y0/yqRn3xmsqj6IqnG0nJmTddZUJyGX8jXF3xNrcshbKk5GR+tdpNt+0ruztzk8VwPiu6EeuG0xh1UMx9M9P5GuWd4rmR6GHqXlYt6bZG6vhHHnGepH416RpGnpb26IoA2jgk5rF8I2ipbfKFLSgb2K/jx6V28cG0YxyOOK0ow5/eZniK13YrJDwST9e9aFtaAW0k7hhH91WHc0R27SOFQfOSAOK6rULJk8OmDb8yAE4/nW/szkdW1kcK64DBgQAOKqXx22iR85LlgPQcD+dasseVY9j6Vn6oreaqY5VQOe3f+tedNNM7ISVjynxrNsuhGCOufwrnoryWPIBLRt261Z8ezs3iCWJWH7oAH8qx7YMdvLevWpjeOqPXp25Fc3o5vOQN91h6VM29ojlhmqtjFIzKFUs3fAziup0rQrm/KxJEzO3RFGS3vgdvxrrU0zOVWMN2cubaS4B8vK+vH9atWmhMimZhggfePQfQV3dhpCxSRp5ahiwDAjPejVYg32pzghsnpisW7syli5SVonBGIGTO5mB6AVatYt5wBx0zTkOHLY5WhbpUBYKfYY610JJalKTe5NcLGikADA4wKqMxGDntgA+lBkZny8ZXuPSopXAGRznnNT7RSNYle5kIkVV5z6dqawO4AHnrnNAVWYnPOeTnpULuu7vgHBNTbqa3ROzqq4AyTXl3j69Wa7SBDwhJYD1rt9Z1FLa3Z1PIBA56cda8k1C5a7u5JWOSTx9K3oxvqePmVZRhyLdkCHBGK1LaTO3JGKyas28u1h7VvKNzysPU5HY6WwlGQAACe/rXYaX/AA4YHHFcFZTYcHgdzXY+H28xweQM9TXLJWPYpyvsd3po3IOeOK2IporeWJ7iFp4gctGG27x6Z7VjWDgbQOp71a1BwFUdaSemhvLRanZadp0Wo2qXNt4XZrdwSrNqBXIzjOD2zxmuD8dQfZvFIt1tRaeVEu6ETebsJGeW9fbtXU6ZqcM9tp4nhvRHJayaXIyR7kOTlWT1bJGVrlPGVyl1rUogWdWggjtma4Ty5JHVcbmU9Cf6V0UNXc8vEzlbl/z6fM9Z8PweVpNqozzu5+mK03+6aoabKW061J+8pbP14q5u3LuPXp+NSrdBTl7zZSvwGjPXn2rm7e2b/hK9O2jKOxPT+ILwa6m4UlG596z9LjxrtnK/QScg1zVaSlKPqaQqtRfodRpjfu0x34zWrEw61g6YzAlScgYrWhyRzXZUhqccWkWXbjFUZWK5AJ/D0qWSQnk9cHpUKo8qt5aSNtGW2gnA9aiMBuSKUxJHByTVSUAirsqtgMOSe/Y4qzaxadJZrHdSSw3jsVEhPyKe2fb3+vNaqInKxy90TIXA6kAAdMmsjRkaK2ihfcH3sTvHueK27m3PmMsmzIfDHPy8Hnn04rz/AOG3i6x8VatrNlaxsn2SQyQkvkywk43fgccdgwrFwtNSNOdctu56DaNudlIJHWrkjfKhI43CqNsCXOBjJyRWl5Ek8cgiAZ418wjrkDriio9Bx0Y5Og9+gpcetRRtkDv9KsBXP8JHvRF6AyM885Axz9aq6hEwchlIDDcB6irxgmAI2M3qcdKl8TSK2oPskXyI41jjJIAwB/jTumriV72PLPijK1r4N1WaN/LKQnawPIOQB+pFed/szW7Xni3Vbh13NBYEA98tIo/pXVfHzV7CDwZNYQXtrJeXM8amGOVWdVU7skA5A4HX1rjv2Z9c03RvFerLrF9bWEFxYELNcSiNdyup25PGcZOPaqoxW5nWqO6imfUUbKFUHqBUV1OUXYrYyOQK5/VviL4JhmlnHiXS/K/hSKTzGAAx0UH0rgNe+OXhi2kK6dDqGpN/eVRDH+bc/pWtSV9iYySWrPR5T1bHFZ84ZnJA2+/WvDNX+Omq3BK6XpVjaJ6zM0zf0H6Vy918TvF16/zay8QzwsESRgfkM1g4NmiqrofRbRlrhV6gDmvn34jao9z421fy2JRJfJBUnnaNp/XNLpvxL8VWrhn1QXI9LiJW/UAGuXMjSyPLI5d3YszHqSTkn86XL3NoyfTQ9s+BXi2KXHh/VJ8XoJa0d2/1q9SmT/EPT0r6Ba2VLSGbehZshkzyp9xXwkoYMD1IIKkEggjuDXoPhT4h31vKINfv7uaI8JctIZGT2cH7y+/WqjPkWiM5wb6n1ZYzrBeRSAKwU54NdPLfQXVhd+TICyxtkdD0NeK+HNUF/bLcaddRSK3P7tgVP0/wrprTUZg22eMqw7g8kVn9Ys7SQSoc+qZoSr8g98Djsazb/Blkboq5Jye3StJLhJwCCOvHtWZqY/cMPlHmttBJ7Cs6kObY3UrM8o1bSBeanc3bsy+ZIScfkBTLXR4xINqce9d8mmyXJ8u1tpZ5P7saFjj14rHktTbzgSfIzEgqeoIOMEdqmeHcTSOJburkmn6cqhSAMACugsIPKPyKc4/IVJpunXEliblLeRoF5MgGR6V0Og2Ec9hqMuSJYot0Y/M5/TFbQoWMKlcw4F23MbHBw4P1rL1aHNtOOBw3WugMQDqQOeuPxqjfx5aVWHUms5wsbQndnleCZnAB2nitXS9M34lnXKdAp7+9XbKyjyzzqDKrE4HQjNbVrD8qk8HtxWbbasjodXSxUk0+JrbHlgelct4g0ryo2kiBXAz+FeiCLKjoccGuW8fxyQ+HNQmg/wBasTFB+GaSjd6ijWcdUea/bFjJDMMA84NU59QRVLbsKOTXHf2kxVd8vUc1R1LVpZkMcQwOhb1FbwpyZrVxkIRuSeJdXa8naKNj5YPOOhrn6U0ldcUkrI+fq1ZVZc0haVSR3pKKZmaVhJxhjXceHZQGB3ZB5FeeW0mxwc966zQ7sRsmDjBrnqxPWwtW8bM9J06cPckZxjB9ue1XdVdiq+WCzeg5rmNNvQXGMCtV9Xms5YrizlaKeLlZF6g9KwitTqnN20Ol8+z1rw/psDaudMmtIjC0csEjIfmJ8xCnc55+lYniu/i1PW4ltmnljtreOLz5l2vOyrjewPc+9b1lqI0rQ9IN74u1fT/PgMq2cFqriJNxGc56Eg4qXXtEE8k+o/23Pqs8aQySNcQBCYZAfLZSDyO2DyK6o+7E8yUuafkdpp7MgCg8A/0rWhYE49RWQoKTKoUZZfTqavWbDzTt4DcgGohsXPcsSDdnHFZ7sUu4ioJw2M9Me9Xpr+yspBJeSRMFP+qJPze3FebeOfidpOjNc22k2l3d3X/LMSlUSPnjceSSPanNxe25EVLqj0/TSCzkk9eK27YKrp5wYx9SFPzH2r5otfjzfQRg3OgWs8+PncXLIpb1AwcfnVfUP2hfEzqyadY6TZA9CY3mYfixx+lb3uYt20Z9Yi6sVX/R9OZ3BwPMAOD+ZNZ8Ut1YgmEGHK8swAHH1r4r1f4q+N9UDLc+JL9EJ+7buIR/44Aa5e+1nUL8H7df3lznr587v/M0tSOeK6H2zrHirQdOITU9e0y3brtkuV3f98g1yOqfFzwLabgNWlumH8NvbuwP4nAr5FLewpCciizF7R9D2j4gfGn+1dNutN8NWMtnBcIY3up3Hm7DwQqrwuR3ye/SvNfAniObwp4ostXgjEogYiSInAkjYYZfyPHvisCiiyJcm3c+jLn486BET9i0LUpwRx58yR7T14xnPpWZdftCXKMTp/h+KBxyrveMSP8AvkD8q8Go/nU+ziy/ayPXtS+P3jC8eR0j0i3kfq8drlv/AB5iP0rmr/4r+N70MsviG7RW6iFUiH/joFcN3op8kexPPLubM/inxBcHM+uapJn+9dyH+tZtxczXBzPNJIfV3LfzqEDnFS+X1707JAk2QmgVKYz16UeWQeRTDlYwM3Y9aTOetOKntSbe9AWEqRR0oVDnpxVgQ9B170my4QbEQ4wBVqEtuxxj09KfHbZUnjPqanWLCjoaybOyELLUao3EYHPpUiRksO46dKntomJxtwP1rRggUj7pDehFRc0tcseGdRv9EuxLplyYmJyyHlH+q17b4c+JNpeWiw6wqWlz0DNnZn1Vv6GvG4bYBQQOcfjUwY4wepPNZSY1T6n0TYeJdIkUkalYBuuROoH86d/aNrqMxFncQ3AjOGMThgPyr5z2RndvCE/7oNdN8ONZ/srxCtu5CW138h9Aw6GtKM1zK5jUi1F2PamuLiJWEE8kIYYIiYrn64rldbDhy6SMREdzJjluOx9a2rrUYYhyc1zWpatC8b5+UA5Jreu9NGZUnrqjpfA/iH+0NIhlt/NhSZPnj3fzFdZENse5TgEYODjIrw7wl4otodYfTVZUaUloTngnuvtXsmm3gliXdww6g1NGo2rMuUUti1IgPrzWTf5MwA9a2JmBTeO3oa5zWLkQRyyEn5FJz+HFZ1VoVB2ZjWfksu4OTKXOVxxt7HP58VsxxRrBBIs6M8mdyDqmPWuZ0vdIExLsYMCflDbh1K/j613fhC8tLO7mTUI1a2uI9jMVzt/+saikkyqknFFOMDB6ZPtWV4qthNoN0r/LhD82OQMVuGJIppUibfGGIRvVe1VtR2tbOrcqwwa0lASlc+Pp7WNAeQeT+VZVzwcA5AFdZ4+01dF8S3lojbowfMQ4xgNzj+dchO2457nvWkdTKq0o2IDQOtFKK0OMVhg8U2pW+6DUbUDaBetadldFFA54rLpysQcjilJXNKVR03c7Oz1DYAe9aEV7JcSDHOOR7muJt7p+FGSxPAA613Xh6yaG28xwPNI4B9TWPJZ3O11rr3T1Lw8kUfh3TV8US6I0exjYrewSSyiPcepQj5N2cA5rRvptTilvbO++yMbho5WngHyvEF/dqnogHOPWsnRL7TbvTrGDXdPnmns08mOa3mCFo9xIVwR2JPIre1qSQ6jF5lukKNbxmGNDuCRbflGfXHWm2ZQVmb17Okal1/g5BrKv/EapG6QxS4PJy2Bmqs0tzfFnKYjXqB0rE1VHEZjiUs7A8LXmKpUlK0Op2csErz6GR4g8SXcgaG02Qg8F1yW59Celeda/an7G75JbqSefrXbyWZGcjJ7mue8TweVp75bG48VvGnKElcyVVSTsebScEkDBqEk81amhZpxFGrO56ADr9Kq16KPPqbidqQ04AdKB19qozEApQOaPxFOB/D8KAAqQAcU0inliQOelNxk0DExRtJ5ANLjkfzqRVyecmkNIiC9O1OCdM5ANOO0E1oaLZpqOpQWzv5au2CcZ/D29M0hpJFW3tzK3yn7oLE+w5P6VP5QAPYnkV1vkW0uovrdksT6VIHieJNqGHIMQix0zyrKe4z3BrlwuyGNnDDJKjjjIx/jUu5vDlsRMm3qDTNm7gZ68etX3RVt/MYko2MZGMcn+gzUKqNvUEeoGRU3NOVFEpjIBy2egFSGGPe20SFccE4B/KrE3lny9gKgKFYk9Tzz7Z9KliXCsxw3bHv8A/qqriVNMhitiOQQcDODxU0cRyOevepxjcJCeP5D1pGcCVEGCjZ+YcHI6ryce/apvfYv4CWBcMeehq8kYIzj2+tZ8k+0RsFctKAVULjj6mpra5maQrJGqRrgEhtzZx27elS07FKa6GnBAAcYGOv0q9DH8wxgA9c1npczllVI4cZ2qhYrk/XuetWra6VzGu1lnf7sZHX6EcGs3c0UrbmqIWMRXOD13Y6D2pskQGWU/L61PBcRKHkGLpYwDMOiDnAUHqRkjmo5LwSqXfAOPuoML+XYVm0yk7lNkBkAG/nj7p9M1BcLt2/P855C55+uKkF558jrA7xxK+DJwC3qB+OOapXSWwX95Ejk5J3cnGf0pxiF7mrD4p1SBfJeT7Qi/KPNHI/Gs3U9fvryMoz+WncLxmqCuxkiWJJJXPKgAs7fh1/Gkm07UPm3Wdyu3qCvPWtLX3J5YrUpxy+VcpMzEFWB3Dr9RXtvhjxjP9miiunYydpNu4EY7968PMkEbkNCXmXgrISFX6gck/lXXeENRuL1Nq2ibYztBWIKn03ev40WMqjvqj3i28SwmMtdXECLjnnFcX428QtqVt5OnsyW27LSkY3Y6AVSCyGDdJCeOuDuH6dK5/W7xY4W89gQBlIwcZxzz7DuauVNOO5z+2k3aw/w94wFte/YrqQbycI543GvStK1zLASo23sTXzDe3lu9y8uPtMjHOSSiD2AGCfqSPpXb+D/HyRlLbVx5aj7ksYyAP9ocmsfYuGsTf2qejPoy3vRIu4Ec8HFZXiXV4NJ0i4vLp9sMS7j9fSvPLz4m6Fp1sXt52vJSBiKIH9SeleUeMvG+p+J5tty4hs1OUtoz8o+vqa3jeW5lKaiUPFWty67rV1qEy7GlbAX0UcAVhMc05nJPPNM61qlY55SuFOWrtjABY3l45AWILEgIzud88f8AfIc/UCqOeKZCJeWR2yo244J5P0qI08KTA79gyj8wf8KjoG3cKSitzw7pH26cSTsqwrzg9W/+tQCTbsix4Z0wmeO4uFBB+4h6n3r0rRLa3F9EdSMwtc/OYAN+3/Zzx1qHTtPVIeirkDAxzj+ldJpemNe6hb29qiLNKQignAPHUn8yazZ0xstDorKLwvEBsbWsN/eEVGuahDfajH9hEwto4EhDSAbjtGO1QrYaKX2PrzFl4LR2bmPPsc5I98Uy/tjptylqZEkDKJI5Y8lZEIyGH4VBcWrlvxB4h0zw5aLBqFxFDO2dkQOXfPtWHY6hPdXH2mEmMsNuB/d9DXhN9pury6rNJclri7En7x3fcSR3JNew+GZIrvSbdL5NkkgxKoOCu0ZyCOnNb4SjFSv1OLF15SVuhtzW4ZCCuOOeK4TxmqvKkC44+YrXa3uoJbWccYnM8rfIJXXbjPTcen41x+rWjxxyzyYLAFiSeaMUkmrE4WozzWK5a217z1UkxByAADj5T29qyR045qybhjfSSqcFtwz7EEf1qPzdygOqkjgMBgj/AB/GhLQ1buyPFGenSpDE+0NgYbp6E+n1pgBGTjkdj60yRVQtwOaQj6D8at3IhDJJbv8AI6BmXH+rbOCPf2+tRohkjcxxsSo3H/d6E/nigqxCRjnsaeiEqWBXAxkZ9aCgBbLZA7irEaKy5VWCyoQMDow5x+ePzpDjrsVT1wc49BUiRjyi3J+cKMc5yD/hTxaTeaI1QsSNxHQjjODnpU8dtM0beWw8pm3rhsAkA/8A6qV0NJshtxGBLLMflVSFQHG5umM+3X8vWktXNtH9ojYiQho15wRkAZB78E1fsbNxaxTOshCuXVVA46Z5PTj2PSp7cyFzHaF4bUKeMDJG7ON3fgcnijmsHI2y7a6taWXhaDS1t/MnmnN1O7fKUwuFA9/Qnpz61lSbhdP5h3J5oCx56B9xGCegH9atW8aXl2zosskBBcsE3Mx9yRgDv61qwWgtbd57qAPFnzYFPzIASTk+oHQA0nMqFPTcxba4ZtCaFM+Z5hlIILYO0gcY6YJxUBWRFcqD5WwE5OAAMAZ/OtaKMR3wWxiMkoQM6DcrBQOCvbp60l+VvDaRwuLjMxZvKYbiQvHJPA4PNTc1S5Y76oxrS3mltztQuUcblU4bjOR9e9akWmXLQGQrgjKAlDt3dQMj1p0krR2RZoWQj5Wn3CYKBwCdp644yaktbW4mskllmuZlcoTEAMOuflHt74NTJtocPd0QyG0nV5g67WhwkmRwG6EAenTn3qv5T+crsVVElyGk7nnkH0+tdPbaWsEjsPMaXaFc9TtGPz/pVe7tJZJkkmsLWcoCPKMuXA6kYIC5GRzn86mMtS5p2szPG1prqSCRrmaVfLdz8wL5+9uPbHXFNKQEJaWXlySKQZ5S2QEHbIPUnsOfpWmulu9oVuJLKytWbfsRNyj03MSB9RjFXNHtbOWzu47TUbOWVzuLQQojJgYGF9ufzpOVlcIq7tsVLGzRdVSNg0kW12jmMYTcwwGCjngA9TzS3UUzXMcUFtDHHIWRGmUs5AHzSADGAAOM8k9q6PZbQ+QrxyTzOdnyxj5emWbPQEU+5UqJjZxqWYYzIcAAfqPoKy5zVx0sc9p0UEFy0T28l/KnCJu2qF675GJwGPP4DpzWu9pbR2Cpc+TbmbmWV5FDRjn5UyQCOnPWs7UpzazDbqyREt80MCqDnoOOSBn15qncwN5qKk1xfalOmJWcJtVQMc5X5Uz6EZqlrqTfQvpLpduoiuRbPHINweC4EgUDuyr8wGM5xmq1lptnqlzJDDcpK2NzSjiKFBxtUD7zc5wTwPfirVlblYxBcpaqEO7y7aPy0kb1Y9wB2pZ9PtojJIWjj3j5NyhY15zyuMNz65o5oopqRLL4Zt2jVVvrhVuG3t5KhjtJ7kdgP4aqReEbE3j28WoswIZChUblYdST6Y55q9p17p1lCYbSSW5uEBd3t1Y8d3PGAKvafvVGhhiVI7lSzTH5y6kklie5ycenNS5NFKKZgnwo8qRtLdTTKd3+sIzs9QeoBH86S/8AB1zdyRTPqix+WB5YWPCIP4VRc8f1rsJ7hcGFZUUBOZWHAA9h/wDqqvb3DSuZHkeSHGIpWUZz6gD8hQqjKdKPUzY4dctoo0tLyCa7kARWaIhnwDzweMDk59qztW8P6rqNrIlxc28lyxCvKEK5TOQvoOeSQMnAreaSO4vHe3t5zdoiIm51URBed24dASeh5Nbls07RbrsgueygAe3+FU6j6ERowfQ8hPgnVI1K77YFupLkEj06Utp4M1RFldo4JGKlEUSgcnjOT9a9ihtQY3d0YTM2S3X6AdsUxrOMRO7RgDOMD5QOeD6n6U/aTB4ameRf8Ijqgtpj9gjE7AJGFmUhQfvMck9sDj1zWZc+FNYil2fYmOAMlWGM45717SsDHBRVb5iOBjH0Hak+wxMEjhJ+Tuy4z3J+n1oVaS6C+qQl1Z4lF4b1AYN1BLCmRwE3ORnGQuR+pGe2ahfSLya7WG1srnngeYAOncnoBjrn869wW2a8XzfLlIZt4ZwBntn26VJ9nRYZIVQBSv3fX/63/wBamq8uqJ+pwto2ePapotxa6HbRR4k2lZptjZBaQNtH4IgP/AzWS2j3gRGMYAb7o3DJ6f417LqkAiSQ+Q880h+UA4DH39B70yPTl8oC/nWWU4CkoFVDjonf8ST0oWIdthLB007XPJtR0uaCDEcZ2vcS7QSN21MAZ/M1Qksp4o1DRfNIocc5+XtXts9jbyW0MYVTMgYZHGQSeBj6nJNUrzRLSSU77VWTIwTxkYAJGPQDH4U1iBPBx7nkMFk6wtdXCbLdDgb+PMb+6vr7+n5V1fh57CfaJF4Cnocbf8a6K/0K3uwiG3j8uMbAoc/Ko5wPc5/OsS/8HOzebBOqMRhVLHgdAOnoK0jWjLRmE6EqfwnSadyVEEjun3VJ9q6TRbm9tb6C4tAzzxOGQhdxz6Ed+K82it9U0kLG6s4PRogWX8cV3nhnxO0WxNzx3S7dksJw2QeBj1zWyUbaMw5pJ2kjt1vrJxmTwrtkbBIUyhM/T0/Gs+/mnvtRNxOojcKESIIUEaAcKAecYrv9Pe+1i8je/l1ixjlZQ2FcA8cuB/Dk9gPWpNc8NaPcs72/iSO4vWUR+XcToHJHbB5J9F4qXBlxqxPkvwfrTS67IL796bpi3XGW9K9FvrxdInt7i4sroxSFokVUByxAPUHHQE844rxW0k+yzxXEMgLxsG2svpXqieMIb3RITagDVYHEiROwCgqPmJJ6gqSMd81tTcUrbHFVg3JPdHduLfUbRDJ8olTPlzptO09iOh/DNcH40nbSNOmspt5SaMi2k+83HGxvXHY9xViXxPp0enI1trsxmeVf9GeJVgKt94AFMLtJz1NcH4ju7vWnmlM4lt4ZSseJFUEY4KoTnt70qsoyHQhJM5p4fLK7nT5hnjNTpDmZBDtnLEAImck/Tg1t2mj6neJ5S2M0sePmY/IXwf7zZAxnGBV6SKyzDbWtjYi7YqoVZjIF9XZx0HtWPOlodapvd6GCow5t5FcZwGhI2sD6jPGasQ6LM2WkbY6ZO2ZcIQO5bgDr09q6PToFMzQssWpIo3IltbmRcnkgP0z9TWtqOp2sUCWtzYyWzRAPDDNEjKgB4YqG+vJwKzdR7I1UE1ds4jTdNmEiu0bywBgfNFtI6Y74IHX8CK07ux0hCj2t/DCjgrkEswPcMpAIx7+tb2m6nqt7KBHdBonPyutsMKAeBuJGfoPzqa6lubS+iunubCXYphnJASXymx87DJyARn9KTm2/MpQUVcwItOBgis1hN3MGMwS3I2Bezlv4T17mmX8EWnkh1jgJBLRSMC+fYDqDWxpPmRpqGtXtmxWfa1qXTHyD7oVfVuOn4VgvBqdzbNcyxRbJCk/KqXkkdxtQMBkduCeBR1swUmtUh6wAyxBzPFcPFtH2iRWYrnKlRnoAO9Wo7WVI9vlblwcmParE5GWAbgHr+tM+yi8s7u1ghkF9CrC8nuCCQ4HCqc9yDz0AFaWh2NnEls0wM07KuQ7syu2ORxweh5FJspdkM0+0jNtKz3Db4W3Etw6kZ6j+8Mjn8aqXyI0ga4djb5wluoJaVsZLEdwBj2zWtHG0slwLRLZWhuGjA+bGFwMk8+tXLi2MaQzX95bwSKTHG4AjJB7Atkdeanns9QS5loYgubKIxi6tJIgWxG9zEPLBI6fLxnvzViK12yTwtNnzMDe75cHH8IHyqPwrev8AStOvvDMiSatPBMgbetyqzQyJ2dSACGXI4zXH6C4ntI4XlLXML+XgIrLIM8fN1Bx09adr6ofM72Yk2mWl6gCGV2LZ3xTFzwPfPP1qtfxm2sopWQyzwDe0y7SepG045K4znNW7szabqhmjmEUsn7p0HQnGBkjsemexx2rNuLwiPUYcvHPLIsaRMRlcrg8DoM9/eqVyXFGsbZXjjvLQSMpXAa2fBYe/So47z7MbaKwuGkbzcPaTBY3A2luGOD9Pc1Vmgk0G7jezJksZBiWN8kIR1Oevvx2q1qSJeXMT6lahbSO3P76HMiZJBzwAeFGe9CSv5Dd7dmXJNXs2jJktLhYiwJnyylGPVTjp61W1N4rB1kXUbqGIjO0TCTORx8hPzDp+FV7fSbiW0lk03UvOhRkMToQQD1AZeqnjrTLe4uYYpnudkkSSbZFX70LHgjBzx3449KFFLYNXv95atNSUtG5091VlJmMa5jkUdHUdjk8j/arpo7mO4h/e2rRyhSqiZChP+zuHQcCuKns5JrdhaxM275lMDBT0646HI47GtHStQu205nW5vEuLVNs8J+dQBxuKnn8iDUuKZSlKGj1Ou0eN0jdHmgRvvRopaRUHcBzyR3wemaimke7823kLwzqSUkjcfMvtkdR3FZGi3Md5qVvc3q+VGEMcEq7vJuHPBwT90Y6Ke/eprrT0/tRZIDPDc4klZovmYBRgAgnByxHXsKlqzsUryVyvYeXFdiK21KGVWb96hCCVvoQBk/XNaAmRLmO1mt7nZIQomRdyDPQMR9306Yq+ltYapCGuLTLwcNFLFhgSOTg9vcVasHtkBjhlhYINpQONygcYYdQfrQ0VGNtnYxbqznjkIs9USKZeBC8aMG9AQTn8QaqWM5lmuLO5tI0vyqs+zpIn95WJ6DIJFbFza2uptcedZJ9nQjzJ3gXfIB2jyM+278qtDTN0Ec8VoGvAWkCtgBN3GB6fLgUJXVmLlW6M20kvorm4kt7dtiphVztWZic5LdsYH0zVkvqyRszxWdtgcYYyqQeoxgEEetWvK1zJEUWmxxg8b97MR7gcUzz/ABJEuZLO0nGeVt2ZG/DP8qVkOzRQSwklkf7VJMsUhURrkbGf3BHH+6eta8kF2dkM7eXK3CyRn5OnHHY0y1uG1K0Z1tpSWDIQ33cj3PcGtezuWa3WKaKaGTbgtKODx6j+tS0awS6Mp2dittA0CDqSdzHJLd2PqavQ2W+EByGccEluWwPYVIsIgj2xrsb72SM/qat7rWNvM2sjsCWxnB44Gc/5zSsbXstCBYJBHtfKBeQBkke9KTErgZV5duQqsC5HrjuKfIY2fzCoKsvGZMn8qgWxc6hDdG7cosZEcRwq5PU+p4GPSqTIdyxIkHVYnZ2XDA4GB24rKuUkS4Mt26pGDxFuyMgdScZP06VpXcLySBI8k4ztU4x+XJqU6ajmMFhPLgsV4BQ+nrSUkPkurmXa3ZlIbJW2ZtpYAgsPY/yNXZ0kWbzdoVc5jQdAOg6nn3qzNbW1qhE8qBRg7M89OOKdC0JaIRf6xgPlUYbPrz0HIpOwcruZoguSB5UW19oQbyOT349OapWujTG433f+l3YyGkcEhCePkXoMf0roGMkc0kkyRrGCRyxZj7ZFMklaP5wzt8vrjI7Agc0nJbD5GUotNjLrvHBzzJ346+1WzZxPJIHG6Qnhuy1Lb2lxLN5glljjdQCiqFCH19c4q9FZGNCGy+e5J68+/wDOlzdilBmYdNSVfuMCTkYH+FVZ9NAyqIWOSpDDn61uOrRKrSMXUjGA2Bj1pygSbQqbQQclj0Hrjr19aXMDpnPx6YbiPyJJZPLYcxoOMdulSaRpmnaXr1peR2AcWsm7cvUD1x0yOtb6puQDDNG3AMg2gD3xVzRjarqNsLraYCw3FlAU88ZA5xQpszlRjZuxy974VhkmNxD4vaPLeZmZZWfrnn3/ABrM8XvPf6sklugu1ihjiE8i4eVkGDIw9TXpd3It3cyWHiEwlt37q4QL+5Y9B8vVD6VV8TWznUYoI2REjtYlZ48HJC849q2WIlHY5XhIydmj5WfUPtkI/tS1UXI2qt8I8EL0PmLjD8d/vcdTVmw8OPdXSLLNBBayAsbp2GwHbuVSAflB4rodB0/TpLqT7FEY7kkMYL5VkbcD2X73PXvXR2kelC/uLKSGN74bXxaW4Yj5eegIUjHQ1u59jlVNdTm7TRphHPqUv2ORGLR+ZOdwGOmAB8wJB6c+1bGm6XqTJE72sEqEHyjJF5SKxPXqcjv0FJdWE51C5nmmttLVsGOS7YTXDKOQyRknB9WPToKm0bwld6vm41S/v3EiHbGJSGYEfePYD2wM+lRK+5rFK+iMu9utPtW+yG9udTvpMtJHCQlvb9ywUMFz7En3Pak0fS0mQ3UpsEd33QLe4ldEH3QwXC9sgDAGea7K30LRtO06Wxjhh8tMC4djycfMd7dumSOOKgvNeljsptQRfs2mxpvjaRT5lwTwpCAfKpPIzyRjpSb6bFOn31MOwv8AWL2ae3spdPSO3Qm5vAjNHE2Pur0BIHJwMD3pll4VMumrcazfsqSuZo1fbEZOflaQnlmI5wT8oNbsOn3GoWdnb3M0sUF9cLm1Q4aRMGSQysedxC9BgDIHNajWOmaW6yTI95qAbAkdvOm3HoB/dzzwAOATTemwRh1OcvfISS2t7QPe3ki7kDSgKFHG8tjhc8cZJzxVa8sorq/S0v5IIGWJJpIwFLyyNlVwDyQqqx5HBIzW/ex3FjqUgjaB9T1BFdVLZW1hTjLHuMknAxuJ9BmrNhpK2l3qcKTSvc3MEMjXbhTIWwytg9BggYA4FTFW1KknL3WZa2+lRD7DEWkaEhn8ydpShxtzyflO04rmdXR7XUrWzjMH2SwiF/HHuJMqRkLtOejKu9s+1dhZNaJcS2EcYU2reU0YBzuIBBJ/iznOe9YXjBY4IbiCKEXt1Cgunkg5MSqeRKD91SpbjPfpRG9yZKPL2OUuJ7WC7vgjSO9zqM6yGMHFxACCFHuW4GPU1r3OnS70kv7UXjZBFtEwEcI9ApI3EdMn8KzD9hk8VWmoyXWywuNVmfaIjgeWFKkcZ5LYxiuj8TXJtNPhutjWqzTquZU2kZySSDyOAeKqaatYimotPmIfCzw+XHbFVS+zJLJblSrj5snIx6Ec9OK3Llbia22pCqsR924XKtjj5gKybWzvdWks7hTNYm2k3wyNgyFCPm3L2B44zXXWN0blZYp0VbuA7Z4kOR7OueqsOnpyKze97m0It+60cJLp95pge+jisYYAcSC0cx9fVX+X9RXLXMMba6kRt5kuJQERclN+enOflPAx94GvWntYroagIgPKExgUSD7w2jcSPTJI/CuM8S2g0m1iuY7US2kM8ci25JBt33DlD1Ktgjb2ODWkJ2diKlL3ebsYVo9jf3D6frhkjkiX93PKCrIP7r9OffoaoeHrSa9W5nBa42NmRc4mKnjKE8MfVT1xjvXonjq0VPD0rm1tpHcLEryqzSgs2BjB6jPp2rP0zwzeWtveWbRxvLauslvc7SscyOo3LweDhc+x5pqStdEyg1JJlXT9OkvdNlEMyMpI8h2GAcdmXqpByCPer1nodzbxpGL/AG2y/wCrSJBlQTnbubJOKWzeWw12CUzLNYXkn2aWfsJcYQyDs/8ACT34NdHcqUJWS1njYHiVNrjHuPf6Vk3pdG0Um1fdHE33h6ZrpXsJzbXDkb7jzSC3P9xV5pl6t5out2LazAk1tN/o0l1AmVljbpuXswOD9MiuutIkvZnjimX7SgDMVAIIPcDr7e1ZXiqLULbTZIHW1mV5YlhZCyvnzAV65G734qoyehM6UbPlRnaz4ei09beXRpLiNHkA2Bsghvu8N/WsW8068h1NdQmhnu7ZgEuDCDCxA4ZWU556Hjg4rt9Yml1SIxh5NOvJGUp5uNpYMCMtyD06ZqVodUFyFuYobz5sB0Yxcg5yynOOnUE0o1HsVKkpK5y2o3VrbssltMsGnXnLI8e6MNjngHGG46HINbXhrcrv9p81bqRVMSTn5vI/hCn+IZJznnpmtKw0i6WK6sbmxsltHcONw8wOh5APABK8jJq3Ja21swgvbwZDK0UE2QyN28uQ9fTFKV2i6asyxAjtbxbnUyBeijis2/0iG5vIriFmt7wAiOeNAuzjvx8w9jWu1jHDMzohjdxtfYdu7046evNQrJLbXX2e5CfZpHCQ3Y42k4wkg7ZPAYcH2rO/Zm7ir+8iLTgbmGCW4uGt5InaG4VnygdTyOe2cEdOCK3FXEWwncGH+sB2qTSw2UdlcXTu25p5BIygghTtC549cD8aSO5gaYW+4Rsi5KnCkrkYwO3Per1BJLRmcwuPtLRQywx7MGTHzOM9Mjt+NTXekQFGe/FxNCoyTJIyqfbC4FaS+QkkkpgzNL/rJFOM46dv51ZlljmhLOrGH7oMrBt56YGetBLjfcraTp1naxL9mggto5SGPl4UOfXv+dWzCroSBv3cHAJx68niuf8ADMkUEF2saf6PDdypb4YsdgxlRjtv3gfTFaib4VE90WRFY/ITkLxwCfxqG2VG1i3aQSRJsSNDFvDcrnp0HPAHtUF/bzXTYaTylVd22FFXAznHHBp8mqQRpgsZt3IMKmTafQ9qdCX1CMyeVJCob+P7xx0PXAzSuaKKIF06HhmkG8cKRjIB9qmgsEXJGA+Ml5MNx/TtVgRI+4/6zIB3E8f5+lTpFH5TEeYxB4bGMH8etK5fKiES2+0BQyqQDnbtA+nrmqn9mxyTM5VvMx8zbs4HUDA7VcnbghI0R/7zcZ/qTTrZZXSWYnYv8RXpSuPkVyBIIzOwmALR9HY5z/n60+GOLiQIvB25UZwPX3qSNA0qEKQp9Pl2gdTk9/pTo3jDbS2whSSSCT9B9felcfKMuIVnBHPzdGPP4EUz7OpwsZICnBA6/pT2G4ld2+RjuKKcn3yfpUkcRYsd+4ZwIwCuw/TvRcaQ+RSNoUk46YP86JSdhwSMnlE5JAPegq0gKRn5RwWPbHoOg+tQyShSsefLUYIkQDj3/wDr0mHKLChQb5h5cjHn+Jh2okgdCFVRwfvON2e/A70+ziitUBaN3z8wLHLEevP9aPtHzSKu55CcsAckr7n09hSVirKw1Yt8m9mZ3HG5j93PQAdKI28yRYbVd8rnaxIyAewHqfYUohcQs+2NYGbBC8MR7egx6Vc0YwwalCQ/lxJ8u8j1B+b6AkUWuKSsrotQabBG5W7vITMvAXk4P+0wGB+H51WnjNqZUcNGUXbKhYcfUjsc9BWoQYNSt3EsiNGix+QkDEuAMFVwNpVuefesnXBC0yIXjeSGIRMgPy5C+v8AERnAHtzVNWRjBuTPnrQNXu9W1ix0+dxFZ7STHAPLz7ZHIHHQEVua9M1jeQWen4s4EZLceQNhKSH5snvyAR70UV2SPLjuzbsfD2nr4k1Gy2SGK2gWcuZWMkzEfxvncQMdAQPXNX7Hfqs+qWUsskFtahERLdjGW3dSxHJ6dM49qKKm7aNaaRfGgWk0mk6U73AsLu9igmiSUqGQliy4HrtAPtmn31nAfGNzCEAhs7aOaJO293YbjnqQF49Mmiih/CaxSUtBus3s1lpubZgkh8sK+MshdwpIz3waXT7aGPxBqNoiBYbBY4oR3+fLOzHqzNgZY84oopF/bRyt1cvHpenXyqhudS1FvtDMuchTIFUegAQcf41f8V6hLZazoVvAsYW9DQysQSQp2tx2Bz7d6KKpGUtm/Qpa8xtLma8h/wBdJptyzZ5BaHayHHqNx/CoGjWw8C3iW+czW0kkrtyzu0YJYnucmiioT0XyIilzv5mZ4T0u0l1LQ4pYg8U9hLNIrchmZEDH8ev1rUvGOoePbS1ujvtbNz5cRGVLeSTvbPVh2Paiitp7nPT+H7jobONSzFhuyxBz3zxTJ/8AQtItruD/AI+VY2YkPJMe7Az6kY4JoorKB1VHuWLaMHwVPd7mFwFnl3g4O7ex/pWWxW+bTo7iNGiumXzUxwf3RP8AOiinNe6mKm2079ijBK95b+F47hi4M8xJPUmKN9pP5Vc1Q7dJsZx/rYpICp/3iFYfQgkUUVKNJbv5FHxbp8Euk61dIDDOkG4tEceZjkbh0OMDB6j1rb069lvrLTZ59peezSV8cfMVzkUUULWndkS92orEcsSOLe62hbiOaMB0+UkM2CCR1BrUjSO6aNZo0YA+nU+v1ooqIbI3mjPvLeKK5EAUNbyj5on+ZemeM1aS0hs7ZkgDBEYFQzFsZxxz29qKKb2Cn8Q6OR3YEnBzjirep20MlttmjWVCvKuNwP4Giip6GtveC3QJACM7UwqpngCrmsWkRSW3dd8JGwq3QgggiiijoEzP0OVnsGjc7zHK0AduWKqSBn3x3rP8URomkS6gqgXdpveKTJyMDp7g55FFFU9jNbI6C2TzGtg5JRlBKduRTYoke8aPbtRSQFXp1xRRQhvb5F6WCC1hgit4I44kIRUUYGMZ7e9OUh7RcomJNu4Yz1+tFFLqC2EmQCN1xwD9M8GoYB++ij7Mu4nvnFFFSbxLEAEYRVA+Zzknk9Kas7eQZFAWT+8M5HNFFIb3EDFCGHL8jcetSuxECE/NzjB6flRRSKRJcHPHqoJPc1VuJWVWC4UBRnHGeCeaKKQIW1c+Q2MD5tvA/GljnZzMCFGAOR1OfeiioRRLP1XHG75Tj0zTEAdFd1DnJxu5waKKY0RRzMJpMYynIPrz3q7OFjaNlRctnJ9eKKKfQT3GEeaxhkyysqEknkgjpn09qoxOZyBJyBnj8aKKlgWTd3Uenp5VzOiuxj2q5wBjPArO+2O9ybYRxonzZKjk7e2ffqfWiiqZKSuf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodules of Kaposi's sarcoma are present on the gingiva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18693=[""].join("\n");
var outline_f18_16_18693=null;
var title_f18_16_18694="Liposomal morphine: Drug information";
var content_f18_16_18694=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liposomal morphine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/37/41555?source=see_link\">",
"    see \"Liposomal morphine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/11/30901?source=see_link\">",
"    see \"Liposomal morphine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8776643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DepoDur&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8776651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8776818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Surgical anesthesia:",
"     </b>",
"     Epidural: Single-dose (extended release, DepoDur&reg;): Lumbar epidural only; not recommended in patients &lt;18 years of age:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cesarean section: 10 mg (after clamping umbilical cord)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;text-align:justify;\">",
"     Lower abdominal/pelvic surgery: 10-15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Major orthopedic surgery of lower extremity: 15 mg;",
"     <b>",
"      Note:",
"     </b>",
"     Some patients may benefit from a 20 mg dose; however, the incidence of adverse effects may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     To minimize the pharmacokinetic interaction resulting in higher peak serum concentrations of morphine, administer the test dose of the local anesthetic at least 15 minutes prior to administration. Use with epidural local anesthetics has not been studied. Other medications should not be administered into the epidural space for at least 48 hours after administration.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8776819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use with caution; may require reduced dosage in the elderly and debilitated patients.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8777267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Dosing adjustment is not required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8777268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Dosing adjustment is not required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8776933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, extended release liposomal suspension, epidural, as sulfate [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DepoDur&reg;: 10 mg/mL (1 mL, 1.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8776649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F8776641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8776913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Epidural: Intended for lumbar administration only. Thoracic administration has not been studied. May be administered undiluted or diluted up to 5 mL total volume in preservative-free NS. Do not use an in-line filter during administration. Not for I.V., I.M., or intrathecal administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Resedation may occur following epidural administration; this may be delayed &ge;48 hours in patients receiving extended-release injections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Administration of an epidural test dose (lidocaine 1.5% and epinephrine 1:200,000) may affect the release of morphine from the liposomal preparation. Delaying the dose for an interval of at least 15 minutes following the test dose minimizes this pharmacokinetic interaction. Except for a test dose, other epidural local anesthetics or medications should not be administered epidurally before or after this product for a minimum of 48 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8776707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Epidural (lumbar) single-dose management of surgical pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8775522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Morphine may be confused with HYDROmorphone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Morphine sulfate may be confused with magnesium sulfate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MSO",
"       <sub>",
"        4",
"       </sub>",
"       and MS are error-prone abbreviations (mistaken as magnesium sulfate)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8776729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention (may be prolonged)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Oxygen saturation decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, insomnia, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, dyspepsia, flatulence, paralytic ileus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Bladder spasm, oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hematocrit decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, hypoesthesia, paresthesia, rigors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea, hypercapnea, hypoxia, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Sweating increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Cardiac arrest, confusion, lethargy, obtundation, respiratory arrest. Apnea and prolonged respiratory depression have occurred following subarachnoid puncture.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8776713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to morphine sulfate or any component of the formulation; severe respiratory depression (without resuscitative equipment); acute or severe asthma; known or suspected paralytic ileus; patients with head injuries or increased intracranial pressure; circulatory shock; upper airway obstruction. Not for use in vaginal labor and delivery.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8776714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), circulatory shock, or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). May cause orthostatic hypotension and syncope in ambulatory patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: May cause respiratory depression. Risk increased in elderly patients, debilitated patients, and patients with conditions associated with hypoxia or hypercapnia. Prolonged, serious respiratory depression has been associated with nonapproved routes of administration (subarachnoid puncture and intrathecal). Although respiratory depression is reversible with naloxone, patients must be monitored for at least 48 hours due to the duration of action of the liposomal formulation and the potential for rebound sedation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions. May worsen gastrointestinal ileus due to the effects on GI motility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction including acute pancreatitis. Use may cause constriction of sphincter of Oddi diminishing biliary and pancreatic secretions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with seizure disorders, may cause seizures if high doses used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Local anesthetics: To minimize the pharmacokinetic interaction resulting in higher peak serum concentrations of morphine, administer the test dose of the local anesthetic at least 15 minutes prior to administration. Use of DepoDur&reg; with epidural local anesthetics has not been studied. Other medications should not be administered into the epidural space for at least 48 hours after administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs, CNS depressants, antihistamines, psychotropic drugs, or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Reduced dosage may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;18 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epidural use:",
"     <b>",
"      For lumbar administration only.",
"     </b>",
"     Intrathecal administration has resulted in prolonged respiratory depression. Monitor for delayed sedation. Physician should evaluate patient for contraindications for epidural injection (eg, anticoagulant therapy, bleeding, diathesis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Storage: Freezing may adversely affect modified-release mechanism of drug; check freeze indicator within carton prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8776766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8776771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8776708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8776709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however reduced growth and behavioral abnormalities in offspring have been observed. Morphine crosses the human placenta. The frequency of congenital malformations has not been reported to be greater than expected in children from mothers treated with morphine during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     DepoDur&reg; is administered as a single dose for acute, surgery-induced pain. It may be used in women undergoing cesarean section following clamping of the umbilical cord; not for use in vaginal labor and delivery.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Refer to the Morphine, Systemic monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8776711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8776712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Morphine concentrates in breast milk, with a milk to plasma AUC ratio of 2.5:1. Detectable serum levels of morphine can be found in infants following morphine administration to nursing mothers. Treatment of the mother with single doses of morphine is not expected to cause detrimental effects in nursing infants. Breast-feeding following chronic use or in neonates with hepatic or renal dysfunction may lead to higher levels of morphine in the infant and a risk of adverse effects. Breast-feeding should be delayed for 48 hours after administration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (DepoDur Epidural)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1 mL): $412.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/1.5 mL (1.5 mL): $618.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8776918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory and mental status, blood pressure; patient should be monitored for at least 48 hours following administration.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8776792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8776795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (patient dependent; dosing must be individualized): &gt;48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3-4 L/kg; binds to opioid receptors in the CNS and periphery (eg, GI tract)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 30% to 35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via conjugation with glucuronic acid primarily to morphine-6-glucoronide (active analgesic) morphine-3-glucuronide (inactive as analgesic); minor metabolites include morphine-3-6-diglucuronide; other minor metabolites include normorphine (active) and morphine 3-ethereal sulfate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as morphine-3-glucuronide, ~2% to 12% excreted unchanged); feces (~7% to 10%). It has been suggested that accumulation of morphine-6-glucuronide might cause toxicity with renal insufficiency. All of the metabolites (ie, morphine-3-glucuronide, morphine-6-glucuronide, and normorphine) have been suggested as possible causes of neurotoxicity (eg, myoclonus).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/16/18694/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hartrick CT and Hartrick KA, \"Extended-Release Epidural Morphine (DepoDur&reg;): Review and Safety Analysis,\"",
"      <i>",
"       Expert Rev Neurother",
"      </i>",
"      , 2008, 8(11):1641-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/16/18694/abstract-text/18986234/pubmed\" id=\"18986234\" target=\"_blank\">",
"        18986234",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9783 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18694=[""].join("\n");
var outline_f18_16_18694=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776643\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776651\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776818\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776819\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8777267\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8777268\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776933\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776649\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776641\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776913\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776707\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775522\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776729\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776713\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776714\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776766\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776771\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776708\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776709\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776711\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776712\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322328\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776918\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776792\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776795\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9783\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9783|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/37/41555?source=related_link\">",
"      Liposomal morphine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/11/30901?source=related_link\">",
"      Liposomal morphine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_16_18695="Drug therapy in Felty's syndrome";
var content_f18_16_18695=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug therapy in Felty's syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/16/18695/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18695/contributors\">",
"     Jonathan Kay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/16/18695/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18695/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/16/18695/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18695/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/16/18695/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Felty's syndrome (FS) is an uncommon but severe subset of seropositive rheumatoid arthritis (RA) complicated by granulocytopenia and splenomegaly. The granulocytopenia in FS may improve when RA is treated with disease-modifying antirheumatic drugs, presumably because these drugs reverse underlying abnormalities in the immune and reticuloendothelial systems. Other therapies for FS increase circulating neutrophils by mechanisms which are not disease specific.",
"   </p>",
"   <p>",
"    The ultimate goal in the treatment of granulocytopenia is to facilitate the resolution of ongoing bacterial infections and to prevent recurrent infections. This may be accomplished by use of medications that raise the granulocyte count [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/1\">",
"     1",
"    </a>",
"    ], but infections are frequently dependent upon granulocyte dysfunction and other disease-related factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Splenectomy is primarily indicated for patients with severe, refractory granulocytopenia and recurrent infections despite medical therapy.",
"   </p>",
"   <p>",
"    The use of drug therapy for FS is described here. The clinical manifestations and diagnosis of FS, as well as the indications for splenectomy in the treatment of FS, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4247?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Felty's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25572?source=see_link\">",
"     \"Indications for splenectomy in Felty's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H685090\">",
"    <span class=\"h1\">",
"     DEFINITION OF TREATMENT RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic improvement in FS primarily refers to partial or complete reversal of granulocytopenia, which should reduce the risk of infection; the RA may also improve independently of any change in the white blood cell count. The criteria for a response have been defined as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete response &mdash; An increase in the granulocyte count to",
"      <span class=\"nowrap\">",
"       2000/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      or more plus two of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Reduced infection rate of at least 50 percent",
"     </li>",
"     <li>",
"      Decreased incidence of cutaneous ulcers of at least 50 percent",
"     </li>",
"     <li>",
"      Reduced incidence of febrile episodes by at least 75 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial response &mdash; An increase in the granulocyte count to between 1000 and",
"      <span class=\"nowrap\">",
"       2000/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      or more plus two of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Reduced infection rate of at least 25 percent",
"     </li>",
"     <li>",
"      Decreased incidence of cutaneous ulcers of at least 25 percent",
"     </li>",
"     <li>",
"      Reduced incidence of febrile episodes by at least 25 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H685425\">",
"    <span class=\"h1\">",
"     APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to the treatment of FS is based upon case reports, small series, and our clinical experience. Nonbiologic DMARDs and several agents that do not affect articular disease in patients with RA have been of benefit in FS, but biologic agents, including tumor necrosis factor inhibitors, have not proven effective.",
"   </p>",
"   <p>",
"    Most patients with FS have RA of long duration and have already received disease-modifying antirheumatic drug (DMARD) therapy. This prior experience and possible adverse effects will determine the choice of a pharmacologic agent to reverse progressive granulocytopenia. We suggest the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    as the initial drug of choice; it is prescribed in the same manner as when treating RA. The dose should be increased to maximum levels before discontinuing methotrexate for inefficacy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are unresponsive to or intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    may be treated with one of the alternative agents described below. The choice should be influenced by several factors including (1) current or recent infection, (2) the patient's prior exposure and response to the drug, (3) severity of concomitant synovitis, and (4) severity of granulocytopenia.",
"   </p>",
"   <p>",
"    We prefer to use glucocorticoids in patients resistant to or intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , but glucocorticoids and other immunosuppressives should generally be avoided in the presence of active infection. Granulocytopenia and synovitis will respond much more slowly to other DMARDs than to methotrexate or to glucocorticoids. The white blood cell count may begin to rise within several weeks in responders. (See",
"    <a class=\"local\" href=\"#H685149\">",
"     'Methotrexate'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Gold also is effective in treating neutropenia in patients with FS, but it may cause hematologic toxicity and is less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in treating articular disease in RA. In view of the many potential complications of gold therapy and its lesser efficacy compared with many other nonbiologic or biologic DMARDs for articular disease, we no longer generally recommend the use of gold for patients with FS ahead of other more widely used agents for RA. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Gold'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients with life-threatening or refractory bacterial infection, we suggest G-CSF to rapidly reverse granulocytopenia. This growth factor is also useful in controlling granulocytopenia during the perioperative period in patients who undergo splenectomy for recurrent infection. Patients who tolerate G-CSF and have good hematologic responses may be candidates for prolonged therapy, particularly if DMARDs or splenectomy are not reasonable therapeutic options.",
"   </p>",
"   <p>",
"    The evidence in support of this approach is described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H685101\">",
"    <span class=\"h1\">",
"     NONBIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS FOR RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the nonbiologic disease-modifying antirheumatic drugs (DMARDs) used in the treatment of RA has been evaluated in FS. However, there have been no randomized trials with these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H685149\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    , the most widely used nonbiologic DMARD in RA, is effective in FS. Low-dose oral pulse therapy results in improvement of both articular disease and neutropenia in most patients, often within one to two months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Short-term experience suggests that the frequency of infection may also decrease. However, these encouraging results are based upon small numbers of patients in each report. In one study, seven patients with FS received methotrexate at a mean dose of 13 mg per week [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/9\">",
"     9",
"    </a>",
"    ]. The mean granulocyte count showed an insignificant rise after one month but doubled after a year. However, since that report in 1998, larger series of FS patients treated with methotrexate and followed for longer than one year have not been published. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the absence of evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is superior to gold in FS, clinicians should choose the therapeutic agent that is most likely to effectively control articular disease. In most cases, this choice is likely to be methotrexate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gold",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although gold salt therapy for RA has declined in popularity during the past two decades, there is more documentation of benefit in FS with gold than with other nonbiologic DMARDs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/2,10-12\">",
"     2,10-12",
"    </a>",
"    ]. In the largest reported series, a good hematologic response was observed in 60 percent of patients, and a partial response occurred in 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/2\">",
"     2",
"    </a>",
"    ]. Another report reconfirmed the value of gold in several cases of FS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/13\">",
"     13",
"    </a>",
"    ]. The granulocytopenia improves slowly with gold therapy and may not return to the normal range until many weeks have elapsed. Oral gold (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"     auranofin",
"    </a>",
"    ) is also effective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/12\">",
"     12",
"    </a>",
"    ], but the reported experience is less than that of injectable gold.",
"   </p>",
"   <p>",
"    One potential concern is that granulocytopenia, due to accelerated peripheral destruction of cells or to bone marrow suppression, is an uncommon adverse effect of gold therapy. However, this complication does not appear to occur more frequently in FS than in other patients with RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20118017\">",
"    <span class=\"h2\">",
"     Hydroxychloroquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two patients with FS, who were unable to continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy because of toxicity, experienced resolution of neutropenia when treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    400 mg daily. However, each patient required concomitant therapy with glucocorticoids to control articular disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Penicillamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited information on the use of D-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    in FS. The largest reported series evaluated eight patients, six of whom exhibited a rise in the neutrophil count after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/15\">",
"     15",
"    </a>",
"    ]. However, penicillamine had to be discontinued in most patients due to side effects, and one patient died. Thus, penicillamine should never be the initial choice for treating FS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few reports of the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    in FS. An excellent clinical response accompanied by a reduction in neutrophil-bound IgG was noted in one case [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other immunosuppressive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    in FS is very limited [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. In one report, cyclophosphamide led to at least a 50 percent increase in the granulocyte count in five of eight patients versus only one of seven with azathioprine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/19\">",
"     19",
"    </a>",
"    ]. The potential toxicity of these drugs, particularly the induction of leukopenia, limits their use to refractory patients or to those in whom vasculitis or other systemic manifestations justify the risk.",
"   </p>",
"   <p>",
"    In a case report, successful treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    was described in a patient who developed FS while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/20\">",
"     20",
"    </a>",
"    ]. After six months of treatment, leg ulcers healed without any adverse effects.",
"   </p>",
"   <p>",
"    The use of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    without stem-cell rescue in two patients with refractory FS resulted in complete remission after 3 and 21 months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/21\">",
"     21",
"    </a>",
"    ]. This aggressive approach may be considered in patients unresponsive to other measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids can raise the granulocyte count in FS both by an immunosuppressive action and by altering granulocyte kinetics. The bone marrow is stimulated to release mature cells, granulocytes are mobilized from the marginal pool, and the egress of cells into tissues is impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    , in doses of 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or more, can often normalize the granulocyte count [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/25\">",
"     25",
"    </a>",
"    ]. However, this effect is usually not sustained when the dose is reduced to the usual RA maintenance level of less than 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    unless other treatments are added.",
"   </p>",
"   <p>",
"    High-dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    pulse therapy has been advocated for the treatment of agranulocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/26\">",
"     26",
"    </a>",
"    ]. This regimen may be particularly effective when T&ndash;cell mediated suppression is the mechanism for myelopoietic failure, since these inhibitory T&ndash;cells are often glucocorticoid-sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/27\">",
"     27",
"    </a>",
"    ]. These patients can be identified by in vitro tests which are not available in most clinical laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/27\">",
"     27",
"    </a>",
"    ]. The possible indications for pulse steroid therapy in FS are currently undefined since the published experience is very limited.",
"   </p>",
"   <p>",
"    Concern about overwhelming infection is the main barrier to the use of high-dose glucocorticoids in FS. Low doses of glucocorticoids, which still increase the risk of infection, do not lead to a consistent improvement in the granulocyte count [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20118084\">",
"    <span class=\"h1\">",
"     TARGETED BIOLOGIC THERAPIES FOR RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with the use of targeted biological agents to treat patients with FS is very limited; published descriptions of this experience are restricted to case reports. However, despite the tremendous efficacy of targeted biological therapies in treating articular disease in RA, these agents do not exhibit similar efficacy for the hematologic manifestations of FS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20118099\">",
"    <span class=\"h2\">",
"     TNF inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In six published case reports involving the use of a tumor necrosis factor (TNF) inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , each was ineffective treatment for the neutropenia of FS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/29\">",
"     29",
"    </a>",
"    ]. Although synovitis improved and although there was a reduction in levels of acute phase reactants in the two FS patients treated with subcutaneous etanercept 25 mg twice weekly, neither experienced improvement in the absolute neutrophil counts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20118138\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five cases of FS have been reported in which synovitis and neutropenia both improved following intravenous treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/29,32-35\">",
"     29,32-35",
"    </a>",
"    ]. However, other cases of FS have been described in which only articular disease, but not neutropenia, improved following a course of intravenous rituximab treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NONSPECIFIC THERAPY FOR GRANULOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several drugs which do not affect the activity of RA have been used to nonspecifically raise the white cell count in patients with granulocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Granulopoietic growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant granulopoietic growth factors are being used with increasing frequency to raise the granulocyte count in FS. Although published reports were previously limited to individual cases or small numbers of patients with short&ndash;term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/36-41\">",
"     36-41",
"    </a>",
"    ], subsequent studies have been performed in larger groups of individuals followed for longer intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both granulocyte macrophage colony-stimulating factor (GM&ndash;CSF) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) effectively reverse granulocytopenia and reduce infectious complications in many patients. However, some patients are unresponsive, and secondary treatment failures have been reported. The incidence of these events is unknown. In addition, cost is often a limiting factor, particularly with extended use. Significant adverse effects with these agents include the exacerbation of synovitis and the development of leukocytoclastic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits and adverse reactions associated with prolonged G-CSF therapy were reported in one study of eight patients with FS who were treated for recurrent infections or because of required joint surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/42\">",
"     42",
"    </a>",
"    ]. Significant side effects occurred in five patients, including nausea, malaise, and exacerbation of joint pain and vasculitic skin lesions. However, only two required discontinuation of G-CSF, while the remaining individuals continued therapy with reduced doses. The authors postulated that therapy for prolonged periods (nearly 3.5 years) with low doses of this agent may be associated with significant benefits without exacerbating underlying arthritis.",
"   </p>",
"   <p>",
"    Although some patients have been treated for extended duration, the colony stimulating factors are primarily recommended for short-term use during periods of neutropenia with active infection. Alternative therapies, such as DMARDs or splenectomy, may be introduced when neutropenia is partially or completely reversed by colony stimulating factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H685848\">",
"    <span class=\"h2\">",
"     Lithium salts",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    salts increase the granulocyte count by stimulating myelopoiesis. Initial reports of lithium therapy in FS were encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/44\">",
"     44",
"    </a>",
"    ], but there is little evidence of long-term benefit or prevention of recurrent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/45\">",
"     45",
"    </a>",
"    ]. One series, for example, noted no improvement in granulocytopenia in seven patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H685906\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral testosterone has been tried in FS. However, reported experience is very limited, and the masculinizing effects prevent its use in women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/46\">",
"     46",
"    </a>",
"    ]. Intravenous gamma globulin has been employed with considerable success in the treatment of thrombocytopenia, but the effect on the granulocytopenia in FS has been disappointing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18695/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The granulocytopenia in FS may improve, thus reducing risk of infection, when RA is treated with disease-modifying antirheumatic drugs (DMARDs); this occurs presumably because these drugs reverse underlying abnormalities in the immune and reticuloendothelial systems. RA may also improve independently of any change in the white blood cell count. Other therapies for FS increase circulating neutrophils by mechanisms which are not disease specific. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H685090\">",
"       'Definition of treatment response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H685425\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of FS is based upon case reports, case series, and clinical experience. We suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      as the initial drug of choice; it is prescribed in the same manner as when treating RA. The white blood cell count may begin to rise within several weeks in responders. (See",
"      <a class=\"local\" href=\"#H685149\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are unresponsive to or intolerant of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      may be treated with one of several alternative agents. The choice should be influenced by several factors including (1) current or recent infection, (2) the patient's prior exposure and response to the drug, (3) severity of concomitant synovitis, and (4) severity of granulocytopenia. (See",
"      <a class=\"local\" href=\"#H685425\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We prefer to use glucocorticoids in patients resistant to or intolerant of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , but glucocorticoids and other immunosuppressives should generally be avoided in the presence of active infection. Glucocorticoids can modify immune function and also raise the granulocyte count nonspecifically. However, glucocorticoid&ndash;induced suppression of neutrophil and monocyte function may further impair the patient's resistance to infection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gold also is effective in treating neutropenia in patients with FS, but it may cause hematologic toxicity and is less effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      in treating articular disease in RA. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Gold'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other nonbiologic DMARDs that have shown benefit in case reports, sometimes inconsistently, include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , D-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H20118017\">",
"       'Hydroxychloroquine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Penicillamine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Sulfasalazine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Other immunosuppressive drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several cases of FS have been reported in which synovitis and neutropenia both improved following intravenous treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . Other case reports have not shown benefit with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H20118084\">",
"       'Targeted biologic therapies for RA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20118099\">",
"       'TNF inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20118138\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with life-threatening or refractory bacterial infection, we suggest G-CSF to rapidly reverse granulocytopenia. This growth factor is also useful in controlling granulocytopenia during the perioperative period in patients who undergo splenectomy for recurrent infection. Results with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      are mixed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Nonspecific therapy for granulocytopenia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Granulopoietic growth factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H685848\">",
"       'Lithium salts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53011800\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Robert S Pinals, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/1\">",
"      Laszlo J, Jones R, Silberman HR, Banks PM. Splenectomy for Felty's syndrome. Clinicopathological study of 27 patients. Arch Intern Med 1978; 138:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/2\">",
"      Dillon AM, Luthra HS, Conn DL, Ferguson RH. Parenteral gold therapy in the Felty syndrome. Experience with 20 patients. Medicine (Baltimore) 1986; 65:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/3\">",
"      Ruderman M, Miller LM, Pinals RS. Clinical and serologic observations on 27 patients with Felty's syndrome. Arthritis Rheum 1968; 11:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/4\">",
"      Breedveld FC, Fibbe WE, Cats A. Neutropenia and infections in Felty's syndrome. Br J Rheumatol 1988; 27:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/5\">",
"      Isasi C, L&oacute;pez-Mart&iacute;n JA, Angeles Trujillo M, et al. Felty's syndrome: response to low dose oral methotrexate. J Rheumatol 1989; 16:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/6\">",
"      Allen LS, Groff G. Treatment of Felty's syndrome with low-dose oral methotrexate. Arthritis Rheum 1986; 29:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/7\">",
"      Fiechtner JJ, Miller DR, Starkebaum G. Reversal of neutropenia with methotrexate treatment in patients with Felty's syndrome. Correlation of response with neutrophil-reactive IgG. Arthritis Rheum 1989; 32:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/8\">",
"      Tan N, Grisanti MW, Grisanti JM. Oral methotrexate in the treatment of Felty's syndrome. J Rheumatol 1993; 20:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/9\">",
"      Wassenberg S, Herborn G, Rau R. Methotrexate treatment in Felty's syndrome. Br J Rheumatol 1998; 37:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/10\">",
"      Gowans JD, Salami M. Response of rheumatoid arthritis with leukopenia to gold salts. N Engl J Med 1973; 288:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/11\">",
"      Mastaglia GL, Owen ET. A study of the response of the leukopenia of rheumatoid arthritis to gold salt therapy. J Rheumatol 1981; 8:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/12\">",
"      Bellelli A, Veneziani M, Tumiati B. Felty's syndrome: long-term followup after treatment with auranofin. Arthritis Rheum 1987; 30:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/13\">",
"      Almoallim H, Klinkhoff A. Longterm outcome of treatment of Felty's syndrome with intramuscular gold: case reports and recommendations for management. J Rheumatol 2005; 32:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/14\">",
"      Mah&eacute;vas M, Audia S, De Lastours V, et al. Neutropenia in Felty's syndrome successfully treated with hydroxychloroquine. Haematologica 2007; 92:e78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/15\">",
"      Lakhanpal S, Luthra HS. D-penicillamine in Felty's syndrome. J Rheumatol 1985; 12:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/16\">",
"      Ishikawa K, Tsukada Y, Tamura S, et al. Salazosulfapyridine-induced remission of Felty's syndrome along with significant reduction in neutrophil-bound immunoglobulin G. J Rheumatol 2003; 30:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/17\">",
"      Wiesner KB, Shapiro RF, Bryan BL, et al. Immunosuppressive therapy in Felty's syndrome. N Engl J Med 1977; 296:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/18\">",
"      Canvin JM, Dalal BI, Baragar F, Johnston JB. Cyclosporine for the treatment of granulocytopenia in Felty's syndrome. Am J Hematol 1991; 36:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/19\">",
"      Campion G, Maddison PJ, Goulding N, et al. The Felty syndrome: a case-matched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine (Baltimore) 1990; 69:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/20\">",
"      Talip F, Walker N, Khan W, Zimmermann B. Treatment of Felty's syndrome with leflunomide. J Rheumatol 2001; 28:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/21\">",
"      Brodsky RA, Petri M, Smith BD, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998; 129:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/22\">",
"      Bishop CR, Athens JW, Boggs DR, et al. Leukokinetic studies. 13. A non-steady-state kinetic evaluation of the mechanism of cortisone-induced granulocytosis. J Clin Invest 1968; 47:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/23\">",
"      Shoenfeld Y, Gurewich Y, Gallant LA, Pinkhas J. Prednisone-induced leukocytosis. Influence of dosage, method and duration of administration on the degree of leukocytosis. Am J Med 1981; 71:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/24\">",
"      Smith MD, Ahern MJ, Brooks PM, Roberts-Thomson PJ. The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. III. Effects on immune and inflammatory indices in synovial fluid. J Rheumatol 1988; 15:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/25\">",
"      Kaprove RE. Felty's syndrome: case report and rationale for disease-suppressant immunosuppressive therapy. J Rheumatol 1981; 8:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/26\">",
"      Job-Deslandre C, Menkes CJ. [Treatment of Felty's syndrome accompanied by agranulocytosis using high-dose corticoids. 3 cases]. Presse Med 1987; 16:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/27\">",
"      Bagby GC Jr, Lawrence HJ, Neerhout RC. T-lymphocyte--mediated granulopoietic failure. In vitro identification of prednisone-responsive patients. N Engl J Med 1983; 309:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/28\">",
"      Breedveld FC, Fibbe WE, Hermans J, et al. Factors influencing the incidence of infections in Felty's syndrome. Arch Intern Med 1987; 147:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/29\">",
"      Narv&aacute;ez J, Domingo-Domenech E, G&oacute;mez-Vaquero C, et al. Biological agents in the management of Felty's syndrome: a systematic review. Semin Arthritis Rheum 2012; 41:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/30\">",
"      Ghavami A, Genevay S, Fulpius T, Gabay C. Etanercept in treatment of Felty's syndrome. Ann Rheum Dis 2005; 64:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/31\">",
"      Ravindran J, Shenker N, Bhalla AK, et al. Case report: Response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-alpha blockade. Rheumatology (Oxford) 2004; 43:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/32\">",
"      Weinreb N, Rabinowitz A, Dellaripa PF. Beneficial response to rituximab in refractory Felty Syndrome. J Clin Rheumatol 2006; 12:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/33\">",
"      Lekharaju V, Chattopadhyay C. Efficacy of rituximab in Felty's syndrome. Ann Rheum Dis 2008; 67:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/34\">",
"      Chandra PA, Margulis Y, Schiff C. Rituximab is useful in the treatment of Felty's syndrome. Am J Ther 2008; 15:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/35\">",
"      Shipley E, H&eacute;raud A, Hennette A, Vernhes JP. Efficacy of rituximab in Felty's syndrome. Joint Bone Spine 2008; 75:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/36\">",
"      Krishnaswamy G, Odem C, Chi DS, et al. Resolution of the neutropenia of Felty's syndrome by longterm administration of recombinant granulocyte colony stimulating factor. J Rheumatol 1996; 23:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/37\">",
"      Moore DF Jr, Vadhan-Raj S. Sustained response in Felty's syndrome to prolonged administration of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Am J Med 1995; 98:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/38\">",
"      Farhey YD, Herman JH. Vasculitis complicating granulocyte colony stimulating factor treatment of leukopenia and infection in Felty's syndrome. J Rheumatol 1995; 22:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/39\">",
"      Vidarsson B, Geirsson AJ, Onundarson PT. Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for Felty's syndrome. Am J Med 1995; 98:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/40\">",
"      Starkebaum G. Use of colony-stimulating factors in the treatment of neutropenia associated with collagen vascular disease. Curr Opin Hematol 1997; 4:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/41\">",
"      Graham KE, Coodley GO. A prolonged use of granulocyte colony stimulating factor in Felty's syndrome. J Rheumatol 1995; 22:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/42\">",
"      Stanworth SJ, Bhavnani M, Chattopadhya C, et al. Treatment of Felty's syndrome with the haemopoietic growth factor granulocyte colony-stimulating factor (G-CSF). QJM 1998; 91:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/43\">",
"      Hellmich B, Schnabel A, Gross WL. Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor. Semin Arthritis Rheum 1999; 29:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/44\">",
"      Gupta RC, Robinson WA, Smyth CJ. Efficacy of lithium in rheumatoid arthritis with granulocytopenia (felty's syndrome). A preliminary report. Arthritis Rheum 1975; 18:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/45\">",
"      Mant MJ, Akabutu JJ, Herbert FA. Lithium carbonate therapy in severe Felty's syndrome. Benefits, toxicity, and granulocyte function. Arch Intern Med 1986; 146:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/46\">",
"      Wimer BM, Sloan MM. Remission of Felty's syndrome with long-term testosterone therapy. JAMA 1973; 223:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18695/abstract/47\">",
"      Breedveld FC, Brand A, van Aken WG. High dose intravenous gamma globulin for Felty's syndrome. J Rheumatol 1985; 12:700.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7486 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-221.179.173.170-A48E13D4B1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18695=[""].join("\n");
var outline_f18_16_18695=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H685090\">",
"      DEFINITION OF TREATMENT RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H685425\">",
"      APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H685101\">",
"      NONBIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS FOR RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H685149\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20118017\">",
"      Hydroxychloroquine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Penicillamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other immunosuppressive drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20118084\">",
"      TARGETED BIOLOGIC THERAPIES FOR RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20118099\">",
"      TNF inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20118138\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NONSPECIFIC THERAPY FOR GRANULOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Granulopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H685848\">",
"      Lithium salts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H685906\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53011800\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4247?source=related_link\">",
"      Clinical manifestations and diagnosis of Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25572?source=related_link\">",
"      Indications for splenectomy in Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_16_18696="Community violence";
var content_f18_16_18696=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Community violence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/16/18696/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18696/contributors\">",
"     Terrence Conway, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/16/18696/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18696/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/16/18696/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18696/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/16/18696/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a long history of concern about violence in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/1\">",
"     1",
"    </a>",
"    ]. However the view of violence as a public health problem is relatively recent and began in the 1970s with the recognition by the United States Public Health Service that homicide was among the leading causes of premature deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This recognition has generated multiple studies of the causes and effects of violence. National goals were set for the reduction of violence through prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These recommendations were combined with growing consideration by individuals and communities that violence was among the major health problems [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Violence has been recognized as a leading health problem with worldwide impact that should be addressed by the world community [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healthcare providers, including primary care clinicians, are expected to recognize violence victims, and those at risk of becoming victims of violence. They are also expected to participate in violence prevention and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Practitioners encounter opportunities to identify and alter the risk of violence in the course of their everyday practice, similar to other behavior-related diseases such as cancer, heart and lung disease, and motor vehicle-related trauma.",
"   </p>",
"   <p>",
"    The issues surrounding violence in the community are reviewed here. Domestic violence is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=see_link\">",
"     \"Intimate partner violence: Epidemiology and health consequences\"",
"    </a>",
"    .) Issues related to violence in the pediatric and adolescent populations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40617?source=see_link\">",
"     \"Peer violence and violence prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14921?source=see_link\">",
"     \"Prevention of firearm injuries in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXTENT AND CONSEQUENCES OF COMMUNITY VIOLENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States experienced a dramatic rise in homicides in the late 1980s, which continued into the mid 1990s. Since that time the homicide rate and violence has returned to the levels that preceded the rise. However, the United States still exceeds other high-income nations in the rate of violent death (",
"    <a class=\"graphic graphic_figure graphicRef57891 \" href=\"UTD.htm?19/33/19998\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/12\">",
"     12",
"    </a>",
"    ]. The homicide rate in 2009 was 5 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/13\">",
"     13",
"    </a>",
"    ]. Gunshot deaths are the leading cause, accounting for 66 percent of homicides [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/13\">",
"     13",
"    </a>",
"    ], and occur 30 times more frequently in the United States than in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/12\">",
"     12",
"    </a>",
"    ]. Homicide is the second leading cause of death for men aged 15 to 24 in the United States and the leading cause of death for African Americans aged 15 to 34 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, approximately 3.8 million violent acts are committed against individuals in the United States yearly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/15\">",
"     15",
"    </a>",
"    ]. In excess of 1.8 million emergency department visits yearly are made due to violent injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/16\">",
"     16",
"    </a>",
"    ]. The costs of interpersonal violence were estimated to be 3.3 percent of the US gross domestic product (GDP), with society bearing the majority of these costs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/17\">",
"     17",
"    </a>",
"    ]. The total costs associated with nonfatal injuries and deaths due to violence in 2000 have been estimated to be at least $70 billion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healthcare providers often fail to recognize victims of violence as suffering from a serious condition. They underestimate its prevalence and the risk it presents to patients they encounter in everyday practice [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Victims suffer from much more than the immediate wounds inflicted by acts of violence; depression, anxiety, fear, posttraumatic stress syndrome, and substance abuse are other sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/22-26\">",
"     22-26",
"    </a>",
"    ], but typically do not link their complaints to past victimization. Additionally, victims of violence are more likely to experience recurrent violence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/27,28\">",
"     27,28",
"    </a>",
"    ] and adolescent victims are more likely themselves to become perpetrators of violence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR COMMUNITY VIOLENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most age groups and populations in the United States are actually at a relatively low risk of violence. A number of risk factors have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Socioeconomic status and race",
"     </li>",
"     <li>",
"      Owning a handgun",
"     </li>",
"     <li>",
"      Alcohol and drug use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specific contribution of each of these factors is complicated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. As an example, while handguns are associated with violence, those who are predisposed to violent behavior may be more likely to purchase a gun. Similarly, while substance abuse is often involved in violent crimes, drug and alcohol use are also recognized as a response to past victimization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Age, gender, socioeconomic status, and race",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important factors in risk for homicide and intentional injury are male sex, being an adolescent or young adult, and low socioeconomic status [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. African Americans have a life expectancy that is six years less than whites; homicide is a leading cause of this health disparity, exceeded only by cancer and heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/34\">",
"     34",
"    </a>",
"    ]. Homicide and firearm deaths reduce the overall US life expectancy and contribute to why it lags behind other industrialized nations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Young African-American males are the group at highest risk for homicide. They are most at risk of death from homicide between the ages of 18 to 24 and are more than eight times more likely to be murdered than their counterparts who are white [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The difference between these groups is not simply race, but poverty [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/37\">",
"     37",
"    </a>",
"    ] and living in regions with large inequalities of income [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gang homicides in particular are more likely to involve young males of racial and ethnic minorities than other homicides and are more likely to occur in public places [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/39\">",
"     39",
"    </a>",
"    ]. Gang homicide victims are significantly younger than non-gang homicide victims; in one survey 27 to 42 percent of gang homicide victims were aged 15 to 19 years.",
"   </p>",
"   <p>",
"    Women and older adults appear more vulnerable than men and younger adults, but their actual risk of injury and death from violence is much lower. In 2007, the homicide rate for men age &lt;65 was four times as high as for women or people over age 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Handguns",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased awareness and concern for violence has been associated with more Americans obtaining and carrying handguns for self-protection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/1\">",
"     1",
"    </a>",
"    ], but this practice appears to increase risk. Handguns are by far the weapons used most frequently to commit homicide in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/41\">",
"     41",
"    </a>",
"    ]. Firearm homicides are most common in the United States, and significantly higher than in countries that are economic counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/42\">",
"     42",
"    </a>",
"    ]. In a study of two comparable cities, one in the United States and the other in Canada, the number of homicides due to handguns was markedly less in Canada because of their limited availability of the weapon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/43\">",
"     43",
"    </a>",
"    ]. Introducing gun control measures in Brazil reduced a historical trend of increasing firearm deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occupants rarely use their handgun to defend themselves in home invasion crimes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Actually, risk of being killed at home increases for the owners of handguns and residents in their households [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/47\">",
"     47",
"    </a>",
"    ]. Carrying a handgun for protection doubles the risk of being killed during an attempted robbery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Alcohol and drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol and drug use are strongly associated with violence. Alcohol use is a constant factor in studies of violent crime [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], and is involved in one-half to two-thirds of all homicides, at least one-half of serious assaults, and more than one-quarter of all rapes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/51\">",
"     51",
"    </a>",
"    ]. In particular, binge drinking correlates highly with violent injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/52\">",
"     52",
"    </a>",
"    ]. Individuals who have a history of illicit drug use are at least four times more likely to become victims of violence than those who have never used drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/20,53\">",
"     20,53",
"    </a>",
"    ]. Communities that have experienced a decrease in the number of commercial outlets for alcohol have seen an accompanying decrease in homicides [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victims of violence, with the exception of late adolescent males [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/55\">",
"     55",
"    </a>",
"    ], are more likely to utilize medical care than non-victims. However, they often do not give a history of violence victimization. Patients who overuse medical care, present repeatedly with vague problems, and seem to respond poorly to appropriate medical treatment may warrant further questioning. Victims of past violence also may present with anxiety, depression, or a variety of somatic complaints that can arise long after the violent event. These problems can also occur in a patient close to the victim, such as a spouse or child [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/56\">",
"     56",
"    </a>",
"    ]. The relationship of the symptoms to the violent event should be discussed in a straightforward manner.",
"   </p>",
"   <p>",
"    Violence victims may experience posttraumatic stress disorder. Symptoms include a persistent re-experience and avoidance of any stimuli associated with the traumatic event, and profound autonomic hyper-arousal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overall risk of violence also can be assessed for individuals. Screening tools have been developed for use in schools, primary care, and emergency rooms (",
"    <a class=\"graphic graphic_table graphicRef78170 \" href=\"UTD.htm?4/22/4459\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67054 \" href=\"UTD.htm?13/45/14043\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52612 \" href=\"UTD.htm?23/46/24299\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65384 \" href=\"UTD.htm?28/57/29598\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. However, legislation proposed or passed by several United States state legislatures would prevent physicians and other health care providers from asking most patients if they own guns and have them in their homes. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Legal issues'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients who report being a victim, the circumstances surrounding the violent event should be elicited. Does the patient know the perpetrator? Are they related, friends, coworkers, or acquaintances? Are the circumstances of the violent event common or recurring for the patient? Was the victim armed? Were alcohol or drugs used by the victim or perpetrator or at the location of the violence? Does the victim have plans to retaliate?",
"   </p>",
"   <p>",
"    Victims may feel generalized vulnerability in their everyday life after having suffered a violent event [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/56,61\">",
"     56,61",
"    </a>",
"    ]. Thus, it is important to ask if they obtained a weapon since experiencing violence. How has a violent event changed their activity or routine?",
"   </p>",
"   <p>",
"    The conventional image of a violent act, and one that elicits intense media attention [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], involves an intruding stranger committing a crime without warning. However, in the case of homicide, the perpetrator is usually someone with whom the victim is acquainted. The location is often in or near the victim's home, and the circumstances most often involve an argument (",
"    <a class=\"graphic graphic_figure graphicRef51051 \" href=\"UTD.htm?35/10/36013\">",
"     figure 2",
"    </a>",
"    ). The victim and the perpetrator typically are of the same race. Women are much more likely to be harmed or killed by a male than by a female; this male is most likely to be an intimate partner [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=see_link\">",
"     \"Intimate partner violence: Epidemiology and health consequences\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physical examination often provides clues to a history of victimization or risk. The presence of a laparotomy scar or evidence of injury may prompt further questioning and uncover a history of gunshot or stab injury. Gang tattoos suggest that the patient is among a group with increased risk of victimization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/65\">",
"     65",
"    </a>",
"    ]. Gang tattoos denote membership and allegiance; they are usually homemade with blue or black ink and consist of symbols such as stars, crosses, and combinations of numbers symbolic to the gang (",
"    <a class=\"graphic graphic_figure graphicRef55202 \" href=\"UTD.htm?23/12/23759\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COUNSELING ABOUT VIOLENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although violence is more common in the United States than in most other developed nations, the risk of becoming a victim is actually quite low for most of the population. Nevertheless, fear of crime causes social isolation and decreased mobility in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], and negatively impacts the mental health of others [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/66\">",
"     66",
"    </a>",
"    ], especially low income mothers and those with mental illness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/68\">",
"     68",
"    </a>",
"    ]. It may be linked to worsening of physical health. Exposure to violence has been associated with worse control of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/69\">",
"     69",
"    </a>",
"    ]. Violence is also a leading reason that individuals obtain firearms, even though firearms increase the risk of harm and death to those who live in the gun owner's household [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A \"fear paradox\" has been described in social studies in which some of the populations most at risk, such as young males, report disproportionately low fear. Others at much lower risk, such as women and the elderly, have much greater fear [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/72\">",
"     72",
"    </a>",
"    ]. Healthcare providers should be aware of the presence of fear of violence, should not unknowingly increase it, and may need to address it directly. Clinicians can lower the risk of high-risk patients and reassure those who feel an inappropriate sense of danger by clarifying the involved risks.",
"   </p>",
"   <p>",
"    High-risk patients should be told their risk in a straightforward manner. Treatment of substance abuse may decrease both the risk of victimization and the risk of violent perpetration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, treatment of drug and alcohol abuse alone may not end the risk of violence and should not be substituted for a comprehensive approach to the patient. The increased risk of firearm ownership, especially of handgun, may be reviewed with young men in particular [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/73\">",
"     73",
"    </a>",
"    ], especially those of low socioeconomic status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14921?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of firearm injuries in children\", section on 'Prevention of firearm injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The population at highest risk of violence, males aged 15 to 35 years, is seen infrequently in most clinical practices. Thus, opportunities should be taken when they arise, such as during acute care visits and school and sports physicals. The Task Force on Community Preventive Services recommends universal school-based programs to decrease violence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Emergency departments and trauma units offer opportunities to take advantage of \"teachable moments\" when interventions may be most effective to decrease future victimization, violence, and high-risk behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/75\">",
"     75",
"    </a>",
"    ]. Secondary prevention for individuals receiving treatment for violent injuries, particularly for gang-related events, may prevent retaliatory homicides [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, walk-in clinics, correctional health facilities, and sexually transmitted disease clinics offer other opportunities to identify violence victims and patients at high-risk [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/20,76\">",
"     20,76",
"    </a>",
"    ]. Locations where mental health and substance abuse services are offered also attract at-risk individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/19\">",
"     19",
"    </a>",
"    ]. Seroprevalence of HIV has been found to be significantly higher in victims of serious violence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/77\">",
"     77",
"    </a>",
"    ]. The ability or willingness of physicians and others to identify victims has been found lacking, even when evidence of recent violence is apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recommendations of various groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics recommends that all clinicians counsel families regarding the creation of a gun-safe home environment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/80\">",
"     80",
"    </a>",
"    ]. This includes informing about the dangers of having a gun in the home and advising removal of guns from the house, particularly in high-risk homes with adolescent boys or individuals who abuse drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alcohol.",
"   </p>",
"   <p>",
"    The American College of Physicians (ACP) stresses the need for physicians to inform patients about the dangers of firearms in the home and to advise them on ways to decrease the risk of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/81\">",
"     81",
"    </a>",
"    ]. The ACP also advocates that physicians should be involved in firearm injury prevention within medicine and in the larger community [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LEGAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare providers who identify victims of violence may be required to report to criminal justice authorities. Injuries that are caused by lethal weapons or have been inflicted as part of a criminal act are required to be reported in most states. The medical community has expressed concern that the protective benefits of this practice have not been demonstrated and patients may avoid revealing victimization if it will be reported. It seems prudent and is ethical to inform patients of reports that are to be submitted. The provider should inquire if the patient feels that a report may put them at any risk and be prepared to help lessen potential harm.",
"   </p>",
"   <p>",
"    Gun ownership and the ability to obtain or carry a firearm within the United States has become an intensely debated legal and constitutional issue. The Supreme Court has established that the Second Amendment",
"    <a class=\"external\" href=\"file://usgovinfo.about.com/b/2008/06/26/supreme-court-backs-individual-gun-rights.htm\">",
"     protects the right of individuals",
"    </a>",
"    to possess firearms, rather than the right of the states to form armed militias (D.C. versus Heller). The extent of the right to bear arms is not entirely clear if a state law restricts it.",
"   </p>",
"   <p>",
"    Although owning and bearing a firearm may be a constitutional right, there is an association between gun ownership and harm. Counseling has been recommended to prevent or decrease health risk due to firearms. However, several state legislatures are considering or have passed laws that may affect health workers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/83\">",
"     83",
"    </a>",
"    ]. Health care providers may be prohibited from asking about gun ownership, especially as a screening procedure, in certain states, but the extent of this prohibition is in debate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IMPACT ON SOCIETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Violence can and should be addressed at the level of individual patients, but its root causes are more socially based. An analogous situation is that of driving safety; while healthcare providers have urged patients to drive safely and use seat belts, they also have helped decrease death and injury from motor vehicles by espousing safer autos and laws aimed at decreasing risks.",
"   </p>",
"   <p>",
"    The use of public health methods, effective against infectious diseases and other causes of injury, have been suggested to address violence both within the United States and internationally [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. This involves understanding that violence has multiple causal factors that can be measured, addressed, and prevented. This approach has been implemented locally through coalitions such as Ceasefire in Chicago, and the San Francisco Department of Public Health. The World Health Organization has successfully reduced injury, including violence, with implementation of community-based programs internationally [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healthcare workers should recognize that the burden of violence falls upon those who also suffer poverty, racism, disintegration of the family, and disregard for human life. The availability of weapons in the United States makes episodes of violence more deadly. Leadership to address these issues locally and nationally can come from physicians and healthcare providers.",
"   </p>",
"   <p>",
"    Individual risk can be reduced and victims can be treated, but experience has shown that a broader approach than individual care is needed to curtail the overall effects of violence. Healthcare providers can advocate limiting the availability of weapons. National physician organizations have advocated public policy positions that limit access to firearms and encourage practitioners to include firearm injury prevention in their clinical care. They urge physicians to take an active role in local and national legislative efforts to decrease the staggering toll from firearms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/84,88\">",
"     84,88",
"    </a>",
"    ]. This position reflects the current opinion of physicians within the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18696/abstract/89\">",
"     89",
"    </a>",
"    ] and may reflect the future clinical and political activity of healthcare practitioners.",
"   </p>",
"   <p>",
"    Physicians and healthcare providers may join a number of organizations and efforts, local and national, that address violence prevention. Some are health-oriented such as Physicians for Social Responsibility and its physician speaker's bureau on handgun violence. Numerous professional organizations of primary care physicians, trauma surgeons, or emergency physicians at the state level also have outreach programs to address violence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large national professional organizations such as the American Academy of Pediatrics have addressed violence in policy recommendations.",
"     </li>",
"     <li>",
"      Physicians for Social Responsibility has included education and advocacy for violence prevention in their organizational priorities and activities.",
"     </li>",
"     <li>",
"      Non-professional organizations such as PREVENT or the Illinois Council Against Handgun Violence welcome healthcare provider membership and involvement and offer tools for their involvement in violence prevention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the same victims assistance programs to which healthcare providers refer patients often need energetic and committed board and committee members to help with networking, program direction, and financial and political stability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATIENT RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous organizations and government programs serve victims of violent crimes. These can be accessed by healthcare providers through local social service directories or via Internet Web sites. Victim's assistance online (",
"    <a class=\"external\" href=\"file://www.vaonline.org/\">",
"     www.vaonline.org",
"    </a>",
"    ) maintains a resource center listing support groups, legal assistance, financial resources, and scholarly and educational publications. Most states have victim's assistance programs, often part of the State Attorney or local prosecutor's office. The United States Department of Justice operates the Office of Victims of Crime Resource Center (800-851-3420 or",
"    <a class=\"external\" href=\"file://ovc.ncjrs.gov/findvictimservices\">",
"     file://ovc.ncjrs.gov/findvictimservices",
"    </a>",
"    ) that offers a directory by state of victim assistance and compensation programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Healthcare providers should recognize violence victims, and those at risk of violence, and participate in violence prevention and treatment. Victims of violence are twice as likely to utilize health services after victimization, but typically do not link their complaints to past victimization. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important factors in risk for homicide and intentional injury are male sex, being an adolescent or young adult, and low socioeconomic status. Owning a handgun and alcohol or drug abuse also increase the risk for violence. Handguns are by far the weapons used most frequently to commit homicide in the United States. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors for community violence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have experienced violence may present repeatedly with vague problems and respond poorly to appropriate medical treatment. Victims of past violence also may present with anxiety, depression, or a variety of somatic complaints that can arise long after the violent event. The physical examination may reveal evidence of a past gunshot wound, stab injury, or gang-related tattoo. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opportunities to identify victims of violence and those at risk occur in the primary care office, as well as in emergency departments, trauma units, walk-in clinics, and sexually transmitted disease clinics. Healthcare providers who identify victims of violence may be required to report to criminal justice authorities. It is ethical to inform patients of reports that are to be submitted. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Counseling about violence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Legal issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individual risk can be reduced and victims can be treated, but a broader approach than individual care is needed to curtail the overall effects of violence. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Impact on society'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Understanding and Preventing Violence, Reiss AJ, Roth JA (Eds), National Academy Press, Washington, DC 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/2\">",
"      Stevens JE. Treating violence as an epidemic. Tech Rev 1994; 97:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/3\">",
"      Koop CE, Lundberg GB. Violence in America: a public health emergency. Time to bite the bullet back. JAMA 1992; 267:3075.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Department of Health and Human Services. Healthy People 2000: National Health Promotion and Disease Prevention Objectives. Department of Health and Human Services; Washington, DC 1990.",
"    </li>",
"    <li>",
"     Green HL. The state of America's cities: The twelfth annual opinion survey of municipal elected officials, National League of Cities, Washington, DC 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/6\">",
"      Conway T, Hu TC, Harrington T. Setting health priorities: community boards accurately reflect the preferences of the community's residents. J Community Health 1997; 22:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/7\">",
"      Phillips P. Visionary medical and other leaders meet to plan healthier communities. JAMA 1996; 275:1529.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Assembly. Prevention of violence: Public health priority. Geneva: World Health Organization, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/9\">",
"      The role of the pediatrician in youth violence prevention in clinical practice and at the community level. American Academy of Pediatrics Task Force on Violence. Pediatrics 1999; 103:173.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Family Physicians. Violence: position paper. Available at: www.aap.org (Accessed on May 26, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/11\">",
"      Walton MA, Chermack ST, Shope JT, et al. Effects of a brief intervention for reducing violence and alcohol misuse among adolescents: a randomized controlled trial. JAMA 2010; 304:527.",
"     </a>",
"    </li>",
"    <li>",
"     The Geneva Declaration Secretariate 2008. The Global Burden of Armed Violence Report. Available at: www.genevadeclaration.org/resources_armed_violence_report.Html (Accessed on April 17, 2010).",
"    </li>",
"    <li>",
"     United States Census Bureau. The 2012 Statistical Abstract. Available at: file://www.census.gov/compendia/statab/cats/law_enforcement_courts_prisons/crimes_and_crime_rates.html (Accessed on May 08, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. National Center for Injury Prevention and Control. WISQARS (Web-based injury statistics query and reporting system). Available at: www.cdc.gov (Accessed on December 05, 2011).",
"    </li>",
"    <li>",
"     Bureau of Justice Statistics. National Victimization Survey. Criminal Victimization in the United States, 2010. February 2010. Available at: www.ojp.usdoj.gov (Accessed on December 11, 2011).",
"    </li>",
"    <li>",
"     National Health Statistics Reports, 2006. Available at: www.cdc.gov/nchs/ (Accessed on May 27, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/17\">",
"      Waters HR, Hyder AA, Rajkotia Y, et al. The costs of interpersonal violence--an international review. Health Policy 2005; 73:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/18\">",
"      Corso PS, Mercy JA, Simon TR, et al. Medical costs and productivity losses due to interpersonal and self-directed violence in the United States. Am J Prev Med 2007; 32:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/19\">",
"      Bell CC, Taylor-Crawford K, Jenkins EJ, Chalmers D. Need for victimization screening in a black psychiatric population. J Natl Med Assoc 1988; 80:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/20\">",
"      Conway T, Hu TC, Kim P, Bullon A. Prevalence of violence victimization among patients seen in an urban public hospital walk-in clinic. J Gen Intern Med 1994; 9:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/21\">",
"      Abbott J, Johnson R, Koziol-McLain J, Lowenstein SR. Domestic violence against women. Incidence and prevalence in an emergency department population. JAMA 1995; 273:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/22\">",
"      Rich RF, Burgess AW. NIMH report. Panel recommends comprehensive program for victims of violent crime. Hosp Community Psychiatry 1986; 37:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/23\">",
"      Couto MT, Lawoko S, Svanstr&ouml;m L. Exposure to workplace violence and quality of life among drivers and conductors in Maputo city, Mozambique. Int J Occup Environ Health 2009; 15:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/24\">",
"      Leung TW, Leung WC, Ng EH, Ho PC. Quality of life of victims of intimate partner violence. Int J Gynaecol Obstet 2005; 90:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/25\">",
"      Apter AJ, Garcia LA, Boyd RC, et al. Exposure to community violence is associated with asthma hospitalizations and emergency department visits. J Allergy Clin Immunol 2010; 126:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/26\">",
"      Conway T, Hu TC, Warshaw C, et al. Violence victims' perception of functioning and well-being: a survey from an urban public hospital walk-in clinic. J Natl Med Assoc 1995; 87:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/27\">",
"      Morrissey TB, Byrd CR, Deitch EA. The incidence of recurrent penetrating trauma in an urban trauma center. J Trauma 1991; 31:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/28\">",
"      Poole GV, Griswold JA, Thaggard VK, Rhodes RS. Trauma is a recurrent disease. Surgery 1993; 113:608.",
"     </a>",
"    </li>",
"    <li>",
"     Menard S. Short and long term consequences of adolescent victimization. Office of Junvenile Justice and Deliquency Prevention; US Department of Justice, Washington, DC 2002.",
"    </li>",
"    <li>",
"     Gelles RJ. Alcohol and other drugs are associated with violence: They are not its cause. In: Current Controversy in Family Violence, Gelles RJ, Donileen RL (Eds), Sage Publications, Newbury Park 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/31\">",
"      Darke S. The toxicology of homicide offenders and victims: A review. Drug Alcohol Rev 2010; 29:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/32\">",
"      Mrug S, Windle M. Initiation of alcohol use in early adolescence: links with exposure to community violence across time. Addict Behav 2009; 34:779.",
"     </a>",
"    </li>",
"    <li>",
"     Homicide trends 1980 to 2007. file://www.census.gov/compendia/statab/2011/tables (Accessed on May 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/34\">",
"      Cubbin C, LeClere FB, Smith GS. Socioeconomic status and the occurrence of fatal and nonfatal injury in the United States. Am J Public Health 2000; 90:70.",
"     </a>",
"    </li>",
"    <li>",
"     Crime in the United States, Murder Victims by Race and Sex 2009. www2.fbi.gov/ucr/cius2009/offenses (Accessed on June 08, 2011).",
"    </li>",
"    <li>",
"     Langley, M. Black Homicide Victimization in the United States: An Analysis of 2007 Homicide Data. Washington, DC: Violence Policy, January 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/37\">",
"      Centerwall BS. Race, socioeconomic status, and domestic homicide. JAMA 1995; 273:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/38\">",
"      Kennedy BP, Kawachi I, Prothrow-Stith D, et al. Social capital, income inequality, and firearm violent crime. Soc Sci Med 1998; 47:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Gang homicides - five U.S. cities, 2003-2008. MMWR Morb Mortal Wkly Rep 2012; 61:46.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. National Center for Health Statistics. Health, United States, 2007. US Government Printing Office, Washington, DC 2007. Available at: www.cdc.gov/nchs/hus.htm (Accessed on February 06, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/41\">",
"      Cummings P, Koepsell TD, Grossman DC, et al. The association between the purchase of a handgun and homicide or suicide. Am J Public Health 1997; 87:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/42\">",
"      Krug EG, Powell KE, Dahlberg LL. Firearm-related deaths in the United States and 35 other high- and upper-middle-income countries. Int J Epidemiol 1998; 27:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/43\">",
"      Sloan JH, Kellermann AL, Reay DT, et al. Handgun regulations, crime, assaults, and homicide. A tale of two cities. N Engl J Med 1988; 319:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/44\">",
"      Marinho de Souza Mde F, Macinko J, Alencar AP, et al. Reductions in firearm-related mortality and hospitalizations in Brazil after gun control. Health Aff (Millwood) 2007; 26:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/45\">",
"      Kellermann AL, Westphal L, Fischer L, Harvard B. Weapon involvement in home invasion crimes. JAMA 1995; 273:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/46\">",
"      Branas CC, Richmond TS, Culhane DP, et al. Investigating the link between gun possession and gun assault. Am J Public Health 2009; 99:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/47\">",
"      Kellermann AL, Rivara FP, Rushforth NB, et al. Gun ownership as a risk factor for homicide in the home. N Engl J Med 1993; 329:1084.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Justice, Federal Bureau of Investigation. Uniform Crime Reports: Crime in the United States, 1991. US Government Printing Office; Washington, DC 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/49\">",
"      Parker RN. Alcohol and violence: connections, evidence and possibilities for prevention. J Psychoactive Drugs 2004; Suppl 2:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/50\">",
"      Hagg&aring;rd-Grann U, Hallqvist J, L&aring;ngstr&ouml;m N, M&ouml;ller J. The role of alcohol and drugs in triggering criminal violence: a case-crossover study*. Addiction 2006; 101:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/51\">",
"      Martin SE. The epidemiology of alcohol-related interpersonal violence. Alcohol Health Res World 1992; 16:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/52\">",
"      Brewer RD, Swahn MH. Binge drinking and violence. JAMA 2005; 294:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/53\">",
"      Hiroeh U, Appleby L, Mortensen PB, Dunn G. Death by homicide, suicide, and other unnatural causes in people with mental illness: a population-based study. Lancet 2001; 358:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/54\">",
"      Yu Q, Scribner R, Carlin B, et al. Multilevel spatio-temporal dual changepoint models for relating alcohol outlet destruction and changes in neighbourhood rates of assaultive violence. Geospat Health 2008; 2:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/55\">",
"      Marcell AV, Klein JD, Fischer I, et al. Male adolescent use of health care services: where are the boys? J Adolesc Health 2002; 30:35.",
"     </a>",
"    </li>",
"    <li>",
"     AuCoin K, Beauchamp D. Canadian Centre for Justice Statistics, Statistics Canada. Impacts and Consequences of Victimization, GSS 2004. file://www.statcan.gc.ca/pub/85-002-x/85-002-x2007001-eng.pdf (Accessed on June 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/57\">",
"      Davidson JR, Hughes D, Blazer DG, George LK. Post-traumatic stress disorder in the community: an epidemiological study. Psychol Med 1991; 21:713.",
"     </a>",
"    </li>",
"    <li>",
"     The GUNS mnemonic; the Handgun Epidemic Lowering Plan (HELP) Children's Memorial Hospital, Chicago.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/59\">",
"      Hayes DN, Sege R. FiGHTS: a preliminary screening tool for adolescent firearms-carrying. Ann Emerg Med 2003; 42:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/60\">",
"      Sege R, Stringham P, Short S, Griffith J. Ten years after: examination of adolescent screening questions that predict future violence-related injury. J Adolesc Health 1999; 24:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/61\">",
"      Kilpatrick DG, Acierno R. Mental health needs of crime victims: epidemiology and outcomes. J Trauma Stress 2003; 16:119.",
"     </a>",
"    </li>",
"    <li>",
"     Colorado shooting: How Americans Deal with Media-Driven Events. Christian Sceince Monitor 2012. Available at: file://www.csmonitor.com/USA/Society/2012/0725/Colorado-shooting-How-Americans-deal-with-media-driven-events (Accessed on July 26, 2012).",
"    </li>",
"    <li>",
"     Gutman M. Trayvon Martin Case: Timeline of Events. ABC News 2012. Available at: file://abcnews.go.com/blogs/headlines/2012/05/trayvon-martin-case-timeline-of-events (Accessed on July 16, 2012).",
"    </li>",
"    <li>",
"     US Department of Justice, Federal Bureau of Investigation, Uniform Crime Reports. Crime in the United States, 2009. www2.fbi.gov/ucr/cius2009 (Accessed on June 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/65\">",
"      May JP, Ferguson MG, Ferguson R, Cronin K. Prior nonfatal firearm injuries in detainees of a large urban jail. J Health Care Poor Underserved 1995; 6:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/66\">",
"      Tonorezos ES, Breysse PN, Matsui EC, et al. Does neighborhood violence lead to depression among caregivers of children with asthma? Soc Sci Med 2008; 67:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/67\">",
"      Bazargan M. The effects of health, environmental, and socio-psychological variables on fear of crime and its consequences among urban black elderly individuals. Int J Aging Hum Dev 1994; 38:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/68\">",
"      Whitley R, Prince M. Fear of crime, mobility and mental health in inner-city London, UK. Soc Sci Med 2005; 61:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/69\">",
"      Wright RJ, Mitchell H, Visness CM, et al. Community violence and asthma morbidity: the Inner-City Asthma Study. Am J Public Health 2004; 94:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/70\">",
"      Weil DS, Hemenway D. Loaded guns in the home. Analysis of a national random survey of gun owners. JAMA 1992; 267:3033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/71\">",
"      Patterns of Gun Acquisition, Carrying, and Use Among Juvenile and Adult Arrestees: Evidence from a High-Crime City. Justice Quarterly 2008; 25:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/72\">",
"      Warr M. Fear of victimization: Why are women and the elderly more afraid? Soc Psychol Q 1984; 65:433.",
"     </a>",
"    </li>",
"    <li>",
"     US Preventive Services Task Force. Guide to Clinical Preventive Services. US Preventive Services Task Force, Washington, DC 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/74\">",
"      Task Force on Community Preventive Services. A recommendation to reduce rates of violence among school-aged children and youth by means of universal school-based violence prevention programs. Am J Prev Med 2007; 33:S112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/75\">",
"      Johnson SB, Bradshaw CP, Wright JL, et al. Characterizing the teachable moment: is an emergency department visit a teachable moment for intervention among assault-injured youth and their parents? Pediatr Emerg Care 2007; 23:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/76\">",
"      Freudenberg N. Jails, prisons, and the health of urban populations: a review of the impact of the correctional system on community health. J Urban Health 2001; 78:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/77\">",
"      Tardiff K, Marzuk PM, Leon AC, et al. Human immunodeficiency virus among trauma patients in New York City. Ann Emerg Med 1998; 32:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/78\">",
"      Bell CC, Jenkins EJ, Kpo W, Rhodes H. Response of emergency rooms to victims of interpersonal violence. Hosp Community Psychiatry 1994; 45:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/79\">",
"      Adolescent assault victim needs: a review of issues and a model protocol. American Academy of Pediatrics Task Force on Adolescent Assault Victim Needs. Pediatrics 1996; 98:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/80\">",
"      Dowd MD, Sege RD, Council on Injury, Violence, and Poison Prevention Executive Committee, American Academy of Pediatrics. Firearm-related injuries affecting the pediatric population. Pediatrics 2012; 130:e1416.",
"     </a>",
"    </li>",
"    <li>",
"     Gun Safety: Keeping Children Safe. The Injury Prevention Program, American Academy of Pediatrics. file://www.healthychildren.org/English/safety-prevention/all-around/Pages/Gun-Safety-Keeping-Children-Safe.aspx (Accessed on June 08, 2011).",
"    </li>",
"    <li>",
"     Firearms: Safety and Regulation. ACP Policy Compendium 2012. Available at: file://www.acponline.org/ (Accessed on July 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/83\">",
"      State bill aims to silence counseling on firearm safety. AAP News 2011; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/84\">",
"      Firearm injury prevention. American College of Physicians. Ann Intern Med 1998; 128:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/85\">",
"      Cohen L, Swift S. A public health approach to the violent epidemic in the United States. Enviornmental and Urbanization 1993; 5:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/86\">",
"      Spinks A, Turner C, Nixon J, McClure R. The 'WHO Safe Communities' model for the prevention of injury in whole populations. Cochrane Database Syst Rev 2005; :CD004445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/87\">",
"      Brundtland GH. From the World Health Organization. Violence prevention: a public health approach. JAMA 2002; 288:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/88\">",
"      Committee on Injury, Violence, and Poison Prevention. Policy statement--Role of the pediatrician in youth violence prevention. Pediatrics 2009; 124:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18696/abstract/89\">",
"      Cassel CK, Nelson EA, Smith TW, et al. Internists' and surgeons' attitudes toward guns and firearm injury prevention. Ann Intern Med 1998; 128:224.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2756 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-EBA391572F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18696=[""].join("\n");
var outline_f18_16_18696=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXTENT AND CONSEQUENCES OF COMMUNITY VIOLENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS FOR COMMUNITY VIOLENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Age, gender, socioeconomic status, and race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Handguns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Alcohol and drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HISTORY AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COUNSELING ABOUT VIOLENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recommendations of various groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LEGAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IMPACT ON SOCIETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATIENT RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2756\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2756|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/33/19998\" title=\"figure 1\">",
"      International homicide rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/10/36013\" title=\"figure 2\">",
"      Circumstances lead to homicide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/12/23759\" title=\"figure 3\">",
"      Gang tattoos",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2756|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/22/4459\" title=\"table 1\">",
"      Screen quest GUNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/45/14043\" title=\"table 2\">",
"      Violence screening questions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/46/24299\" title=\"table 3\">",
"      Screen quest adol firearm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/57/29598\" title=\"table 4\">",
"      Screen quest future injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=related_link\">",
"      Intimate partner violence: Epidemiology and health consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40617?source=related_link\">",
"      Peer violence and violence prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14921?source=related_link\">",
"      Prevention of firearm injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_16_18697="Seizures in patients with primary and metastatic brain tumors";
var content_f18_16_18697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Seizures in patients with primary and metastatic brain tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/16/18697/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18697/contributors\">",
"     Jan Drappatz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18697/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18697/contributors\">",
"     Edward K Avila, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/16/18697/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18697/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18697/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/16/18697/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18697/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18697/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/16/18697/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are a common and potentially devastating complication of both primary and metastatic brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/1\">",
"     1",
"    </a>",
"    ]. Such seizures are focal in origin and may either remain focal or secondarily generalize. The diagnosis of a seizure disorder is usually made clinically.",
"   </p>",
"   <p>",
"    The epidemiology and treatment of seizures, prophylactic use of antiepileptic drugs (AEDs), and complications of therapy in patients with brain tumors will be reviewed here. The clinical manifestations of brain tumors and the general management of seizures are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical presentation and diagnosis of brain tumors\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784669456\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are a relatively common problem in patients with brain tumors. Seizures may be the initial manifestation of a brain tumor or may occur during the course of disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical presentation and diagnosis of brain tumors\", section on 'Seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors that influence the incidence of seizures include tumor-type and location:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with primary brain tumors, seizures are less common with high-grade compared with low-grade gliomas [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/2\">",
"       2",
"      </a>",
"      ]. As an example, the prevalence rates of epilepsy in a series of 1028 patients with primary brain tumors were 49, 69, and 85 percent among patients with glioblastoma (GBM), anaplastic glioma, and low-grade glioma, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/3\">",
"       3",
"      </a>",
"      ]. However, in one carefully studied series of 75 high-grade gliomas, seizures were present at diagnosis in 35 (52 percent), but occurred at some time during the course of the disease in 60 (80 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/4\">",
"       4",
"      </a>",
"      ]. Dysregulation of adenosine kinase in the peritumoral region of astrocytic brain tumors has been postulated to play a role in tumor-related epileptogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other less common tumor types also appear to have a high incidence of seizures. As an example, ganglioglioma and dysembryoplastic neuroepithelial tumors have an incidence of seizures greater than 80 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seizures are less common in patients with metastatic lesions compared to those with primary brain tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/3,8\">",
"       3,8",
"      </a>",
"      ]. In a retrospective series that included 470 patients with brain metastases, seizures were diagnosed in 24 percent at some point during the illness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/9\">",
"       9",
"      </a>",
"      ]. Seizures were most common in melanoma, 67 percent (possibly result of the tendency of melanoma to involve the cerebral cortex and to hemorrhage) and least common in breast cancer, 16 percent. Lung (29 percent) and unknown primary sources (25 percent) were intermediate.",
"     </li>",
"     <li>",
"      Clinical situations in which the risk of seizures may be relatively higher include patients with metastases involving of areas of high epileptogenicity such as the motor cortex or when metastases involving both the brain and leptomeninges.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seizures may be caused by factors other than metastases in patients with tumors arising outside the central nervous system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the first seizure in adults\", section on 'Etiology'",
"    </a>",
"    .) Examples of other potential etiologies of seizures that are more common in cancer patients than in the general population include metabolic encephalopathies such as hyponatremia or hypoglycemia, opportunistic infections, or side effects of therapy. Paraneoplastic encephalitis is another potential cause of seizures in patients with systemic cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link\">",
"     \"Paraneoplastic and autoimmune encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4357978\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures that arise in patients with brain tumors are either partial or secondarily generalized. The specific ictal and peri-ictal manifestations typically reflect the tumor&rsquo;s location within the brain and are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with brain tumors can also develop status epilepticus which may be either convulsive or nonconvulsive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link\">",
"     \"Status epilepticus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4357903\">",
"    <span class=\"h2\">",
"     Nonconvulsive status epilepticus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonconvulsive status epilepticus (NCSE) has been reported in patients with systemic cancer. The clinical manifestations of NCSE are often nonspecific, such as an altered personality or a decreased level of alertness. These can be difficult to distinguish from, and may co-exist, with other causes of altered mental status.",
"   </p>",
"   <p>",
"    Case series emphasize that NCSE may occur in patients with systemic cancer who do not have intracranial metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. One study of patients with systemic cancer reported NCSE in 6 percent of those with impaired mental status; none had brain metastasis, and the origin of the seizure activity was presumably related to systemic factors such as metabolic encephalopathy (eg, hyponatremia or hypoglycemia), infection, or side effects of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/10\">",
"     10",
"    </a>",
"    ]. Paraneoplastic encephalitis is another potential cause of seizures and altered mental status in a patient with systemic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4358123\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new seizure should prompt a neuroimaging study (CT or MRI depending on the clinical setting) in a patient regardless of a known diagnosis of systemic or brain tumor (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link&amp;anchor=H25#H25\">",
"     \"Evaluation of the first seizure in adults\", section on 'Neuroimaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13082?source=see_link\">",
"     \"Neuroimaging in the evaluation of seizures and epilepsy\"",
"    </a>",
"    .). Seizures themselves, particularly if prolonged, can produce changes on brain MRI or PET, which broadens the differential for patients with brain tumors and new imaging abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22871?source=see_link\">",
"     \"Magnetic resonance imaging changes related to acute seizure activity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An electroencephalogram (EEG) may not be required in a patient who has had a clinically obvious seizure and has recovered. EEG is also not routinely needed for those without clinical evidence of a seizure. However, EEG is essential for making the diagnosis of NCSE and should be considered in patients with systemic or brain cancer who have altered mental status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures in and of themselves are an important source of morbidity and mortality in patients with primary and secondary brain tumors and require aggressive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784669449\">",
"    <span class=\"h2\">",
"     Antiepileptic drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who experience a seizure due to a brain tumor should be treated with monotherapy with a standard first-line antiepileptic drug (AED) because of the high risk of recurrence. There are no randomized trials that have established the superiority of one agent over others. To minimize toxicity, patients should be treated with the lowest effective dose of the AED, and serum levels monitored, when applicable, at the recommended intervals. Potential interactions between the AED and any chemotherapeutic agent should also be considered when choosing an AED and monitoring levels (see new table). &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of epilepsy in adults\", section on 'Selection of an AED'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Newer AEDs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/19/35125?source=see_link\">",
"     lacosamide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , are generally preferred for seizure treatment in this setting, since these agents have a more favorable safety profile compared with older agents and avoid potential drug-drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. As an example, a prospective observational study of 176 consecutive patients with glioma that included 82 patients with a history of epilepsy found that levetiracetam was safe in this population and appeared to be at least as effective as older agents [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/15\">",
"     15",
"    </a>",
"    ]. While it is not in general possible to predict what AED is likely to be most efficacious, a preliminary study of 34 patients with glioma and epilepsy found that tumoral expression of synaptic vesicle protein 2A (SV2A) was associated with a positive response to levetiracetam monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/18\">",
"     18",
"    </a>",
"    ].(See",
"    <a class=\"local\" href=\"#H9\">",
"     'Drug-drug interactions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of epilepsy in adults\", section on 'Selection of an AED'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    may be a drug of choice in patients with glioma who are also treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    . A retrospective analysis of AED use among patients enrolled in a clinical trial of temozolomide found that the 97 patients on valproic acid alone (whether for seizure therapy or prophylaxis) appeared to have an increased survival benefit from treatment with radiation therapy and temozolomide compared with patients on either no AED or enzyme-inducing AEDs (HR = 0.39 versus 0.69 versus 0.67) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/19\">",
"     19",
"    </a>",
"    ]. The mechanism underlying this finding is unclear; it is postulated that valproate may enhance the antitumor effects of radiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    temozolomide [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/20\">",
"     20",
"    </a>",
"    ]. Valproate is a histone deacetylase (HDAC) inhibitor and may have an antitumor affect on its own [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/21\">",
"     21",
"    </a>",
"    ]. However, valproate treatment was also associated with a higher rate of hematologic toxicity that can lead to treatment delays. Further studies are required to define the role of valproate in the management of patients with glioma.",
"   </p>",
"   <p>",
"    The initial use of multidrug regimens should be avoided whenever possible. Monotherapy increases the likelihood of compliance, provides a wider therapeutic window, and is more cost-effective than combination drug treatment. There are fewer side effects and idiosyncratic reactions associated with single drug therapy and drug-drug interactions are avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Subsequent drug trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If patients experience recurrent seizures after initiation of therapy, doses of the initial agent should be escalated and adequate serum concentrations should be verified before switching drugs or adding a second agent. If inadequate seizure control cannot be obtained, an alternative AED should be prescribed or a second AED added. In one series of 140 brain tumor patients, 99 of whom had seizures, only 45 responded to a single AED (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/4\">",
"     4",
"    </a>",
"    ]. The most effective regimen was a combination of valproate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784669734\">",
"    <span class=\"h2\">",
"     Nonpharmacological approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of the causal tumor including surgery, radiation therapy, or systemic therapy (chemotherapy, molecularly targeted agents) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/22\">",
"     22",
"    </a>",
"    ] may ameliorate seizure activity whether or not patients can be adequately managed with drug therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery &mdash; Experts widely agree on gross total resection of a primary brain tumor with clear margins when this is feasible. A systematic review of 910 reported patients with low-grade glioneuronal tumors (gangliomas and dysembryoplastic neuroepithelial tumors (DNETs)) found that seizure remission was achieved after gross total resection in 80 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/23\">",
"       23",
"      </a>",
"      ]. While some studies have suggested that extratemporal epilepsy may be more difficult to control with surgery compared with temporal lobe epilepsy, outcomes in this report were not different between those with temporal lobe versus extratemporal tumors. As has been suggested in other reports, extended resection of temporal lobe tumors with hippocampectomy conferred additional benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/23-25\">",
"       23-25",
"      </a>",
"      ] (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=see_link\">",
"       \"Surgical therapy of epilepsy in adults\"",
"      </a>",
"      .). Prognostic factors that have been associated with improved seizure outcomes after brain tumor resection have been shorter duration of epilepsy prior to surgery, a single focus on EEG, a single lesion on neuroimaging, and complete tumor resection [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiation therapy &mdash; The EORTC study compared the efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/27\">",
"       27",
"      </a>",
"      ]. Early radiation treatment was associated with a lower seizure rate, 25 versus 41 percent, although it did not affect overall survival. &nbsp;",
"     </li>",
"     <li>",
"      Systemic therapy &mdash; There are reports of patients with low grade primary brain tumors and epilepsy having improved seizure control and a few achieving seizure freedom with the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      or nitrosoureas [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. The mTOR inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      , has been shown to decrease the size of subependymal giant-cell astrocytomas in tuberous sclerosis and also resulted in improved seizure control in an open label study of 28 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/31\">",
"       31",
"      </a>",
"      ]. It was unclear if seizure reduction with everolimus was a result of decreased tumor burden or perhaps an antiepileptic effect of mTOR inhibition, such as regulating protein synthesis and microanatomical changes that underlie synaptic, long-term potentiation and depression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784669897\">",
"    <span class=\"h2\">",
"     Patients without a history of a seizure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antiepileptic drugs (AEDs) are generally not recommended for patients with a primary or metastatic brain tumor and without a history of antecedent seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis that included data from five randomized trials using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , or valproic acid as prophylactic AEDs concluded that there was no evidence to support their use in patients with brain tumors without a history of seizures, regardless of the type of tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/33\">",
"     33",
"    </a>",
"    ]. A subsequent systemic review by the Cochrane collaboration also concluded that there was no difference between placebo and treatment with phenobarbital, phenytoin, or valproic acid in preventing a first seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/34\">",
"     34",
"    </a>",
"    ]. Moreover, adverse events were more frequent with AED therapy. A more recent systematic review of the evidence also concluded that routine prophylactic use of AEDs is not recommended, but the recommendation is not based upon randomized clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since these guidelines were published, a number of new AEDs have been introduced into clinical practice. Although comparative studies have not been conducted on patients with brain tumors, some evidence from patients with cranial trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/36\">",
"     36",
"    </a>",
"    ], brain surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/37\">",
"     37",
"    </a>",
"    ], or subarachnoidal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] suggests that newer AEDs with a more favorable safety profile are preferable to older AEDs. However, there is no evidence that they are more effective in preventing seizures in patients with brain tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Postoperative prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;AED prophylaxis is suggested for patients undergoing surgery for brain tumors. The data supporting this approach are drawn from observational studies and a limited number of small randomized trials, some but not all of which have shown a lower risk of early postoperative seizures in patients treated with a prophylactic AED [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/37,40-46\">",
"     37,40-46",
"    </a>",
"    ]. This recommendation places a high value on prevention of early postoperative seizures, which are uncommon but can be devastating, and a lower value on the potential adverse effects of AEDs, which are of particular concern for older AEDs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     Levetiracetam",
"    </a>",
"    is probably the most widely used alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and appears to be effective and well tolerated in the postoperative setting. Support for the use of levetiracetam is drawn from observational data [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/37,43\">",
"     37,43",
"    </a>",
"    ] and a single-center randomized study in which 81 post-craniotomy patients (50 percent with intracranial tumors) were treated with three days of intravenous levetiracetam or phenytoin followed by up to three months of oral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/47\">",
"     47",
"    </a>",
"    ]. Levetiracetam was similarly tolerated compared with phenytoin, and there was no difference in discontinuation rate or number of patients reporting side effects. Seizures occurred in significantly fewer patients taking levetiracetam (zero versus six), and there was a trend towards more major side effects in patients assigned to phenytoin (mostly allergy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drug rash). Mood",
"    <span class=\"nowrap\">",
"     disturbance/irritability",
"    </span>",
"    was the most common side effect in patients taking levetiracetam (19 percent).",
"    <br/>",
"    <br/>",
"    The optimal duration of postoperative seizure prophylaxis is not well established. Based upon a review of older studies, the Quality Standards Subcommittee of the American Academy of Neurology recommends that AEDs should be gradually tapered beginning one to two weeks after the surgery and then discontinued in patients who remain free of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS OF AED THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784670660\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The important side effects of the commonly used AEDs are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef59755 \" href=\"UTD.htm?3/28/3533\">",
"     table 1",
"    </a>",
"    ). In patients with brain tumors, the incidence of adverse effects from AEDs ranges from 30 to 40 percent, which is higher than that observed in seizure patients without brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/8,32\">",
"     8,32",
"    </a>",
"    ]. Overall, 24 percent of patients with brain tumors who are receiving AEDs experience side effects that are severe enough to warrant a change in or discontinuation of AED therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/32\">",
"     32",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    is associated with a higher incidence of shoulder-hand syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Drug rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with brain tumors who are undergoing radiation therapy have a higher likelihood of drug rash with AEDs; a small percentage develop Stevens-Johnson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. In addition, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , cranial irradiation, and the gradual reduction of concomitant steroid therapy may be particularly associated with erythema multiforme",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Stevens-Johnson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/51\">",
"     51",
"    </a>",
"    ]. The mechanism is unknown but may result from depletion of suppressor T cells by the radiation therapy, allowing the development of a hypersensitivity reaction to phenytoin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/50\">",
"     50",
"    </a>",
"    ]. Stevens-Johnson syndrome has also been described in glioma patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Cross-sensitivity rash is common particularly when switching from carbamazepine to phenytoin or vice versa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/54\">",
"     54",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     Levetiracetam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    rarely causes rash [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/54\">",
"     54",
"    </a>",
"    ]. Patients of Asian ancestry should be tested for the HLA-B*1502 allel before prescribing carbamazepine and possibly phenytoin or other AEDs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial treatment of epilepsy in adults\", section on 'Potential adverse events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Drug-drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to direct adverse effects, several AEDs have clinically significant interactions with other medications commonly used in brain tumor patients. These drug-drug interactions can have several different mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction of the cytochrome P450 enzyme system &ndash; Induction of hepatic metabolism via the cytochrome P450 system can significantly increase the clearance of other agents. AEDs that induce the P450 system can significantly reduce serum levels of antitumor agents such as the nitrosoureas,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and others (",
"      <a class=\"graphic graphic_table graphicRef69769 \" href=\"UTD.htm?35/24/36236\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef85983 \" href=\"UTD.htm?39/22/40300\">",
"       table 3",
"      </a>",
"      ). As a result, a higher dose of these antineoplastic drugs may be required in patients taking enzyme-inducing AEDs. Examples of AEDs that are potent inhibitors of hepatic drug metabolism include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      In addition, antitumor drugs may induce the cytochrome P450 enzymes, thus changing the serum levels of AEDs (",
"      <a class=\"graphic graphic_table graphicRef85983 \" href=\"UTD.htm?39/22/40300\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      AEDs may also interact with corticosteroids used to control cerebral edema. As an example, phenytoin induces the hepatic metabolism of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , significantly reducing its half-life and bioavailability [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/2\">",
"       2",
"      </a>",
"      ]. Conversely, dexamethasone induction of these enzymes may reduce serum phenytoin levels, potentially compromising seizure control.",
"     </li>",
"     <li>",
"      Displacement of protein-bound agents &ndash; AEDs and chemotherapy agents that are highly protein bound can interact by displacing each other. This displacement can alter levels of free and protein-bound drug for both AEDs and the chemotherapy drug.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       Levetiracetam",
"      </a>",
"      has little protein binding.",
"     </li>",
"     <li>",
"      Enzyme inhibition &ndash; Valproic acid inhibits multiple components of the cytochrome p450 system. This can result in decreased metabolism of chemotherapy agents such as the nitrosoureas and therefore increased toxicity due to bone marrow suppression [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Newer AEDs that are not metabolized via the cytochrome P450 enzyme system and do not inhibit these enzymes thus have important advantages over older agents. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/19/35125?source=see_link\">",
"     lacosamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4358429\">",
"    <span class=\"h1\">",
"     DRIVING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uncontrolled seizures should not drive.",
"   </p>",
"   <p>",
"    There are no general guidelines on driving restrictions for patients with seizures that are controlled on medication or during the period of AED taper. State regulations differ as to the duration a patient must be seizure free in order to legally drive. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32568?source=see_link\">",
"     \"Driving restrictions for patients with seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with intracranial tumors who have not had seizures and who drive are often placed on prophylactic AEDs despite the lack of evidence that this practice reduces the incidence of seizures.",
"   </p>",
"   <p>",
"    The implications for driving in patients who have not experienced a seizure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link&amp;anchor=H876240#H876240\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\", section on 'Driving'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13080767\">",
"    <span class=\"h1\">",
"     END OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures have been reported in 35 to 50 percent of brain tumor patients in the last month of life [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. Patients with a history of seizures, particularly those with late-onset epilepsy, appear to be at highest risk. In a retrospective study of 157 patients with malignant glioma cared for at home, 37 percent of patients had at least one seizure in the month before death; 79 percent were focal, 18 percent were generalized, and 2.5 percent were status epilepticus. The risk of seizure was as high as 76 percent in patients with late-onset epilepsy and 11 percent in patients with no prior history of seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/59\">",
"     59",
"    </a>",
"    ]. In one study, the risk of seizure in the last month of life was higher for patients with malignant glioma than for those with brain metastases (34 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of seizures and epilepsy in brain tumor patients at the end of life has not been well studied, but several general principles apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a history of seizures should continue antiepileptic drug (AED) therapy as long as they are able to take oral medications. As with earlier stages of the disease, there is no clear role for prophylactic AEDs in patients who have never had a seizure.",
"     </li>",
"     <li>",
"      Dysphagia is common in brain tumor patients at the end of life [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/60\">",
"       60",
"      </a>",
"      ], and the route of administration of AEDs may need to be adapted. In some cases, switching to a suspension or sprinkles (for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ) can extend the length of time a patient is able to continue on oral therapy. When patients can no longer take medication orally, clinical judgment should be used as to whether to continue AEDs in this setting; it can be appropriate to simply stop AEDs, particularly if the patient&rsquo;s life expectancy is short. Rectal or transdermal routes can be used, although the availability of alternative routes varies by AED and pharmacokinetic data for rectal administration are limited for many drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/57\">",
"       57",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       Phenobarbital",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , valproic acid, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      can be given rectally without the need for dose adjustments [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/62\">",
"       62",
"      </a>",
"      ]. Rectal administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      suspension may lead to steady state trough concentrations of 50 percent less than with oral administration, suggesting that a dosing adjustment of approximately 2:1 may be necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18697/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is useful for clinicians to discuss an end of life AED strategy in advance with home care nurses and with the patient and family members.",
"     </li>",
"     <li>",
"      When prolonged seizures occur, benzodiazepines should be available for use as an abortive medication. Rectal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      (0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 10 to 20mg) can be repeated hourly until the seizure stops. Sublingual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      is also available. For patients who develop frequent seizures, scheduled doses of diazepam or lorazepam can be given.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are a common complication of both primary and metastatic brain tumors. Management of seizures caused by brain tumors is similar to that in noncancer patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have experienced one or more seizures associated with a primary or metastatic brain tumor, we recommend initial treatment with a single agent antiepileptic drug (AED) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H784669449\">",
"       'Antiepileptic drug therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Drug-drug interactions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link&amp;anchor=H5#H5\">",
"       \"Initial treatment of epilepsy in adults\", section on 'Selection of an AED'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To avoid clinically significant drug-drug interactions, we suggest monotherapy with a non-enzyme inducing AED such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, use of other AEDs that can be titrated quickly when drug interactions are not a concern should also be considered. (See",
"      <a class=\"local\" href=\"#H784669449\">",
"       'Antiepileptic drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If patients have incomplete seizure control while on therapy, adequate serum levels should be verified before switching drugs or adding a second agent. (See",
"      <a class=\"local\" href=\"#H784669449\">",
"       'Antiepileptic drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients without a history of seizures and who have not undergone a neurosurgical procedure, we recommend NOT using prophylactic AEDs (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H784669897\">",
"       'Patients without a history of a seizure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients without a history of seizures who undergo brain tumor resection, we suggest that prophylactic AEDs be given perioperatively (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Prophylactic AEDs can be gradually tapered postoperatively if the patient remains seizure free. To avoid clinically significant drug-drug interactions, we suggest the use of non-enzyme inducing AEDs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Long-term seizure prophylaxis is not required. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Postoperative prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Drug-drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Seizures are common in brain tumor patients at the end of life, particularly in patients with late-onset epilepsy. It is useful to discuss an AED strategy in advance with home care nurses and family members. For patients receiving hospice care, benzodiazepines should be available in the home for use as an abortive medication. (See",
"      <a class=\"local\" href=\"#H13080767\">",
"       'End of life'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/1\">",
"      Avila EK, Graber J. Seizures and epilepsy in cancer patients. Curr Neurol Neurosci Rep 2010; 10:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/2\">",
"      van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/3\">",
"      Lote K, Stenwig AE, Skullerud K, Hirschberg H. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 1998; 34:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/4\">",
"      van Breemen MS, Rijsman RM, Taphoorn MJ, et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 2009; 256:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/5\">",
"      de Groot M, Iyer A, Zurolo E, et al. Overexpression of ADK in human astrocytic tumors and peritumoral tissue is related to tumor-associated epilepsy. Epilepsia 2012; 53:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/6\">",
"      Herman ST. Epilepsy after brain insult: targeting epileptogenesis. Neurology 2002; 59:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/7\">",
"      Villemure JG, de Tribolet N. Epilepsy in patients with central nervous system tumors. Curr Opin Neurol 1996; 9:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/8\">",
"      Pace A, Bove L, Innocenti P, et al. Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998; 17:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/9\">",
"      Oberndorfer S, Schmal T, Lahrmann H, et al. [The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna]. Wien Klin Wochenschr 2002; 114:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/10\">",
"      Cocito L, Audenino D, Primavera A. Altered mental state and nonconvulsive status epilepticus in patients with cancer. Arch Neurol 2001; 58:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/11\">",
"      Drislane FW. Nonconvulsive status epilepticus in patients with cancer. Clin Neurol Neurosurg 1994; 96:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/12\">",
"      Hormigo A, Liberato B, Lis E, DeAngelis LM. Nonconvulsive status epilepticus in patients with cancer: imaging abnormalities. Arch Neurol 2004; 61:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/13\">",
"      Morris PG, Gutin PH, Avila EK, et al. Seizures and radionecrosis from non-small-cell lung cancer presenting as increased fluorodeoxyglucose uptake on positron emission tomography. J Clin Oncol 2011; 29:e324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/14\">",
"      Rossetti AO, Stupp R. Epilepsy in brain tumor patients. Curr Opin Neurol 2010; 23:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/15\">",
"      Rosati A, Buttolo L, Stefini R, et al. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol 2010; 67:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/16\">",
"      Usery JB, Michael LM 2nd, Sills AK, Finch CK. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol 2010; 99:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/17\">",
"      Maschio M, Dinapoli L, Gomellini S, et al. Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. J Neurooncol 2010; 98:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/18\">",
"      de Groot M, Aronica E, Heimans JJ, Reijneveld JC. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. Neurology 2011; 77:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/19\">",
"      Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011; 77:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/20\">",
"      Wen PY, Schiff D. Valproic acid as the AED of choice for patients with glioblastoma? The jury is out. Neurology 2011; 77:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/21\">",
"      Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008; 34:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/22\">",
"      Rud&agrave; R, Trevisan E, Soffietti R. Epilepsy and brain tumors. Curr Opin Oncol 2010; 22:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/23\">",
"      Englot DJ, Berger MS, Barbaro NM, Chang EF. Factors associated with seizure freedom in the surgical resection of glioneuronal tumors. Epilepsia 2012; 53:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/24\">",
"      Phi JH, Kim SK, Cho BK, et al. Long-term surgical outcomes of temporal lobe epilepsy associated with low-grade brain tumors. Cancer 2009; 115:5771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/25\">",
"      Luyken C, Bl&uuml;mcke I, Fimmers R, et al. The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 2003; 44:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/26\">",
"      Chan CH, Bittar RG, Davis GA, et al. Long-term seizure outcome following surgery for dysembryoplastic neuroepithelial tumor. J Neurosurg 2006; 104:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/27\">",
"      van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005; 366:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/28\">",
"      Pace A, Vidiri A, Gali&egrave; E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003; 14:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/29\">",
"      Frenay MP, Fontaine D, Vandenbos F, Lebrun C. First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. Eur J Neurol 2005; 12:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/30\">",
"      Sherman, JH, Moldovan, K, Yoeh, HK, et, al. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg 2011; 0:in press.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/31\">",
"      Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/32\">",
"      Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/33\">",
"      Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004; 79:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/34\">",
"      Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2008; :CD004424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/35\">",
"      Mikkelsen T, Paleologos NA, Robinson PD, et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/36\">",
"      Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care 2010; 12:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/37\">",
"      Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 2008; 71:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/38\">",
"      Rosengart AJ, Huo JD, Tolentino J, et al. Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg 2007; 107:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/39\">",
"      Shah D, Husain AM. Utility of levetiracetam in patients with subarachnoid hemorrhage. Seizure 2009; 18:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/40\">",
"      Lwu S, Hamilton MG, Forsyth PA, et al. Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience. J Neurooncol 2010; 96:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/41\">",
"      Sughrue ME, Rutkowski MJ, Chang EF, et al. Postoperative seizures following the resection of convexity meningiomas: are prophylactic anticonvulsants indicated? Clinical article. J Neurosurg 2011; 114:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/42\">",
"      Kuijlen JM, Teernstra OP, Kessels AG, et al. Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure 1996; 5:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/43\">",
"      Zachenhofer I, Donat M, Oberndorfer S, Roessler K. Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery. J Neurooncol 2011; 101:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/44\">",
"      Komotar RJ, Raper DM, Starke RM, et al. Prophylactic antiepileptic drug therapy in patients undergoing supratentorial meningioma resection: a systematic analysis of efficacy. J Neurosurg 2011; 115:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/45\">",
"      Wu AS, Trinh VT, Suki D, et al. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg 2013; 118:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/46\">",
"      Pulman J, Greenhalgh J, Marson AG. Antiepileptic drugs as prophylaxis for post-craniotomy seizures. Cochrane Database Syst Rev 2013; 2:CD007286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/47\">",
"      Fuller KL, Wang YY, Cook MJ, et al. Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study. Epilepsia 2013; 54:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/48\">",
"      Taylor LP, Posner JB. Phenobarbital rheumatism in patients with brain tumor. Ann Neurol 1989; 25:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/49\">",
"      Mamon HJ, Wen PY, Burns AC, Loeffler JS. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia 1999; 40:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/50\">",
"      Delattre JY, Safai B, Posner JB. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 1988; 38:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/51\">",
"      Khafaga YM, Jamshed A, Allam AA, et al. Stevens-Johnson syndrome in patients on phenytoin and cranial radiotherapy. Acta Oncol 1999; 38:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/52\">",
"      Hoang-Xuan K, Delattre JY, Poisson M. Stevens-Johnson syndrome in a patient receiving cranial irradiation and carbamazepine. Neurology 1990; 40:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/53\">",
"      Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998; 39 Suppl 7:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/54\">",
"      Hirsch LJ, Arif H, Nahm EA, et al. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008; 71:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/55\">",
"      Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol 2009; 22:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/56\">",
"      Bourg V, Lebrun C, Chichmanian RM, et al. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001; 12:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/57\">",
"      Krouwer HG, Pallagi JL, Graves NM. Management of seizures in brain tumor patients at the end of life. J Palliat Med 2000; 3:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/58\">",
"      Oberndorfer S, Lindeck-Pozza E, Lahrmann H, et al. The end-of-life hospital setting in patients with glioblastoma. J Palliat Med 2008; 11:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/59\">",
"      Pace A, Villani V, Di Lorenzo C, et al. Epilepsy in the end-of-life phase in patients with high-grade gliomas. J Neurooncol 2013; 111:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/60\">",
"      Sizoo EM, Braam L, Postma TJ, et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro Oncol 2010; 12:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/61\">",
"      Pace A, Di Lorenzo C, Lorenzo CD, et al. End of life issues in brain tumor patients. J Neurooncol 2009; 91:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18697/abstract/62\">",
"      Davis MP, Walsh D, LeGrand SB, Naughton M. Symptom control in cancer patients: the clinical pharmacology and therapeutic role of suppositories and rectal suspensions. Support Care Cancer 2002; 10:117.",
"     </a>",
"    </li>",
"    <li>",
"     Gustafson MC, Penovich PE, Frost MD. Levetiracetam absorption after rectal administration: 2 case reports (Abstr 2.358). Epilepsia 2005; 46 Suppl 8:2011.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5181 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18697=[""].join("\n");
var outline_f18_16_18697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H784669456\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4357978\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4357903\">",
"      Nonconvulsive status epilepticus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4358123\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H784669449\">",
"      Antiepileptic drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H784669734\">",
"      Nonpharmacological approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H784669897\">",
"      Patients without a history of a seizure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Postoperative prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ADVERSE EFFECTS OF AED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H784670660\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Drug rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Drug-drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4358429\">",
"      DRIVING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13080767\">",
"      END OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5181\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5181|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/28/3533\" title=\"table 1\">",
"      Common side effects of AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/24/36236\" title=\"table 2\">",
"      Cytochrome enzymes involv",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/22/40300\" title=\"table 3\">",
"      Interactions between antiepileptic drugs and cytotoxic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32568?source=related_link\">",
"      Driving restrictions for patients with seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22871?source=related_link\">",
"      Magnetic resonance imaging changes related to acute seizure activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13082?source=related_link\">",
"      Neuroimaging in the evaluation of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=related_link\">",
"      Surgical therapy of epilepsy in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_16_18698="Group B streptococcal infection in neonates and young infants";
var content_f18_16_18698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Group B streptococcal infection in neonates and young infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/16/18698/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18698/contributors\">",
"     Karen M Puopolo, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18698/contributors\">",
"     Carol J Baker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/16/18698/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18698/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18698/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/16/18698/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/16/18698/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/16/18698/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group B streptococcus (GBS or",
"    <em>",
"     Streptococcus agalactiae",
"    </em>",
"    ) is an encapsulated gram-positive diplococcus that colonizes the gastrointestinal and genital tracts of 15 to 40 percent of pregnant women. GBS colonization is usually asymptomatic. However, maternal colonization is the primary risk factor for GBS infection in neonates and young infants (younger than 90 days of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Vertical transmission generally occurs after the onset of labor or rupture of the fetal membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GBS infection in neonates and young infants will be reviewed here. The microbiology of GBS infections, the prevention of GBS infection in neonates, and the management of infants whose mother received GBS chemoprophylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9621?source=see_link\">",
"     \"Group B streptococcus: Virulence factors and pathogenic mechanisms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2552?source=see_link\">",
"     \"Management of the infant whose mother has received group B streptococcal chemoprophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group B streptococcal (GBS) infection in neonates and young infants is classified by age at onset [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Early-onset GBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early-onset GBS generally presents at or within 24 hours of birth [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/4\">",
"     4",
"    </a>",
"    ], but can occur through day six of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Late-onset GBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-onset GBS usually occurs at four to five weeks of age (range 7 to 89 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Late, late-onset GBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late, late-onset GBS (also called very-late-onset GBS or GBS beyond early infancy) occurs in infants older than three months of age. Late, late-onset GBS infections are most common in infants who are born before 28 weeks&rsquo; gestation or in children with a history of immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal GBS infection is acquired in utero or during passage through the vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/7\">",
"     7",
"    </a>",
"    ]. Evidence suggests that vaginal colonization with a high inoculum (&gt;10",
"    <span class=\"nowrap\">",
"     cfu/mL)",
"    </span>",
"    of GBS during pregnancy increases the risk of vertical transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/8,9\">",
"     8,9",
"    </a>",
"    ] and early-onset disease in neonates. After discharge from the hospital, young infants also can acquire GBS from colonized household contacts and go on to develop late-onset bacteremia, meningitis, or other focal infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention (CDC) began active surveillance for group B streptococcus (GBS) in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidence of early-onset GBS disease declined from 1.8 to 0.50 cases per 1000 live births between 1990 and 2000; surveillance data from 2010 demonstrate a decline to 0.25 cases per 1000 live births (",
"    <a class=\"graphic graphic_figure graphicRef54049 \" href=\"UTD.htm?41/60/42958\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/10-16\">",
"     10-16",
"    </a>",
"    ]. There is an ongoing ethnic disparity, with black neonates at significantly greater risk of infection than white neonates (approximately 0.22 versus 0.43 per 1000 live births for white and black infants, respectively) (",
"    <a class=\"graphic graphic_figure graphicRef80131 \" href=\"UTD.htm?31/6/31854\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/11-14,16,17\">",
"     11-14,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall decline in early-onset GBS disease has been attributed to universal screening of pregnant women for GBS colonization and the widespread use of intrapartum antibiotic prophylaxis (IAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/2,18-20\">",
"     2,18-20",
"    </a>",
"    ]. Despite implementation of prevention policies, however, early-onset neonatal GBS disease continues to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. For decades, the majority of early-onset GBS disease has occurred in term neonates, although the risk and mortality are substantially higher in preterm neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/13,22-24\">",
"     13,22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of late-onset GBS disease in the United States has remained between approximately 0.3 and 0.4 per 1000 live births since 1990 (",
"    <a class=\"graphic graphic_figure graphicRef54049 \" href=\"UTD.htm?41/60/42958\">",
"     figure 1",
"    </a>",
"    ) and is unaffected by maternal intrapartum chemoprophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/10-14,16,26\">",
"     10-14,16,26",
"    </a>",
"    ]. Slightly more than one-half of infants with late-onset disease are born before 37 weeks&rsquo; gestation, with a median gestational age of 30 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/13,26\">",
"     13,26",
"    </a>",
"    ]. As with early-onset GBS disease, there is an ongoing racial disparity (",
"    <a class=\"graphic graphic_figure graphicRef62741 \" href=\"UTD.htm?11/38/11886\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary risk factor for early-onset GBS infection is maternal GBS genitourinary or gastrointestinal colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link&amp;anchor=H2#H2\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\", section on 'Identification of colonized gravidas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of transmission from colonized mothers to infants is approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. However, only 1 to 2 percent of all infants born to colonized pregnant women develop early-onset GBS disease without maternal intrapartum antibiotic prophylaxis (IAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Up to 50 percent of late-onset disease was thought to be attributable to vertical transmission before the widespread introduction of maternal IAP for GBS carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/9\">",
"     9",
"    </a>",
"    ]. IAP has had no impact on the incidence of late-onset disease, which is not surprising given that IAP eliminates or diminishes neonatal exposure only during labor and delivery; women given IAP continued to be colonized postpartum. This suggests that the GBS exposures of infants with late-onset disease occur in the home, from colonized parents or siblings, or in the community and that these exposures are important in the pathogenesis of late-onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several maternal obstetrical factors have been associated with increased risk of developing early-onset GBS disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/2,18,31-33\">",
"     2,18,31-33",
"    </a>",
"    ]. These clinical risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delivery at less than 37 weeks of gestation",
"     </li>",
"     <li>",
"      Premature rupture of membranes at any gestation",
"     </li>",
"     <li>",
"      Rupture of membranes for 18 or more hours before delivery",
"     </li>",
"     <li>",
"      Chorioamnionitis",
"     </li>",
"     <li>",
"      GBS bacteriuria during the current pregnancy (&gt;10",
"      <sup>",
"       4",
"      </sup>",
"      <span class=\"nowrap\">",
"       cfu/mL)",
"      </span>",
"     </li>",
"     <li>",
"      Temperature &ge;38&ordm;C, or 100.4&deg;F, during labor",
"     </li>",
"     <li>",
"      Prior delivery of an infant with GBS disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], but not all, studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], the risk of GBS disease is increased in multiple-gestation pregnancies.",
"   </p>",
"   <p>",
"    Bacterial and immunologic risk factors include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/8,9,38-41\">",
"     8,9,38-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      GBS strain with enhanced virulence",
"     </li>",
"     <li>",
"      Heavy maternal colonization (vaginal inoculum &gt;10",
"      <sup>",
"       5",
"      </sup>",
"      <span class=\"nowrap\">",
"       cfu/mL)",
"      </span>",
"     </li>",
"     <li>",
"      Deficient maternal GBS capsular type-specific IgG at term delivery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These risk factors have been used to develop guidelines for screening pregnant women for GBS and administration of IAP to prevent neonatal GBS infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serotype distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBS serotype corresponds to the capsular polysaccharide. Surface proteins, including the C proteins, also are used for the classification of GBS strains. There are 10 GBS serotypes: Ia, Ib, and II through IX [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/3,42\">",
"     3,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serotypes Ia, Ib, II, III, and V account for more than 95 percent of early-onset cases in the United States and more than 90 percent of late-onset cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/13\">",
"     13",
"    </a>",
"    ]. Serotype III has a propensity to cause meningitis and is responsible for a high proportion of late-onset infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/13,43\">",
"     13,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distribution of serotypes and surface proteins among GBS isolates has important implications for the development of vaccines to prevent GBS disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40984?source=see_link\">",
"     \"Vaccines for the prevention of group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Early-onset disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early-onset group B streptococcal (GBS) infection most commonly manifests as generalized sepsis, pneumonia, or meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/13\">",
"     13",
"    </a>",
"    ]. The clinical signs in more than 90 percent of cases are apparent in the first 24 hours of life.",
"   </p>",
"   <p>",
"    Infants whose mothers receive intrapartum antibiotic prophylaxis (IAP) are less likely to have sepsis, need assisted ventilation, or have documented GBS bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/44\">",
"     44",
"    </a>",
"    ]. Exposure to intrapartum antibiotic prophylaxis (IAP) does not appear to alter the clinical spectrum of disease or the time of onset of clinical signs of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27,45\">",
"     27,45",
"    </a>",
"    ]. However, IAP may inhibit the growth of GBS in blood and cerebrospinal fluid (CSF) cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis without a focus of infection occurs in 80 to 85 percent of cases of early-onset GBS disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/13\">",
"     13",
"    </a>",
"    ]. Signs of sepsis are non-specific and include irritability, lethargy, respiratory symptoms (eg, tachypnea, grunting, hypoxia), temperature instability, poor perfusion, and hypotension. Most infants presenting at less than 24 hours of life do not have fever, although fever can occur in term infants on the second or third days of life. Sepsis syndromes range from non-specific signs to profound septic shock. Early-onset disease can be associated with persistent pulmonary hypertension of the newborn (PPHN). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"     \"Persistent pulmonary hypertension of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory evaluation for early-onset disease should be interpreted within the time frame of the evaluation as well as the gestational age of the infant. A multicenter study of infants born at &ge;34 weeks&rsquo; gestation, evaluated within the first 24 hours of life, reveals that low",
"    <span class=\"nowrap\">",
"     (&lt;5000/microL)",
"    </span>",
"    total white blood cell count (WBC); absolute (&lt;1000 granulocytes",
"    <span class=\"nowrap\">",
"     (PMN)/microL)",
"    </span>",
"    or relative (&lt;5000",
"    <span class=\"nowrap\">",
"     PMN/microL)",
"    </span>",
"    neutropenia; or a predominance of immature PMN&rsquo;s relative to the total PMN count",
"    <span class=\"nowrap\">",
"     (immature/total",
"    </span>",
"    ratio 0.3 or above) are associated with blood-culture-proven early-onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/47\">",
"     47",
"    </a>",
"    ]. However, a normal WBC count is not infrequent, and elevated WBC count",
"    <span class=\"nowrap\">",
"     (&gt;20,000/microL)",
"    </span>",
"    is not predictive of early-onset disease. Thrombocytopenia also can be observed, usually in association with septic shock; platelet count does not independently predict early-onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia occurs in approximately 10 percent of cases of early-onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/13\">",
"     13",
"    </a>",
"    ]. Pneumonia occurred with bacteremia in 35 to 55 percent of cases of early-onset GBS disease during the 1970s and 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/48\">",
"     48",
"    </a>",
"    ]. However, once maternal factors, such as intrapartum fever or chorioamnionitis, were recognized in the pathogenesis of early-onset infection, initiation of maternal antimicrobial therapy during labor was associated with significantly fewer cases with radiographic features of pneumonia. The diagnosis of early-onset pneumonia included isolation of GBS from culture of blood, abnormal radiographic findings, and clinical findings. Autopsy studies in the 1970s demonstrated the presence of GBS, as well as histologic evidence of pneumonitis and atypical hyaline membrane formation in lung tissue of infants who died of clinical GBS sepsis and pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Signs of pneumonia include tachypnea, grunting, hypoxia, and increased work of breathing. GBS pneumonia also may be associated with PPHN in term infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=see_link\">",
"     \"Neonatal pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"     \"Persistent pulmonary hypertension of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic findings of GBS pneumonia include a diffuse alveolar pattern that can be difficult to distinguish from hyaline membrane disease or transient tachypnea of the newborn [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/52\">",
"     52",
"    </a>",
"    ]. Pleural effusions are more common in GBS pneumonia than in hyaline membrane disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/31,53,54\">",
"     31,53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19656?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link\">",
"     \"Prevention and treatment of respiratory distress syndrome in preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=see_link\">",
"     \"Transient tachypnea of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBS meningitis occurs in 7 percent of cases of early-onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/13\">",
"     13",
"    </a>",
"    ]. Early-onset GBS meningitis uncommonly presents with signs of central nervous system (CNS) inflammation; respiratory abnormalities (eg, tachypnea, grunting, apnea) are the most frequent presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=see_link\">",
"     \"Clinical features and diagnosis of bacterial meningitis in the neonate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Late-onset disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-onset GBS disease most often presents as bacteremia without a focus (about 65 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/13,57\">",
"     13,57",
"    </a>",
"    ]. However, meningitis (25 to 30 percent) and focal infections also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/58\">",
"     58",
"    </a>",
"    ]. Compared with those with early-onset disease, infants with late-onset disease are less likely to manifest profound shock and, among those with meningitis, are more likely to have clinically apparent seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with late-onset infection commonly present with fever &ge;38&ordm;C. These infants may have a history of a preceding or intercurrent upper respiratory infection. Other clinical findings can include irritability, lethargy, poor feeding, tachypnea, grunting, and occasionally apnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningitis accounts for about 30 percent of cases of late-onset GBS disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27\">",
"     27",
"    </a>",
"    ]. Late-onset GBS meningitis is preceded by upper respiratory infection in 20 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/1,55,59\">",
"     1,55,59",
"    </a>",
"    ]. Although there is a spectrum of severity, clinical manifestations typically include fever, irritability, lethargy, poor feeding, and tachypnea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27\">",
"     27",
"    </a>",
"    ]. The classic signs of meningitis (eg, bulging fontanel, nuchal rigidity, focal neurologic findings) are more common in late-onset than early-onset GBS meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=see_link\">",
"     \"Clinical features and diagnosis of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other focal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-onset disease also can present as pneumonia, septic arthritis, osteomyelitis, cellulitis, and adenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/58\">",
"     58",
"    </a>",
"    ]. Rare presentations of late-onset GBS disease include endocarditis, myocarditis, pericarditis, pyelonephritis, endophthalmitis, and brain abscess, among others [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Bone/joint",
"      </span>",
"      infection &ndash; Late-onset GBS infection manifests as septic arthritis and osteomyelitis in approximately 5 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27\">",
"       27",
"      </a>",
"      ]. GBS septic arthritis generally has an acute presentation and involves the lower extremity; the mean age of onset is 20 days. GBS osteomyelitis typically has an insidious onset; the most frequent sites include the humerus, especially the right proximal humerus, femur, and tibia; the mean age of onset is 31 days. These manifestations of late-onset disease have decreased in frequency, most likely due to more prompt diagnosis and empiric treatment of GBS bacteremia without a focus.",
"      <br/>",
"      <br/>",
"      Decreased movement of the involved extremity and pain with manipulation are important clues to GBS bone and joint infection [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27,61\">",
"       27,61",
"      </a>",
"      ]. Fever is absent in the majority of patients. Concomitant bacteremia is present in more than one-half of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cellulitis-adenitis &ndash; Late-onset GBS infection can manifest as facial cellulitis, submandibular cellulitis, or cellulitis-adenitis in other regions [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27\">",
"       27",
"      </a>",
"      ]. Cellulitis-adenitis accounted for 4 percent of late-onset GBS infections in an 11-year series from one institution [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/62\">",
"       62",
"      </a>",
"      ]. Associated examination findings can include ipsilateral otitis media; infected or thyroglossal duct cyst also has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/63\">",
"       63",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a review of 32 cases of GBS cellulitis-adenitis, bacteremia was documented in 91 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/64\">",
"       64",
"      </a>",
"      ]. Among the 25 infants in whom CSF was obtained, six grew GBS from the CSF; three infants died: two had CNS involvement and one fulminant GBS septicemia. Lack of fever and well appearance at presentation did not predict subsequent clinical course.",
"      <br/>",
"      <br/>",
"      These observations suggest that lumbar puncture should be performed in young infants with cellulitis-adenitis and that empirical antibiotics should include coverage for GBS meningitis until CNS infection is excluded [",
"      <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/60,64\">",
"       60,64",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Evaluation'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H28\">",
"       'Empirical therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Late, late-onset disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late, late-onset GBS disease typically manifests as bacteremia without a focus in infants born at less than 28 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/5,27,57\">",
"     5,27,57",
"    </a>",
"    ]. Focal sites of infection may include the CNS, soft tissues, bones and joints, and intravascular catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/5,13,27\">",
"     5,13,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GBS infection after six months of age can be the first sign of immune deficiency, including HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/5,65,66\">",
"     5,65,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Index patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for suspected group B streptococcal (GBS) infection in the index patient includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count (CBC) with differential",
"     </li>",
"     <li>",
"      Blood culture",
"     </li>",
"     <li>",
"      Chest radiograph (if respiratory signs present)",
"     </li>",
"     <li>",
"      Lumbar puncture for cerebrospinal fluid (CSF) cell count, protein and glucose concentration, Gram stain and culture",
"     </li>",
"     <li>",
"      Urine culture (if the infant is &gt;6 days of age) by sterile collection method (urinary catheter or suprapubic aspirate)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lumbar puncture should be performed before the institution of antibiotic therapy, unless the infant is clinically unstable, and in that circumstance the lumbar puncture can be deferred.",
"   </p>",
"   <p>",
"    Additional studies may be necessary if osteoarticular infection is suspected. These include radiographs of the involved site, magnetic resonance imaging (MRI), bone biopsy, or joint aspiration with culture and susceptibility testing. Neither nuclear bone scans nor computed tomography scans are recommended, given their poor sensitivity when compared with MRI and the need for radiation exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Twin sibling",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a twin (or other infant product of a multiple-birth gestation) is diagnosed with GBS disease, the sibling of the index case should be observed carefully [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/3\">",
"     3",
"    </a>",
"    ]. If any signs of illness occur, he or she should be evaluated (as described for the index patient above) and treated empirically for GBS. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Index patient'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H28\">",
"     'Empirical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolation of group B streptococcus (GBS) from a normally sterile body site (eg, blood, cerebrospinal fluid [CSF], pleural fluid, bone, joint) confirms the diagnosis of GBS infection. GBS antigen may be detected in CSF, which occasionally can assist in the diagnosis of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/3\">",
"     3",
"    </a>",
"    ]. However, antigen testing of other body fluids is not recommended because of poor specificity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meticulous supportive care and antimicrobial therapy combined with drainage of purulent collections as necessary are the cornerstones of treatment of group B streptococcal (GBS) disease in neonates and young infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care for neonates and young infants with GBS infection can include ventilatory support (including endotracheal intubation and mechanical ventilation), prompt recognition and treatment of shock, careful maintenance of fluid and electrolyte balance, treatment of anemia, and effective seizure control [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27\">",
"     27",
"    </a>",
"    ]. Management in an intensive care unit is often required. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy for neonates and infants has not been evaluated in randomized, controlled trials. Recommendations for treatment are based upon in vitro susceptibility testing and response to therapy in observational studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Empirical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial empirical antibiotic therapy of suspected sepsis includes broad coverage for organisms known to cause early- and late-onset disease in neonates and infants younger than three months of age (eg, GBS and other streptococci, gram-negative enteric organisms, and, rarely,",
"    <em>",
"     Listeria monocytogenes",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27\">",
"     27",
"    </a>",
"    ]. Recommended regimens for empirical therapy vary depending upon the focus of infection and whether the infection is early onset (",
"    <a class=\"graphic graphic_table graphicRef71720 \" href=\"UTD.htm?5/19/5436\">",
"     table 1",
"    </a>",
"    ) or late onset (",
"    <a class=\"graphic graphic_table graphicRef66906 \" href=\"UTD.htm?1/32/1549\">",
"     table 2",
"    </a>",
"    ). In the era of GBS intrapartum antibiotic prophylaxis (IAP), with decreases in the incidence of early-onset GBS disease, up to 40 percent of early-onset sepsis is due to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    -resistant gram-negative organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. The addition of a third-generation cephalosporin to the empiric treatment of early-onset sepsis may be warranted, but only among severely ill neonates. The empiric treatment of suspected late-onset disease is strongly influenced by the clinical setting",
"    <span class=\"nowrap\">",
"     (hospital-acquired/central-line-associated,",
"    </span>",
"    or community-acquired disease) and by local bacterial resistance patterns.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     Ampicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/46/14054?source=see_link\">",
"     penicillin G",
"    </a>",
"    should be added to the regimen of infants receiving empirical",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    until GBS meningitis has been excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/60\">",
"     60",
"    </a>",
"    ]. In vitro, vancomycin is inhibitory rather than bactericidal against GBS, and if the inoculum of GBS in the cerebrospinal fluid (CSF) is high, the CSF concentration of vancomycin will not exceed the mean inhibitory concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Empirical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empirical antibiotic therapy is continued until the causative organism is identified and blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CSF culture is sterile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Definitive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When GBS is identified as the sole causative organism, we recommend that antimicrobial therapy be changed to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/46/14054?source=see_link\">",
"     penicillin G",
"    </a>",
"    alone if the patient has improved clinically (",
"    <a class=\"graphic graphic_table graphicRef71720 \" href=\"UTD.htm?5/19/5436\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66906 \" href=\"UTD.htm?1/32/1549\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/3\">",
"     3",
"    </a>",
"    ]. For infants with GBS meningitis, we suggest repeat lumbar puncture at 24 to 48 hours of therapy to document sterilization of CSF before changing antimicrobial therapy.",
"   </p>",
"   <p>",
"    GBS is susceptible to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/46/14054?source=see_link\">",
"     penicillin G",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    , extended-spectrum penicillins, first- and second-generation cephalosporins, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    , but penicillin G is the most narrow-spectrum and active agent in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/13,69-72\">",
"     13,69-72",
"    </a>",
"    ]. Approximately 30 percent of GBS isolates are resistant to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    and 20 percent to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , rates that appear to be increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/13,69,73-75\">",
"     13,69,73-75",
"    </a>",
"    ]. Although most isolates show in vitro resistance to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    , gentamicin provides synergy with penicillin or ampicillin during initial therapy at achievable serum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional aspects of the management of neonates and young infants with meningitis, including the need for repeat lumbar puncture and neuroimaging studies, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=see_link\">",
"     \"Clinical features and diagnosis of bacterial meningitis in the neonate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone and joint infections that involve the hip or shoulder require surgical drainage in addition to antimicrobial therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24730?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of hematogenous osteomyelitis in children\", section on 'Overview of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary tract infection either reflects seeding of the bladder or kidney by the hematogenous route or primary infection. In either case, a urine culture growing GBS at &gt;10",
"    <sup>",
"     4",
"    </sup>",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    indicates true infection, and the infant should be treated in the same manner as infants with bacteremia (",
"    <a class=\"graphic graphic_table graphicRef71720 \" href=\"UTD.htm?5/19/5436\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66906 \" href=\"UTD.htm?1/32/1549\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of therapy should be 10 days for sepsis without a focus, 14 to 21 days for meningitis, 14 to 21 days for septic arthritis, and 21 to 28 days for osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Adjunctive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive treatment of early-onset GBS meningitis with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    has not been studied in and is not used in most centers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'Use of dexamethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Standard preparations of intravenous immunoglobulin (IVIG) and GBS hyperimmune globulin have been studied in small numbers of term and preterm infants with GBS infection, with variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. Neither of these preparations is routinely used at most centers.",
"   </p>",
"   <p>",
"    A meta-analysis of 10 studies of IVIG found insufficient evidence to support its use as an adjunct to antimicrobial therapy in infants with suspected or proven all-cause bacterial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/79\">",
"     79",
"    </a>",
"    ]. A subsequent multicenter trial (the International Neonatal Immunotherapy Study, INIS trial) randomly assigned 3493 infants receiving antibiotics for suspected or proven infection to receive two doses of IVIG (500",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/80\">",
"     80",
"    </a>",
"    ]. Treatment with IVIG had no effect on outcome, including death or major disability at age two years. These results do not support the routine use of adjunctive IVIG in neonates with suspected or proven infection.",
"   </p>",
"   <p>",
"    Recombinant granulocyte stimulating factors (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/27/44470?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    [G-CSF] and granulocyte-macrophage colony-stimulating factor [GM-CSF]) also have been studied in preclinical models of GBS infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/81,82\">",
"     81,82",
"    </a>",
"    ] and in several small human trials of neonates with suspected or proven sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/83-86\">",
"     83-86",
"    </a>",
"    ]. There is insufficient evidence to support the adjuvant use of recombinant granulocyte stimulating factors to reduce neonatal infection-related mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     RECURRENT INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent group B streptococcal (GBS) infections are infrequent, with reported incidences ranging from 1 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/3,27,62,87\">",
"     3,27,62,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent GBS infections usually represent persistent mucosal colonization, but occasionally reinfection occurs. This is illustrated by two studies in which GBS isolates from infants with recurrent infection were analyzed with serotyping and pulsed-field gel electrophoresis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Paired isolates from 13 of 15 patients were serotypically and genetically identical; two infants had infections with newly acquired, genetically distinct strains of GBS.",
"   </p>",
"   <p>",
"    Vulnerability to recurrent infection probably is caused by a combination of host and pathogen factors. Infants usually fail to have a specific antibody response after infection with GBS, and GBS can be isolated from mucosal surfaces of infants even after parenteral antibiotic treatment for invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27\">",
"     27",
"    </a>",
"    ]. Recurrent infections frequently have been associated with prematurity, but rarely with improperly treated focal infections such as endocarditis or brain abscess, and an evaluation for these rare entities is almost never indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/87\">",
"     87",
"    </a>",
"    ]. Cases of recurrent neonatal GBS infection related to infected breast milk have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/89-93\">",
"     89-93",
"    </a>",
"    ]. In each case report, it is unclear whether breast milk caused the recurrent infection or if exposure to the infected infant caused maternal GBS mastitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When treating recurrent GBS infection, susceptibility testing of the GBS isolate to penicillin is recommended. All GBS isolates to date are susceptible in vitro to penicillin. Treatment for recurrent infection is suggested to be continued for one week longer than the usual course, but there are no data to indicate efficacy of this recommendation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Duration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"     Rifampin",
"    </a>",
"    , which eliminates colonization in other infections, such as meningococcal disease, does not reliably eradicate mucous membrane colonization with GBS, and it is not recommended for routine use [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Neonatal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the recognition that maternal colonization is the single most important risk factor for early-onset group B streptococcal (GBS) infection, a number of strategies are recommended to prevent GBS disease in the infant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Screening pregnant women for GBS colonization and intrapartum antibiotic prophylaxis (IAP) during labor for those colonized",
"     </li>",
"     <li>",
"      Treatment of all women during labor who have specific risk factors for early-onset GBS infection",
"     </li>",
"     <li>",
"      Vaccination of all women when GBS vaccines become available",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening programs, IAP, and vaccination to prevent GBS disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40984?source=see_link\">",
"     \"Vaccines for the prevention of group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Health care-associated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine hand hygiene by health care professionals is the best way to prevent health care-associated spread of GBS infection. Infants admitted to the hospital with suspected GBS infection should be placed on standard isolation precautions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H2#H2\">",
"     \"General principles of infection control\", section on 'Standard precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the rare event of a nursery outbreak of GBS infection, cohorting ill and colonized infants and the use of contact precautions are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H11#H11\">",
"     \"General principles of infection control\", section on 'Contact precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case fatality rates for early-onset group B streptococcal (GBS) disease range from 2 to 3 percent for term infants without meningitis to 20 percent for preterm infants. Case fatality rates for late-onset GBS disease range from to 1 to 2 percent for term infants to 5 to 6 percent for preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/13,27\">",
"     13,27",
"    </a>",
"    ]. Clinical features associated with mortality in early-onset GBS infection include birth weight less than 2500 g, absolute neutrophil count less than 1500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    hypotension, apnea, and pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little information about the long-term outcome of survivors of GBS bacteremia or sepsis without a focus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/27\">",
"     27",
"    </a>",
"    ]. Most information regarding outcome in survivors of GBS meningitis is based on reports of infants cared for before the late 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/55,98-103\">",
"     55,98-103",
"    </a>",
"    ]. In those reports, one-fourth to one-half of survivors had permanent neurologic sequelae (eg, profound intellectual disability, spastic quadriplegia, cortical blindness, deafness, uncontrolled seizures, hypothalamic dysfunction).",
"   </p>",
"   <p>",
"    Modern outcomes may not be much improved. A study of 53 term and near-term (36 weeks&rsquo; gestation) infants with neonatal GBS meningitis occurring from 1998 to 2006 revealed that despite advances in intensive care, 26 percent of the study infants died or had neurologic impairment at hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/104\">",
"     104",
"    </a>",
"    ]. In multivariate analysis, the single predictor of death or a poor neurologic outcome was seizures after hospital admission. Among 43 survivors of GBS meningitis occurring from 1998 to 2006 who underwent follow-up examination at age 3 through 12 years, 24 (56 percent) demonstrated age-appropriate development, 8 (19 percent) had severe impairment (eg, cognitive skills &gt;2 standard deviations [SD] below the mean in at least one domain, severe neurologic or functional impairment), and 11 (25 percent) had mild-to-moderate impairment (eg, cognitive skills within 1 to 2 SD below the mean in any domain, academic underachievement, evidence of mild neurologic or functional impairment) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/16/18698/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Outcome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in the neonate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/42/42657?source=see_link\">",
"       \"Patient information: Group B streptococcal disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11248?source=see_link\">",
"       \"Patient information: Group B streptococcus and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group B streptococcus (GBS or",
"      <em>",
"       Streptococcus agalactiae",
"      </em>",
"      ) infection in neonates and young infants is classified by age at onset into early-onset (&lt;7 days of age), late-onset (7 to 89 days), and late, late-onset infection (&ge;90 days). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early-onset GBS infection in neonates is acquired in utero or during passage through the vagina. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathogenesis'",
"      </a>",
"      above.) Late-onset GBS infection also can be acquired vertically at birth and horizontally in household and community settings.",
"     </li>",
"     <li>",
"      Universal antenatal screening of pregnant women for GBS colonization at 35 to 37 weeks&rsquo; gestation and widespread use of intrapartum chemoprophylaxis have resulted in a decline in early-onset GBS disease in the United States but have had no effect on late-onset GBS disease (",
"      <a class=\"graphic graphic_figure graphicRef54049 \" href=\"UTD.htm?41/60/42958\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Incidence'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link\">",
"       \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Risk factors for early-onset GBS disease include delivery at &lt;37 weeks' gestation, premature rupture of membranes, rupture of membranes for &ge;18 hours before delivery, chorioamnionitis, maternal temperature &ge;38&ordm;C during labor, maternal GBS bacteriuria during the current pregnancy, prior delivery of an infant with GBS disease, and heavy maternal colonization. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early-onset GBS infection most commonly manifests as generalized sepsis, and less commonly as pneumonia or meningitis. Clinical signs usually are apparent in the first 24 hours of life. Respiratory signs (grunting, tachypnea, hypoxia) are a prominent aspect of the presentation for each of these clinical syndromes. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Early-onset disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late-onset GBS disease most often presents as bacteremia without a focus or meningitis. Less common but well-described late-onset GBS focal infections include septic arthritis, osteomyelitis, and cellulitis-adenitis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Late-onset disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation for suspected GBS infection includes complete blood count with differential; blood culture; chest radiograph if respiratory signs are present; lumbar puncture for cerebrospinal fluid cell count, protein and glucose concentration, and Gram stain and culture; and urine culture (if the infant is &gt;6 days of age). Radiographs of affected extremities, magnetic resonance imaging (MRI), and bone biopsy or joint aspiration with culture and susceptibility testing are suggested if osteoarticular infections are suspected. Neither nuclear bone scans nor computed tomography scans are recommended, given their poor sensitivity when compared with MRI and the need for radiation exposure. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolation of GBS from a normally sterile body site confirms the diagnosis of GBS infection. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meticulous supportive care and antimicrobial therapy, with drainage of purulent material as needed, are the cornerstones of treatment of GBS disease in neonates and young infants. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial empirical antibiotic therapy for the neonate or young infant with suspected GBS disease should include broad coverage for the most likely pathogens in this age group (GBS and other streptococci, gram-negative enteric organisms, and, rarely, Listeria monocytogenes). Recommended regimens vary depending upon the focus of infection and whether the infection is early onset (",
"      <a class=\"graphic graphic_table graphicRef71720 \" href=\"UTD.htm?5/19/5436\">",
"       table 1",
"      </a>",
"      ) or late onset (",
"      <a class=\"graphic graphic_table graphicRef66906 \" href=\"UTD.htm?1/32/1549\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Empirical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When GBS is identified as the causative organism, we recommend that antimicrobial therapy be changed to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/46/14054?source=see_link\">",
"       penicillin G",
"      </a>",
"      alone if the patient has improved clinically (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For infants with GBS meningitis, we suggest repeating a lumbar puncture at 24 to 48 hours of therapy to document sterilization of CSF before changing antimicrobial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Definitive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine hand hygiene by health care professionals is the best way to prevent health care-associated spread of GBS infection. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Health care-associated infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Case fatality rates for early-onset GBS disease range from 2 to 3 percent (term) to 20 percent (preterm), compared with 1 to 2 percent (term) to 5 to 6 percent (preterm) for late-onset GBS disease. For both early- and late-onset GBS, mortality is increased in preterm compared with term infants. Morbidity from GBS meningitis is substantial. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/1\">",
"      Baker CJ, Barrett FF. Transmission of group B streptococci among parturient women and their neonates. J Pediatr 1973; 83:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/2\">",
"      Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.680.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/4\">",
"      Eichenwald EC. Perinatally transmitted neonatal bacterial infections. Infect Dis Clin North Am 1997; 11:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/5\">",
"      Hussain SM, Luedtke GS, Baker CJ, et al. Invasive group B streptococcal disease in children beyond early infancy. Pediatr Infect Dis J 1995; 14:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/6\">",
"      Guilbert J, Levy C, Cohen R, et al. Late and ultra late onset Streptococcus B meningitis: clinical and bacteriological data over 6 years in France. Acta Paediatr 2010; 99:47.",
"     </a>",
"    </li>",
"    <li>",
"     Madoff LC, Kasper DL. Group B streptococcal infection. In: Obstetric and Perinatal Infections, Charles D (Ed), Mosby Year Book, Boston 1993. p.210.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/8\">",
"      Ancona RJ, Ferrieri P, Williams PP. Maternal factors that enhance the acquisition of group-B streptococci by newborn infants. J Med Microbiol 1980; 13:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/9\">",
"      Pass MA, Gray BM, Khare S, Dillon HC Jr. Prospective studies of group B streptococcal infections in infants. J Pediatr 1979; 95:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/10\">",
"      Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ 1992; 41:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Early-onset and late-onset neonatal group B streptococcal disease--United States, 1996-2004. MMWR Morb Mortal Wkly Rep 2005; 54:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Perinatal group B streptococcal disease after universal screening recommendations--United States, 2003-2005. MMWR Morb Mortal Wkly Rep 2007; 56:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/13\">",
"      Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Trends in perinatal group B streptococcal disease - United States, 2000-2006. MMWR Morb Mortal Wkly Rep 2009; 58:109.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. 2009. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2008. www.cdc.gov/abcs/reports-findings/survreports/gbs08.html (Accessed on November 30, 2010).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2010. www.cdc.gov/abcs/reports-findings/survreports/gbs10.html (Accessed on May 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/17\">",
"      Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/18\">",
"      Prevention of perinatal group B streptococcal disease: A public health perspective. Centers for Disease Control and Prevention (published erratum appears in MMWR Morb Mortal Wkly Rep 1996; 45:679). MMWR Morb Mortal Wkly Rep 1996; 45(RR-7):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/19\">",
"      Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/20\">",
"      Eberly MD, Rajnik M. The effect of universal maternal screening on the incidence of neonatal early-onset group B streptococcal disease. Clin Pediatr (Phila) 2009; 48:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/21\">",
"      Pulver LS, Hopfenbeck MM, Young PC, et al. Continued early onset group B streptococcal infections in the era of intrapartum prophylaxis. J Perinatol 2009; 29:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/22\">",
"      Van Dyke MK, Phares CR, Lynfield R, et al. Evaluation of universal antenatal screening for group B streptococcus. N Engl J Med 2009; 360:2626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/23\">",
"      Puopolo KM, Madoff LC, Eichenwald EC. Early-onset group B streptococcal disease in the era of maternal screening. Pediatrics 2005; 115:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/24\">",
"      Puopolo KM, Madoff LC. Type IV neonatal early-onset group B streptococcal disease in a United States hospital. J Clin Microbiol 2007; 45:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/25\">",
"      Stoll BJ, Hansen NI, S&aacute;nchez PJ, et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011; 127:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/26\">",
"      Jordan HT, Farley MM, Craig A, et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J 2008; 27:1057.",
"     </a>",
"    </li>",
"    <li>",
"     Edwards, MS, Nizet, V. Group B streptococcal infections. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington, JS, Klein, JO, Wilson, CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.419.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/28\">",
"      Anthony BF, Okada DM, Hobel CJ. Epidemiology of the group B streptococcus: maternal and nosocomial sources for infant acquisitions. J Pediatr 1979; 95:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/29\">",
"      Easmon CS, Hastings MJ, Clare AJ, et al. Nosocomial transmission of group B streptococci. Br Med J (Clin Res Ed) 1981; 283:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/30\">",
"      Paredes A, Wong P, Mason EO Jr, et al. Nosocomial transmission of group B Streptococci in a newborn nursery. Pediatrics 1977; 59:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/31\">",
"      Baker CJ. Group B streptococcal infections. Clin Perinatol 1997; 24:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/32\">",
"      Polin RA, Committee on Fetus and Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics 2012; 129:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/33\">",
"      Puopolo KM, Draper D, Wi S, et al. Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors. Pediatrics 2011; 128:e1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/34\">",
"      Edwards MS, Jackson CV, Baker CJ. Increased risk of group B streptococcal disease in twins. JAMA 1981; 245:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/35\">",
"      Pass MA, Khare S, Dillon HC Jr. Twin pregnancies: incidence of group B streptococcal colonization and disease. J Pediatr 1980; 97:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/36\">",
"      Schuchat A, Oxtoby M, Cochi S, et al. Population-based risk factors for neonatal group B streptococcal disease: results of a cohort study in metropolitan Atlanta. J Infect Dis 1990; 162:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/37\">",
"      Schuchat A, Deaver-Robinson K, Plikaytis BD, et al. Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. The Active Surveillance Study Group. Pediatr Infect Dis J 1994; 13:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/38\">",
"      Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/39\">",
"      Lin FY, Weisman LE, Azimi PH, et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004; 190:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/40\">",
"      Adderson EE, Takahashi S, Bohnsack JF. Bacterial genetics and human immunity to group B streptococci. Mol Genet Metab 2000; 71:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/41\">",
"      Gotoff SP, Odell C, Papierniak CK, et al. Human IgG antibody to group b Streptococcus type III: comparison of protective levels in a murine model with levels in infected human neonates. J Infect Dis 1986; 153:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/42\">",
"      Slotved HC, Kong F, Lambertsen L, et al. Serotype IX, a Proposed New Streptococcus agalactiae Serotype. J Clin Microbiol 2007; 45:2929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/43\">",
"      Fluegge K, Supper S, Siedler A, Berner R. Serotype distribution of invasive group B streptococcal isolates in infants: results from a nationwide active laboratory surveillance study over 2 years in Germany. Clin Infect Dis 2005; 40:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/44\">",
"      Escobar GJ, Li DK, Armstrong MA, et al. Neonatal sepsis workups in infants &gt;/=2000 grams at birth: A population-based study. Pediatrics 2000; 106:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/45\">",
"      Bromberger P, Lawrence JM, Braun D, et al. The influence of intrapartum antibiotics on the clinical spectrum of early-onset group B streptococcal infection in term infants. Pediatrics 2000; 106:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/46\">",
"      Carbonell-Estrany X, Figueras-Aloy J, Salcedo-Abizanda S, et al. Probable early-onset group B streptococcal neonatal sepsis: a serious clinical condition related to intrauterine infection. Arch Dis Child Fetal Neonatal Ed 2008; 93:F85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/47\">",
"      Newman TB, Puopolo KM, Wi S, et al. Interpreting complete blood counts soon after birth in newborns at risk for sepsis. Pediatrics 2010; 126:903.",
"     </a>",
"    </li>",
"    <li>",
"     Edwards MS, Nizet V, Baker CJ. Group B streptococcal infections. In: Infectious Diseases of the Fetus and Newborn Infant, 6th, Remington JS, Klein JO, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.403.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/49\">",
"      Ablow RC, Driscoll SG, Effmann EL, et al. A comparison of early-onset group B steptococcal neonatal infection and the respiratory-distress syndrome of the newborn. N Engl J Med 1976; 294:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/50\">",
"      Katzenstein AL, Davis C, Braude A. Pulmonary changes in neonatal sepsis to group B beta-hemolytic Streptococcus: relation of hyaline membrane disease. J Infect Dis 1976; 133:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/51\">",
"      Vollman JH, Smith WL, Ballard ET, Light IJ. Early onset group B streptococcal disease: clinical, roentgenographic, and pathologic features. J Pediatr 1976; 89:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/52\">",
"      Baker CJ. Early onset group B streptococcal disease. J Pediatr 1978; 93:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/53\">",
"      Long WA, Lawson EE, Harned HS Jr, Kraybill EN. Pleural effusion in the first days of life: a prospective study. Am J Perinatol 1984; 1:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/54\">",
"      Weller MH, Katzenstein AA. Radiological findings in group B streptococcal Sepsis. Radiology 1976; 118:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/55\">",
"      Baker CJ, Barrett FF, Gordon RC, Yow MD. Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr 1973; 82:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/56\">",
"      Weisman LE, Stoll BJ, Cruess DF, et al. Early-onset group B streptococcal sepsis: a current assessment. J Pediatr 1992; 121:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/57\">",
"      Pe&ntilde;a BM, Harper MB, Fleisher GR. Occult bacteremia with group B streptococci in an outpatient setting. Pediatrics 1998; 102:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/58\">",
"      Berardi A, Rossi C, Lugli L, et al. Group B streptococcus late-onset disease: 2003-2010. Pediatrics 2013; 131:e361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/59\">",
"      Franciosi RA, Knostman JD, Zimmerman RA. Group B streptococcal neonatal and infant infections. J Pediatr 1973; 82:707.",
"     </a>",
"    </li>",
"    <li>",
"     Pannaraj PS, Baker, CJ.. Group B streptococcal infections. In: Textbook of Pediatric Infectious Diseases, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.1239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/61\">",
"      Edwards MS, Baker CJ, Wagner ML, et al. An etiologic shift in infantile osteomyelitis: the emergence of the group B streptococcus. J Pediatr 1978; 93:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/62\">",
"      Yagupsky P, Menegus MA, Powell KR. The changing spectrum of group B streptococcal disease in infants: an eleven-year experience in a tertiary care hospital. Pediatr Infect Dis J 1991; 10:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/63\">",
"      Baker CJ. Group B streptococcal cellulitis-adenitis in infants. Am J Dis Child 1982; 136:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/64\">",
"      Albanyan EA, Baker CJ. Is lumbar puncture necessary to exclude meningitis in neonates and young infants: lessons from the group B streptococcus cellulitis- adenitis syndrome. Pediatrics 1998; 102:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/65\">",
"      Di John D, Krasinski K, Lawrence R, et al. Very late onset of group B streptococcal disease in infants infected with the human immunodeficiency virus. Pediatr Infect Dis J 1990; 9:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/66\">",
"      De Witt CC, Ascher DP, Winkelstein J. Group B streptococcal disease in a child beyond early infancy with a deficiency of the second component of complement (C2). Pediatr Infect Dis J 1999; 18:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/67\">",
"      Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis 2003; 3:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/68\">",
"      Puopolo KM, Eichenwald EC. No change in the incidence of ampicillin-resistant, neonatal, early-onset sepsis over 18 years. Pediatrics 2010; 125:e1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/69\">",
"      Biedenbach DJ, Stephen JM, Jones RN. Antimicrobial susceptibility profile among beta-haemolytic Streptococcus spp. collected in the SENTRY Antimicrobial Surveillance Program--North America, 2001. Diagn Microbiol Infect Dis 2003; 46:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/70\">",
"      Schauf V, Deveikis A, Riff L, Serota A. Antibiotic-killing kinetics of group B streptococci. J Pediatr 1976; 89:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/71\">",
"      Murdoch DR, Reller LB. Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective. Antimicrob Agents Chemother 2001; 45:3623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/72\">",
"      Lin FY, Azimi PH, Weisman LE, et al. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998. Clin Infect Dis 2000; 31:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/73\">",
"      Pearlman MD, Pierson CL, Faix RG. Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin. Obstet Gynecol 1998; 92:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/74\">",
"      Manning SD, Foxman B, Pierson CL, et al. Correlates of antibiotic-resistant group B streptococcus isolated from pregnant women. Obstet Gynecol 2003; 101:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/75\">",
"      de Azavedo JC, McGavin M, Duncan C, et al. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob Agents Chemother 2001; 45:3504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/76\">",
"      Weisman LE, Anthony BF, Hemming VG, Fischer GW. Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates. J Pediatr 1993; 122:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/77\">",
"      Weisman LE, Stoll BJ, Kueser TJ, et al. Intravenous immune globulin therapy for early-onset sepsis in premature neonates. J Pediatr 1992; 121:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/78\">",
"      Fischer GW, Weisman LE, Hemming VG. Directed immune globulin for the prevention or treatment of neonatal group B streptococcal infections: a review. Clin Immunol Immunopathol 1992; 62:S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/79\">",
"      Ohlsson A, Lacy J. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev 2010; :CD001239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/80\">",
"      INIS Collaborative Group, Brocklehurst P, Farrell B, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011; 365:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/81\">",
"      Givner LB, Nagaraj SK. Hyperimmune human IgG or recombinant human granulocyte-macrophage colony-stimulating factor as adjunctive therapy for group B streptococcal sepsis in newborn rats. J Pediatr 1993; 122:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/82\">",
"      Wheeler JG, Givner LB. Therapeutic use of recombinant human granulocyte-macrophage colony-stimulating factor in neonatal rats with type III group B streptococcal sepsis. J Infect Dis 1992; 165:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/83\">",
"      K&uuml;c&uuml;k&ouml;d&uuml;k S, Sezer T, Yildiran A, Albayrak D. Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis. Scand J Infect Dis 2002; 34:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/84\">",
"      Ahmad A, Laborada G, Bussel J, Nesin M. Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants. Pediatr Infect Dis J 2002; 21:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/85\">",
"      Bilgin K, Yarami A, Haspolat K, et al. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 2001; 107:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/86\">",
"      Miura E, Procianoy RS, Bittar C, et al. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics 2001; 107:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/87\">",
"      Green PA, Singh KV, Murray BE, Baker CJ. Recurrent group B streptococcal infections in infants: clinical and microbiologic aspects. J Pediatr 1994; 125:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/88\">",
"      Moylett EH, Fernandez M, Rench MA, et al. A 5-year review of recurrent group B streptococcal disease: lessons from twin infants. Clin Infect Dis 2000; 30:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/89\">",
"      Wang LY, Chen CT, Liu WH, Wang YH. Recurrent neonatal group B streptococcal disease associated with infected breast milk. Clin Pediatr (Phila) 2007; 46:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/90\">",
"      Kotiw M, Zhang GW, Daggard G, et al. Late-onset and recurrent neonatal Group B streptococcal disease associated with breast-milk transmission. Pediatr Dev Pathol 2003; 6:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/91\">",
"      Jones SM, Steele RW. Recurrent group B streptococcal bacteremia. Clin Pediatr (Phila) 2012; 51:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/92\">",
"      Soukka H, Rantakokko-Jalava K, V&auml;h&auml;kuopus S, Ruuskanen O. Three distinct episodes of GBS septicemia in a healthy newborn during the first month of life. Eur J Pediatr 2010; 169:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/93\">",
"      Gagneur A, H&eacute;ry-Arnaud G, Croly-Labourdette S, et al. Infected breast milk associated with late-onset and recurrent group B streptococcal infection in neonatal twins: a genetic analysis. Eur J Pediatr 2009; 168:1155.",
"     </a>",
"    </li>",
"    <li>",
"     Edwards MS, Baker CJ. Streptococcus agalactiae (Group B streptococcus. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG (Eds), Elsevier Saunders, Edinburgh 2012. p.707.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/95\">",
"      Fernandez M, Rench MA, Albanyan EA, et al. Failure of rifampin to eradicate group B streptococcal colonization in infants. Pediatr Infect Dis J 2001; 20:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/96\">",
"      Schuchat A. Group B streptococcus. Lancet 1999; 353:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/97\">",
"      Payne NR, Burke BA, Day DL, et al. Correlation of clinical and pathologic findings in early onset neonatal group B streptococcal infection with disease severity and prediction of outcome. Pediatr Infect Dis J 1988; 7:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/98\">",
"      Edwards MS, Rench MA, Haffar AA, et al. Long-term sequelae of group B streptococcal meningitis in infants. J Pediatr 1985; 106:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/99\">",
"      Chin KC, Fitzhardinge PM. Sequelae of early-onset group B hemolytic streptococcal neonatal meningitis. J Pediatr 1985; 106:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/100\">",
"      Haslam RH, Allen JR, Dorsen MM, et al. The sequelae of group B beta-hemolytic streptococcal meningitis in early infancy. Am J Dis Child 1977; 131:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/101\">",
"      McReynolds EW, Roy S 3rd. Case report. Diabetes insipidus secondary to group B beta streptococcal meningitis. J Tenn Med Assoc 1974; 67:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/102\">",
"      Wald ER, Bergman I, Taylor HG, et al. Long-term outcome of group B streptococcal meningitis. Pediatrics 1986; 77:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/103\">",
"      Barton LL, Feigin RD, Lins R. Group B beta hemolytic streptococcal meningitis in infants. J Pediatr 1973; 82:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/104\">",
"      Levent F, Baker CJ, Rench MA, Edwards MS. Early outcomes of group B streptococcal meningitis in the 21st century. Pediatr Infect Dis J 2010; 29:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/16/18698/abstract/105\">",
"      Libster R, Edwards KM, Levent F, et al. Long-term outcomes of group B streptococcal meningitis. Pediatrics 2012; 130:e8.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5961 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-C9C7C661E2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18698=[""].join("\n");
var outline_f18_16_18698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Early-onset GBS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Late-onset GBS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Late, late-onset GBS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serotype distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Early-onset disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Sepsis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Late-onset disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other focal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Late, late-onset disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Index patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Twin sibling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Empirical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Definitive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Adjunctive therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      RECURRENT INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Neonatal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Health care-associated infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5961\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5961|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/60/42958\" title=\"figure 1\">",
"      Incidence of invasive group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/6/31854\" title=\"figure 2\">",
"      Incidence of early onset GBS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/38/11886\" title=\"figure 3\">",
"      Rate late onset GBS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5961|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/19/5436\" title=\"table 1\">",
"      Early-onset GBS infection rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/32/1549\" title=\"table 2\">",
"      Late-onset GBS infection rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=related_link\">",
"      Clinical features and diagnosis of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9621?source=related_link\">",
"      Group B streptococcus: Virulence factors and pathogenic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2552?source=related_link\">",
"      Management of the infant whose mother has received group B streptococcal chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=related_link\">",
"      Neurologic complications of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19656?source=related_link\">",
"      Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/42/42657?source=related_link\">",
"      Patient information: Group B streptococcal disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11248?source=related_link\">",
"      Patient information: Group B streptococcus and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=related_link\">",
"      Prevention and treatment of respiratory distress syndrome in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=related_link\">",
"      Transient tachypnea of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=related_link\">",
"      Treatment and outcome of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24730?source=related_link\">",
"      Treatment of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40984?source=related_link\">",
"      Vaccines for the prevention of group B streptococcal disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_16_18699="Annual HIV and syphilis screening for adolescents";
var content_f18_16_18699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for annual human immunodeficiency virus and syphilis screening in adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        History of sexually transmitted diseases, or patients seeking care for STD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sexual partners",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        More than one sexual partner in the last six months, or since last HIV test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exchange of sex for drugs or money by patient or a sexual partner",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Injection drug use by patient or&nbsp;a sexual partner",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Admittance to jail or other detention facility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Residence in areas with high prevalence of HIV and syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For males: Sex with males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sex partner with known or suspected HIV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     STD: sexually transmitted disease; HIV: human immunodeficiency virus.",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Adapted from Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006; 55(RR14):1.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18699=[""].join("\n");
var outline_f18_16_18699=null;
var title_f18_16_18700="Epid clin types KS";
var content_f18_16_18700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epidemiologic and clinical types of Kaposi sarcoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type",
"      </td>",
"      <td class=\"subtitle1\">",
"       Predominant risk groups",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cutaneous presentation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Visceral involvement",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical course",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Classic (sporadic)",
"      </td>",
"      <td>",
"       <p>",
"        &sim;3:1 male:female ratio",
"       </p>",
"       <p>",
"        Age &gt;60",
"       </p>",
"       <p>",
"        Mediterranean or Central/Eastern European Origin; Middle East",
"       </p>",
"      </td>",
"      <td>",
"       Distal lower extremities",
"      </td>",
"      <td>",
"       Uncommon",
"      </td>",
"      <td>",
"       Usually indolent; rarely aggressive &amp; disseminated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Endemic (African)",
"      </td>",
"      <td>",
"       <p>",
"        Male adults",
"       </p>",
"       <p>",
"        Children of both sexes",
"       </p>",
"       <p>",
"        Equatorial Africa",
"       </p>",
"      </td>",
"      <td>",
"       Various (may be similar to classic or more locally aggressive); lower extremity lymphedema in adults; cutaneous disease often absent in children",
"      </td>",
"      <td>",
"       <p>",
"        Internal organs involved in a subset of adult patients",
"       </p>",
"       <p>",
"        Common (lymph nodes and viscera) in children",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Indolent to locally invasive in adults",
"       </p>",
"       <p>",
"        Occasional rapid progression with visceral disease in adults",
"       </p>",
"       <p>",
"        Aggressive in children",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Iatrogenic (immunosuppression-related)",
"      </td>",
"      <td>",
"       <p>",
"        Exogenous immunosuppression, esp. solid organ transplant",
"       </p>",
"       <p>",
"        Older patients (&gt;50)",
"       </p>",
"       <p>",
"        Use of cyclosporin A",
"       </p>",
"      </td>",
"      <td>",
"       Distal lower extremities; may be disseminated",
"      </td>",
"      <td>",
"       Relatively common",
"      </td>",
"      <td>",
"       <p>",
"        May regress with modification of immunosuppression",
"       </p>",
"       <p>",
"        May be aggressive",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       AIDS-associated",
"      </td>",
"      <td>",
"       <p>",
"        Men who have sex with men (developed countries)",
"       </p>",
"       <p>",
"        Heterosexual men &amp; women (Africa)",
"       </p>",
"      </td>",
"      <td>",
"       Localized or disseminated",
"      </td>",
"      <td>",
"       Common with poor HIV control",
"      </td>",
"      <td>",
"       <p>",
"        Aggressive or indolent",
"       </p>",
"       <p>",
"        May regress with effective HIV treatment",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18700=[""].join("\n");
var outline_f18_16_18700=null;
var title_f18_16_18701="EMIAT beta blocker amiodarone";
var content_f18_16_18701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Possible interaction between beta blockers and amiodarone after acute MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 224px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An intention to treat analysis of the two-year total cardiac mortality in 1486 patients with a recent acute myocardial infarction (MI) and a left ventricular ejection fraction below 40 percent in the EMIAT trial. Those receiving a beta blocker with amiodarone had a trend toward a better outcome compared to patients receiving amiodarone alone (P = 0.06). No effect of concomitant therapy with digoxin or ACE inhibitors was noted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kennedy HL. Am J Cardiol 1997; 80:1208.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18701=[""].join("\n");
var outline_f18_16_18701=null;
var title_f18_16_18702="Effects of diet and exercise on lipids are sex dependent";
var content_f18_16_18702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    The effects of diet and exercise on lipids are different in men and women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 218px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effects of a prudent weight-reducing diet with (DE) or without exercise (D) in overweight men and women compared to control (C) on serum triglycerides (T), low density lipoprotein cholesterol (LDL), and high density lipoprotein cholesterol (HDL). In men, diet plus exercise reduced serum triglycerides and raised serum HDL cholesterol compared to control or diet alone. In women, exercise abolished the increase in serum triglycerides and reduction in serum HDL cholesterol levels that occurred with diet alone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Wood PD, Stefanick ML, Williams PT, et al. N Engl J Med 1991; 325:461.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_16_18702=[""].join("\n");
var outline_f18_16_18702=null;
var title_f18_16_18703="Contents: Inflammatory bowel disease";
var content_f18_16_18703=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/12/3278\">",
"       Gastroenterology and Hepatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Inflammatory bowel disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Inflammatory bowel disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Crohn's disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/55/29559\">",
"           Adalimumab for treatment of Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/44/25289\">",
"           Arthritis associated with gastrointestinal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/40/10886\">",
"           Budesonide in the treatment of Crohn's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/2/33829\">",
"           Certolizumab pegol for treatment of Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/7/24693\">",
"           Clinical manifestations of Crohn's disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/0/20490\">",
"           Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/7/25722\">",
"           Colorectal cancer surveillance in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/13/3288\">",
"           Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/14/25834\">",
"           Fertility, pregnancy, and nursing in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/26/44455\">",
"           Genetic factors in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/31/7673\">",
"           Immunomodulator therapy in Crohn's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/4/44105\">",
"           Infliximab in Crohn's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/34/17962\">",
"           Investigational therapies in the medical management of Crohn's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/50/809\">",
"           Medical prophylaxis of postoperative Crohn's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/22/3429\">",
"           Natalizumab for treatment of Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/47/41722\">",
"           Overview of the management of Crohn's disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/54/19305\">",
"           Overview of the medical management of mild to moderate Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/11/6329\">",
"           Overview of the medical management of severe or refractory Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/43/25273\">",
"           Perianal complications of Crohn's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/50/4906\">",
"           Surgical management of ulcerative colitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         IBD",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/33/44566\">",
"           6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/34/20008\">",
"           Antibiotics for treatment of inflammatory bowel diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/44/25289\">",
"           Arthritis associated with gastrointestinal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/25/40342\">",
"           Colorectal cancer and primary sclerosing cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/7/25722\">",
"           Colorectal cancer surveillance in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/17/7450\">",
"           Definition, epidemiology, and risk factors in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/48/14089\">",
"           Endoscopic diagnosis of inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/13/3288\">",
"           Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/14/25834\">",
"           Fertility, pregnancy, and nursing in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/26/44455\">",
"           Genetic factors in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/37/22103\">",
"           Glucocorticoid withdrawal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/31/22006\">",
"           Hepatobiliary manifestations of inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/48/27401\">",
"           Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/5/8279\">",
"           Irritable bowel syndrome in patients with inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/47/27386\">",
"           Major side effects of systemic glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/36/22090\">",
"           Management of mild to moderate ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/14/6377\">",
"           Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/54/30569\">",
"           Metabolic bone disease in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/22/3429\">",
"           Natalizumab for treatment of Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/6/43113\">",
"           Nutrient deficiencies in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/7/44152\">",
"           Nutrition and dietary interventions in adults with inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29034\">",
"           Pulmonary complications of inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/24/41350\">",
"           Skin and eye manifestations of inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/55/20344\">",
"           Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/50/4906\">",
"           Surgical management of ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/34/4650\">",
"           Treatment of ulcerative colitis in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Non-IBD inflammatory gastrointestinal diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/12/9414\">",
"           Diversion colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/43/43703\">",
"           Eosinophilic gastroenteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/32/35334\">",
"           Epidemiology and pathogenesis of primary sclerosing cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6246\">",
"           Factitious diarrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/50/5928\">",
"           Gastrointestinal manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24968\">",
"           Gastrointestinal manifestations of vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/56/27530\">",
"           Lymphocytic and collagenous colitis (microscopic colitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/3/8247\">",
"           Management of familial Mediterranean fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/10/2218\">",
"           Management of patients with a colostomy or ileostomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/32/32261\">",
"           Pathophysiology of familial Mediterranean fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/35/11833\">",
"           Whipple's disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Radiation enteritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/29/25049\">",
"           Clinical features, diagnosis, and treatment of radiation proctitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/41/13975\">",
"           Diagnosis and management of chronic radiation enteritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ulcerative colitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/1/26647\">",
"           Anti-tumor necrosis factor therapy in ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/43/24250\">",
"           Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/44/25289\">",
"           Arthritis associated with gastrointestinal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/5/21592\">",
"           Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/7/11386\">",
"           Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/7/25722\">",
"           Colorectal cancer surveillance in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/29/34263\">",
"           Delayed surgical management of the disrupted anal sphincter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/13/3288\">",
"           Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/14/25834\">",
"           Fertility, pregnancy, and nursing in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/26/44455\">",
"           Genetic factors in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/36/22090\">",
"           Management of mild to moderate ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/15/3319\">",
"           Management of severe ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/63/32759\">",
"           Pouchitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/50/4906\">",
"           Surgical management of ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/30/18920\">",
"           Toxic megacolon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/34/4650\">",
"           Treatment of ulcerative colitis in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-EA362125BD-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f18_16_18703=[""].join("\n");
var outline_f18_16_18703=null;
